Clinical trial NCT02508532
Conditions: Gastrointestinal Stromal Tumors (GIST) Other Relapsed or Refractory Solid Tumors
Keywords: 2L GIST GIST second line GIST gleevec GIST imatinib Second-line GIST clinical trial BLU-285 BLU 285 BLUE-285 BLUE 285 Avapritinib GIST imatinib relapse GIST gleevec relapse GIST KIT GIST relapse GIST refractory GIST imatinib intolerance GIST TKI treatment GIST tyrosine kinase inhibitor treatment GIST TKI GIST tyrosine kinase inhibitor Advanced GIST GIST mutations GIST treatments Blueprint GIST Relapsed GIST clinical trial Refractory GIST clinical trial KIT-mutant GIST cancer gist gastrointestinal stromal tumor gist cancer PDGFRA
Sponsor: Blueprint Medicines Corporation
Start date: 2015-08-01; Completion date: 2021-06-03
Enrollment: 250 participants; Allocation: NON_RANDOMIZED; Intervention model: SEQUENTIAL

Brief summary:
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).

Detailed description:

Arms: arm 1: Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation. arm 2: Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation. arm 3: Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation. arm 4: Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation. arm 5: Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation. . arm 6: Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis. arm 7: Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation.

Patients that received at least one dose of avapritinib were included in the Part 2 analysis. arm 8: Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.

Patients received avapritinib in continuous 28 day cycles until discontinuation. arm 9: Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.

Patients received avapritinib in continuous 28 day cycles until discontinuation.
Interventions: intervention 1: Avapritinib
Intervention descriptions: intervention 1: avapritinib tablets

Protocol documents:
Prot_000.pdf: 
Protocol BLU-285-1101  
Avapritinib 
 
ClinicalTrials.gov Document Cover Page 
 
Protocol 
 
Study BLU-285-1101 
 
Study Title: A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) 
and other Relapsed and Refractory Solid Tumors 
 
Document Date: 28 February 2018 
 
NCT Number: 02508532 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 1 of 110
 
 
28 February 2018
 
CLINICAL RESEARCH PROTOCOL 
DRUG: 
Avapritinib (also known as BLU-285) 
STUDY NUMBER(S): 
BLU-285-1101 
PROTOCOL(S) TITLE: 
A Phase 1 Study of BLU-285 in Patients with 
Gastrointestinal Stromal Tumors (GIST) and 
other Relapsed and Refractory Solid Tumors 
IND NUMBER: 
125379 
EudraCT NUMBER 
2015-001660-18 
SPONSOR: 
Blueprint Medicines Corporation 
ORIGINAL PROTOCOL DATE: 
28 May 2015 
VERSION NUMBER: 
Amendment 8 
VERSION DATE: 
28 February 2018 
 
CONFIDENTIALITY STATEMENT 
The information contained herein is confidential and the proprietary property of Blueprint Medicines 
Corporation and any unauthorized use or disclosure of such information without the prior written 
authorization of Blueprint Medicines Corporation is expressly prohibited. 
 
 




Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 3 of 110
28 February 2018
 
 
  
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 4 of 110
 
 
28 February 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 5 of 110
 
 
28 February 2018
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 6 of 110
 
 
28 February 2018
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 7 of 110
 
 
28 February 2018
 
 
 
  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 8 of 110
 
 
28 February 2018
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
   
 
 
  
 
 
 
 
 
  
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 9 of 110
 
 
28 February 2018
 
 
 
  
 
  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 10 of 110
 
 
28 February 2018
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 11 of 110
 
 
28 February 2018
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 12 of 110
 
 
28 February 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
  
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 13 of 110
28 February 2018
STUDY SUMMARY 
Title: 
A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal 
Tumors (GIST) and other Relapsed and Refractory Solid Tumors 
Study 
Centers 
The study will be conducted at multiple study centers in the United 
States (US), European Union (EU), and Asia. 
Introduction 
and 
Rationale: 
Gastrointestinal stromal tumors are the most common mesenchymal 
tumors occurring in the gastrointestinal (GI) tract, representing 
approximately 0.1-3.0% of all GI malignancies. Approximately 90% of 
patients with GIST have a tumor that is dependent on a mutation in 
either v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (KIT) (75-80%) or the highly related protein platelet-derived 
growth factor receptor alpha (PDGFRα) (10-15%), most commonly a 
substitution of valine for aspartic acid at amino acid 842 (D842V). On 
a molecular level, the most common sites for mutations in KIT at the 
time of diagnosis are exon 11 (60-70%) and exon 9 (5-15%), though 
exon 17 mutations are identified in approximately 1% of patients. 
Disease progression during treatment with a tyrosine kinase inhibitor 
(TKI) is associated with new mutations in KIT, with an increasing 
prevalence of mutations in exon 17 to approximately 95-99% 
following second-line TKI therapy.  
No currently approved TKI selectively inhibits mutations in exon 17 of 
KIT or at PDGFRα D842. Thus, GIST dependent on either of these 
mutations represents an unmet medical need. Avapritinib (also known 
as BLU-285) has demonstrated potent and selective activity against 
KIT exon 17 and PDGFRα D842 mutants in vitro and growth 
inhibition in TKI-resistant models in vivo. Avapritinib has been shown 
to be tolerable at active doses in toxicology and safety pharmacology 
studies. In the ongoing Phase 1 GIST trial, clinical activity was also 
observed in a broad range of KIT mutations beyond exon 17, such as 
exons 9, 11, 13, and 18. Given the poor prognosis and potential 
risk/benefit of avapritinib for patients with advanced GIST, further 
development of this agent is warranted. 
Number of 
Patients: 
Approximately 235 patients will be enrolled in this study, including: 
•
Approximately 50 patients in Part 1 (Dose Escalation)
•
Approximately 185 patients in Part 2 (Expansion)
The total number of patients to be enrolled in Part 1 is dependent upon 
the observed safety profile, which will determine the number of 
patients per dose cohort, as well as the number of dose escalations 
required to achieve the maximum tolerated dose (MTD). 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 14 of 110
28 February 2018
Objectives: 
Primary Objectives: 
Part 1 
•
To determine the MTD and recommended Phase 2 dose
(RP2D) of avapritinib.
•
To determine the safety and tolerability of avapritinib.
Part 2 
•
To determine the overall response rate (ORR) by the Response
Evaluation Criteria in Solid Tumors, version 1.1 modified for
patients with GIST (mRECIST version 1.1) criteria at the
MTD/RP2D of avapritinib in patients with GIST who have a
D842V mutation in PDGFRα.
•
To determine the ORR by mRECIST version 1.1 criteria at the
MTD/RP2D of avapritinib in patients with GIST that has
progressed following treatment with imatinib and at least
another kinase-inhibitor agent, and who are not known to have
a D842V mutation in PDGFRα.
•
To determine the ORR by mRECIST version 1.1 criteria at the
MTD/R2PD of avapritinib in patients with GIST who have
progressed or patients who experienced intolerance to imatinib,
including in the adjuvant setting, and who have not received
additional kinase-inhibitor therapy and do not have a known
D842V mutation in PDGRα.
•
To determine the safety and tolerability of avapritinib.
Secondary Objectives: 
•
To characterize the pharmacokinetic (PK) profile of avapritinib,
and correlate drug exposure with safety assessments, including
changes in electrocardiogram (ECG) intervals.
•
To assess evidence of antineoplastic activity of avapritinib as
measured by duration of response (DOR), progression free
survival (PFS), and clinical benefit rate (CBR).
•
To assess antitumor activity as measured by Choi Criteria.
•
To compare PFS on avapritinib with PFS on last prior
anti-cancer therapy.
•
To assess mutations in KIT, PDGFRα and other cancer-relevant
genes in tumor tissue at baseline and at the end of treatment
(EOT).


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 15 of 110
28 February 2018
•
To assess the KIT, PDGFRα and other cancer-relevant gene
mutant allele fractions measured in circulating tumor
deoxyribonucleic acid (ctDNA) at baseline, and changes in the
mutant allele fractions measured in ctDNA after treatment with
avapritinib.
 
 
 
Study 
Design: 
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation 
study designed to evaluate the safety, tolerability, PK, PD and 
preliminary antineoplastic activity of avapritinib, administered orally 
(PO), in adult patients with unresectable GIST or other relapsed or 
refractory solid tumors. 
The study consists of 2 parts: dose-escalation (Part 1) and expansion 
(Part 2). 
After provision of written informed consent, patients will be evaluated 
for study eligibility during the Screening period within 56 days 
(weeks) before study drug administration on Day -3 for patients 
participating in the PK lead-in stage (Part 1) or Cycle 1 Day 1 (C1D1) 
for patients not participating in the PK lead-in stage (Part 2). 
A treatment cycle is 28 days in duration. Patients in Part 1 
(Dose-Escalation) will present to the study center on Day -3 for the 
first dose of study drug and serial PK sampling, PD sample collection, 
vital sign measurement, ECG monitoring, safety monitoring and 
adverse event (AE) recording. The dose received on D -3 will be the 
dose of the patient’s assigned cohort. On Days -2, -1, and 1 (24, 48, 
and 72 hours after study drug administration) patients will return for 
PK sampling and safety monitoring. Immediately after the 72-hour PK 
sample is obtained, the C1D1 dose will be administered.  
Patients in Part 2 will present to the study center on C1D1 for the first 
dose of study drug and serial PK sampling (Groups 1 and 2), PD 
sample collection, vital sign measurement, ECG monitoring, safety 
monitoring and AE recording. Approximately 20 patients in Groups 1 
and 2, at selected sites will participate in continuous ECG (Holter) 
monitoring for extraction of ECGs at the times of PK sampling; Holter 
recordings will be collected in Cycle 1 on Days 1, 2, and 15. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 16 of 110
28 February 2018
During Cycle 1 (C1) following the PK Lead-in (Part 1), patients are to 
attend study center visits on C1D1 (Parts 1 and 2) Days 8, 15, and 22 
(Part 1), and Days 2 (Part 2, Groups 1 and 2) and 15 (Part 2). On C1D8 
and C1D22, patients will undergo safety monitoring, on C1D15, safety 
monitoring and dense PK sampling (Part 1), and on Day 15 (Part 2) 
patients will undergo simplified safety monitoring, dense PK sampling 
(Groups 1 and 2), and sparse PK sampling (Group 3). 
During Cycle 2 (C2), all patients are to attend study center visits on 
Day 1 (D1) and Day 15 (Part 1), and on Day 1 only (Part 2) for safety 
monitoring and PK blood draws, and then on D1 of subsequent cycles. 
After C2, patients will return to the study center on Day 1 of each 
subsequent cycle to Cycle 13 for safety monitoring and (through 
Cycle 4 Day 1) PK blood draws. After C2 (C3D1) and every 2 cycles 
thereafter (e.g., C5D1, C7D1), patient’s tumor status will be assessed 
by computed tomography (CT) or magnetic resonance imaging (MRI) 
through Cycle 13. After 13 cycles have been completed on trial, 
patients are to attend study center visits every 3 cycles on Day 1 for 
safety monitoring and a tumor status assessment (e.g., C16D1, C19D1, 
C22D1). This decreases the visit frequency and radiation exposure to 
the patient.  
It is anticipated that patients will receive at least 1 cycle of avapritinib; 
no maximum treatment duration has been set. After C1, patients may 
continue to receive avapritinib until precluded by toxicity, 
noncompliance, withdrawal of consent, physician decision, progressive 
disease, death, or closure of the study by the Sponsor. 
All patients will attend an EOT visit within 14 (±7) days after the last 
dose of study drug. A Safety Follow-up that may be performed by 
telephone contact for resolution of any residual AE will be made on 
Day 30 (+7 days) after the last dose of study drug, or at the time the 
patient initiates another antineoplastic therapy. Thereafter, patients are 
to be followed for disease assessment, subsequent antineoplastic 
therapy and survival approximately every 3 months until death, 
withdrawal of consent, or closure of the study by the Sponsor. 
Part 1 (Dose Escalation) 
The dose escalation part of the study will enroll patients with 
unresectable GIST or another advanced solid tumor. Patients with 
GIST must have disease that has progressed following imatinib and at 
least 1 of the following: sunitinib, regorafenib, sorafenib, dasatinib, 
pazopanib or an experimental kinase-inhibitor, or disease with a D842 
mutation in the PDGFRα gene. Patients with an advanced solid tumor 
other than GIST must have relapsed or refractory disease without an 
available effective therapy. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 17 of 110
 
 
28 February 2018
 
The first cohort of patients will receive avapritinib at a starting dose of 
30 mg once daily (QD). The dose escalation increment for the first 
escalation step will be a maximum of 100%; however, if ≥ 1 patient 
treated at the starting dose level has a ≥ Grade 2 non-hematologic AE 
or a ≥ Grade 3 hematologic AE and the AE (non-hematologic or 
hematologic) is not clearly attributable to a cause other than 
avapritinib, then the maximum dose escalation increment for the first 
escalation step will be 50%. All subsequent dose escalation increments 
will be a maximum of 50%.  
Three patients will be enrolled initially in each cohort and an 
additional 3 patients (for a total of 6) will be enrolled should the cohort 
require expansion due to dose-limiting toxicity (DLT). After the 
current escalation cohort is full, up to 3 additional patients, all of 
whom must have the diagnosis of GIST, may be enrolled into an 
enrichment cohort at a lower dose that included only 3 patients 
evaluable for DLT, was reviewed at a dose-escalation meeting, and did 
not exceed the MTD. Data from these patients will allow for further 
exploration of PK, PD, and safety in patients with GIST. Enrollment of 
patients into an enrichment cohort requires written approval from the 
Sponsor. In cohorts in which the administered dose is < 100 mg QD, 
enrolled patients may have the diagnosis of either GIST or a 
relapsed/refractory solid tumor. In cohorts in which the administered 
dose is ≥ 100 mg QD, at least 2 patients in each cohort (4 if the cohort 
is expanded to 6 patients) must have the diagnosis of GIST. 
The specific dose for each subsequent cohort will be determined at a 
dose-escalation meeting that includes the Study Investigators and the 
Sponsor Clinical Study Team, and must be agreed to by the Study 
Investigator at each study center and the Sponsor Clinical Study Team. 
Dose-escalation meetings will occur after all patients in the current 
cohort have completed at least 28 days of observation after their first 
dose of avapritinib, or have experienced a DLT. 
Dose escalation will continue until the MTD or a RP2D below the 
MTD has been determined. In addition, based on evaluation of the 
data, alternative dosing regimens (e.g., twice daily [BID]) or schedules 
(e.g., 3 weeks on, 1-week rest) may be explored. 
Part 2 (Expansion) 
Once the MTD or RP2D has been determined, 3 groups of patients 
with the following characteristics will be enrolled and treated with 
avapritinib:  
• Group 1: Patients with unresectable GIST that has progressed 
following treatment with imatinib and at least 1 of the following: 
sunitinib, regorafenib, sorafenib, dasatinib, pazopanib, or an 
experimental kinase-inhibitor therapy and who do not have a 
D842V mutation in PDGFRα (N~100). 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 18 of 110
 
 
28 February 2018
 
• Group 2: Patients with unresectable GIST harboring a D842V 
mutation in the PDGFRα gene (N~35) The PDGFRα mutation will 
be identified by local and central assessment, either in archival 
tissue or a new tumor biopsy obtained, prior to treatment with 
avapritinib. 
• Group 3: Patients with unresectable GIST that has progressed 
and/or those who have experienced intolerance following treatment 
with imatinib (including in the adjuvant setting) and who have not 
received additional kinase-inhibitor therapy and do not have a 
known D842V mutation in PDGFRα (N~50). 
Patients with GIST harboring a D842V mutation in the PDGFRα gene 
may be enrolled based on local mutation testing. However, during 
Part 2 of the study, Group 1 and 2 patients will be required to submit a 
formalin-fixed, paraffin-embedded tumor sample for PDGFRα 
mutational testing at a central laboratory prior to beginning treatment 
with avapritinib. 
During Part 2, patient safety will be reviewed on an ongoing basis at 
teleconferences (approximately every 1 - 2 months) that include the 
Study Investigators and the Sponsor Clinical Study Team. All safety 
data collected to date will be reviewed to confirm that no unexpected, 
significant, or unacceptable risk to patients enrolled in the study has 
been discovered. Available tumor response, PK, and PD data will also 
be reviewed.  
Duration of 
Treatment 
It is anticipated that patients will receive at least 1 cycle of avapritinib; 
no maximum treatment duration has been set. After C1, patients may 
continue to receive avapritinib until precluded by toxicity, 
noncompliance, withdrawal of consent, physician decision, progressive 
disease, death, or closure of the study by the Sponsor. 
Duration of 
Patient 
Participation 
The minimum duration of patient participation is approximately 
3 months, including a screening period to assess study eligibility up to 
8 weeks (56 days); a PK Lead-in stage (3 days) for all patients in Part 
1; a treatment period of at least 1 cycle (28 days); an EOT visit at least 
14 (± 7) days following the last dose of study drug; and a Follow-up 
telephone contact for resolution of any AEs 30 (+7) days following the 
last dose of study drug or at the time the patient initiates another 
antineoplastic therapy. Thereafter, patients are to be followed for 
disease assessment, subsequent antineoplastic therapy and survival 
approximately every 3 months until death, withdrawal of consent or 
closure of the study by the Sponsor. 
Duration of 
Study 
The expected enrollment period is approximately 45 months and the 
expected duration of the study is approximately 60 months. 
Target 
Population 
Main entry criteria: 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 19 of 110
 
 
28 February 2018
 
o Patient is ≥ 18 years of age. 
o For Part 1: Histologically- or cytologically-confirmed diagnosis 
of unresectable GIST or another advanced solid tumor. Patients 
with unresectable GIST must have disease that has progressed 
following imatinib and at least 1 of the following: sunitinib, 
regorafenib, sorafenib, dasatinib, pazopanib or an experimental 
kinase-inhibitor agent, or disease with a D842 mutation in the 
PDGFRα gene. Patients with an advanced solid tumor other 
than GIST must have relapsed or refractory disease without an 
available effective therapy. 
o For Part 2: 
o Group 1:  Patients must have a confirmed diagnosis of 
unresectable GIST that has progressed following imatinib and 
at least 1 of the following: sunitinib, regorafenib, sorafenib, 
dasatinib, pazopanib, or an experimental kinase-inhibitor agent 
and the patient does not have a D842V mutation in PDGFRα. 
o Group 2:  Patients must have a confirmed diagnosis of 
unresectable GIST with a D842V mutation in the PDGFRα 
gene. The PDGFRα mutation will be identified by local or 
central assessment, either in an archival tissue sample or a new 
tumor biopsy obtained prior to treatment with avapritinib. 
o  Group 3:  Patients must have a confirmed diagnosis of 
unresectable GIST that has progressed and/or patients must 
have experienced intolerance to imatinib and not received 
additional kinase-inhibitor therapy. Patients must not have a 
known D842V mutation in PDGFRα. 
o Groups 1, 2, and 3:  At least 1 measurable lesion defined by 
mRECIST version 1.1 for patients with GIST. 
o Groups 1 and 2: A tumor sample (archival tissue or a new 
tumor biopsy) has been submitted for mutational testing. 
Primary 
Endpoints:  
Part 1 
• MTD and RP2D of avapritinib. 
• Overall safety profile of BLU-285, as assessed by the type, 
frequency, severity, timing, and relationship to study drug of 
any AEs, serious adverse events (SAEs), and changes in vital 
signs, ECGs, and safety laboratory tests. 
Part 2 
• ORR, defined as the rate of confirmed complete response (CR) 
or partial response (PR) by mRECIST version 1.1. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 20 of 110
28 February 2018
Secondary 
Endpoints: 
 
•
Overall safety profile of avapritinib, as assessed by the type, 
frequency, severity, timing, and relationship to study drug of 
any AEs, SAEs, and changes in vital signs, ECGs, and safety 
laboratory tests.
•
PK parameters of avapritinib: Maximum plasma drug 
concentration (Cmax), time to maximum plasma drug 
concentration (Tmax), time of last quantifiable plasma drug 
concentration (Tlast), area under the plasma concentration versus 
time curve from time 0 to 24 hours postdose (AUC0-24), plasma 
drug concentration at 24 hours postdose (C24); apparent volume 
of distribution (Vz/F), terminal elimination half-life (t½), 
apparent oral clearance (CL/F), accumulation ratio (R), and 
correlations between PK parameters and safety findings of 
interest, including ECG intervals.
•
DOR, PFS, and CBR as per mRECIST version 1.1.
•
Response rate as defined by Choi Criteria.
•
PFS on last prior anti-cancer therapy.
•
KIT, PDGFRα, and other cancer-relevant mutations present in 
tumor tissue at baseline and at EOT.
•
Change from baseline in the levels of KIT, PDGFRα, and other 
cancer-relevant mutant allele fractions in peripheral blood.
 
. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 21 of 110
28 February 2018
STUDY SCHEMATIC 
Abbreviations: GIST = gastrointestinal stromal tumor; PDGFRα = platelet-derived growth factor 
receptor alpha; R/R = relapsed/refractory; TKI = tyrosine kinase inhibitor. 
GIST (progressed following imatinib and ≥ 1 other TKI 
or a D842 mutation in PDGFRα gene) and R/R solid 
tumors (≥ 100 mg/d) 
 At least 2 (4 if cohort is expanded) patients with GIST 
per cohort 
N~30 
GIST (progressed following imatinib and ≥ 1 
other TKI or a D842 mutation in PDGFRα 
gene) and R/R solid tumors (< 100 mg/d) 
N~20 
GIST 
(progressed 
following imatinib 
and ≥ 1 other TKI) 
N~100 
GIST 
(PDGFRα D842V 
mutant) 
N~35 
Part 1: Dose-Escalation
Part 2:  Expansion 
GIST 
(progressed and/or 
imatinib-intolerant) 
N~50 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 22 of 110
28 February 2018
TABLE OF CONTENTS 
1 
INTRODUCTION AND RATIONALE .................................................................29 
1.1 
Background ..........................................................................................................29 
1.1.1 
Preclinical Pharmacology ..............................................................................32 
1.1.2 
Toxicology .......................................................................................................35 
1.2 
Study Rationale ....................................................................................................36 
1.3 
Rationale for the Starting Dose and Dosing Regimen ......................................37 
1.4 
BLU-285-1101 Study Update ..............................................................................37 
2 
STUDY OBJECTIVES ............................................................................................40 
2.1 
Primary Objectives: .............................................................................................40 
2.1.1 
Part 1 ...............................................................................................................40 
2.1.2 
Part 2 ...............................................................................................................40 
2.2 
Secondary Objectives...........................................................................................40 
2.3 
Exploratory Objectives ........................................................................................41 
3 
STUDY ENDPOINTS ..............................................................................................42 
3.1 
Primary Endpoints...............................................................................................42 
3.1.1 
Part 1 ...............................................................................................................42 
3.1.2 
Part 2 ...............................................................................................................42 
3.2 
Secondary Endpoints ...........................................................................................42 
3.3 
Exploratory Endpoints ........................................................................................42 
4 
STUDY PLAN ...........................................................................................................44 
4.1 
Study Design .........................................................................................................44 
4.2 
Study Schematic ...................................................................................................47 
5 
POPULATION ..........................................................................................................48 
5.1 
Number of Patients ..............................................................................................48 
5.2 
Inclusion Criteria .................................................................................................48 
5.3 
Exclusion Criteria ................................................................................................49 
5.4 
Patient Identification and Registration ..............................................................51 
5.5 
Study Completion.................................................................................................51 
5.6 
Patient Withdrawal Criteria ...............................................................................52 
5.7 
Replacement of Patients ......................................................................................52 
6 
STUDY CONDUCT..................................................................................................54 
6.1 
General Conduct ..................................................................................................54 
6.2 
Early Study Termination ....................................................................................54 
6.2.1 
Rules for Early Termination of Enrollment in Dose Expansion ...............54 
6.3 
Dose and Administration .....................................................................................56 
6.4 
Guidelines for Dose Escalation ...........................................................................56 
6.4.1 
Intra-patient Dose Modification ...................................................................59 
6.4.2 
Dose Limiting Toxicity ..................................................................................59 
6.4.3 
Dose Modifications .........................................................................................60 
6.4.4 
Maximum Tolerated Dose .............................................................................62 
6.4.5 
Recommended Phase 2 Dose .........................................................................62 
6.4.6 
Alternate Dosing Schedule ............................................................................62 
6.5 
Prior and Concomitant Therapy ........................................................................63 
6.5.1 
Prohibited Concomitant Therapy ................................................................63 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 23 of 110
28 February 2018
6.5.2 
Concomitant Therapy to be used with Caution ..........................................63 
6.5.3 
Permitted Concomitant Therapy..................................................................64 
6.6 
Additional Precautions ........................................................................................64 
7 
DESCRIPTION OF STUDY PROCEDURES .......................................................72 
7.1 
Screening ...............................................................................................................72 
7.2 
Safety Assessments ...............................................................................................73 
7.2.1 
Physical Examination ....................................................................................73 
7.2.2 
Eastern Cooperative Oncology Group Performance Status ......................73 
7.2.3 
Vital Signs .......................................................................................................73 
7.2.4 
ECGs ...............................................................................................................73 
7.2.5 
Clinical Laboratory Tests..............................................................................74 
7.2.6 
Imaging of the Brain ......................................................................................74 
7.2.7 
Adverse Events and Concomitant Medications ..........................................74 
7.3 
Pharmacokinetic Assessment ..............................................................................75 
7.4 
Pharmacodynamic / Biomarker Assessment .....................................................75 
7.4.1 
Blood Samples for Pharmacodynamic / Biomarker Assessment ...............75 
7.4.2 
Tumor Samples for Biomarker Assessment ................................................75 
7.5 
Disease Response Assessment .............................................................................76 
7.6 
End-of-treatment, Safety Follow-up, and PFS Follow-up ................................77 
7.7 
Sample Processing, Storage, and Shipment .......................................................77 
8 
STUDY DRUG MANAGEMENT ...........................................................................78 
8.1 
Description ............................................................................................................78 
8.1.1 
Formulation ....................................................................................................78 
8.1.2 
Storage ............................................................................................................78 
8.2 
Packaging and Shipment .....................................................................................78 
8.3 
Accountability ......................................................................................................78 
8.4 
Compliance ...........................................................................................................79 
9 
ADVERSE EVENTS ................................................................................................80 
9.1 
Definitions .............................................................................................................80 
9.1.1 
Definition of Adverse Event ..........................................................................80 
9.1.2 
Suspected Adverse Reaction .........................................................................80 
9.1.3 
Unexpected Adverse Event............................................................................80 
9.2 
Documenting Adverse Events .............................................................................81 
9.3 
Assessment of Intensity........................................................................................81 
9.4 
Assessment of Causality ......................................................................................82 
9.5 
Pretreatment Events ............................................................................................82 
9.6 
Pregnancy Reporting ...........................................................................................82 
9.6.1 
Contraception Requirements ........................................................................83 
9.6.2 
Gamete and Embryo Banking ......................................................................84 
10 SERIOUS ADVERSE EVENT ................................................................................85 
10.1 
Definition of Serious Adverse Event ..................................................................85 
10.2 
Reporting Serious Adverse Events .....................................................................86 
10.2.1 
Overdose .........................................................................................................87 
11 STATISTICS .............................................................................................................88 
11.1 
General Procedures .............................................................................................88 
11.2 
Analysis Populations ............................................................................................88 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 24 of 110
28 February 2018
11.3 
Sample Size ...........................................................................................................89 
11.4 
Procedures for Handling Missing, Unused, and Spurious Data ......................90 
11.5 
Statistical Methods ...............................................................................................90 
11.5.1 
Disposition ......................................................................................................90 
11.5.2 
Demographic and Baseline Characteristics .................................................90 
11.5.3 
Exposure Analysis ..........................................................................................90 
11.5.4 
Primary Endpoint(s) ......................................................................................90 
11.5.5 
Secondary Endpoint(s) ..................................................................................92 
11.5.6 
Exploratory Endpoints ..................................................................................93 
11.6 
Procedures for Reporting Deviations to Original Statistical Analysis 
Plan ........................................................................................................................94 
12 ETHICS AND RESPONSIBILITIES .....................................................................95 
12.1 
Good Clinical Practice .........................................................................................95 
12.2 
Data and Safety Monitoring Committee ............................................................95 
12.3 
Institutional Review Board/Independent Ethics Committee ...........................95 
12.4 
Informed Consent ................................................................................................96 
12.5 
Records Management ..........................................................................................96 
12.6 
Source Documentation.........................................................................................96 
12.7 
Study Files and Record Retention ......................................................................97 
12.8 
Liability and Insurance .......................................................................................97 
13 AUDITING AND MONITORING ..........................................................................98 
14 AMENDMENTS .......................................................................................................99 
15 STUDY REPORT AND PUBLICATIONS ..........................................................100 
16 STUDY DISCONTINUATION .............................................................................101 
17 CONFIDENTIALITY ............................................................................................102 
18 REFERENCES .......................................................................................................103 
19 APPENDICES .........................................................................................................106 
19.1 
Appendix 1 ..........................................................................................................106 
19.2 
Appendix 2 ..........................................................................................................107 
19.3 
Appendix 3 ..........................................................................................................108 
19.4 
Appendix 4 ..........................................................................................................109 
19.5 
Appendix 5 ..........................................................................................................110 
LIST OF TABLES 
Table 1: 
Biochemical Activity of BLU-285 and GIST Agents against KIT Exon 
17 D816V and PDGFRα D842V Mutants ..............................................32 
Table 2: 
Best Radiological Response with BLU-285 by Central Assessment per 
mRECIST Version 1.1 .............................................................................38 
Table 3: 
Overall Summary of Adverse Events by Severity and Relationship in 
≥ 20% of Patients (BLU-285-1101, Safety Population, N=116) ...........39 
Table 4: 
Examples of Implementing the Early Stopping Rule ...........................55 
Table 5: 
Dose-escalation Scheme ...........................................................................58 
Table 6: 
Provisional Dose-escalation levels ..........................................................58 
Table 7: 
Dose Modification Guidelines for BLU-285-related Toxicity ..............61 
Table 8: 
Schedule of Assessments ..........................................................................65 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 25 of 110
28 February 2018
Table 9: 
Pharmacokinetics Sample Collection and ECG Schedule – Part 1 .....69 
Table 10: 
Pharmacokinetics Sample Collection and Holter Monitoring/ECG 
Schedule - Part 2 (Groups 1 and 2) ........................................................70 
Table 11: 
Pharmacokinetics Sample Collection and ECG Schedule - Part 2 
(Group 3)...................................................................................................71 
Table 12: 
Schedule for Pharmacodynamic Biomarker Sample Collection .........76 
Table 13: 
Confidence Interval of Observed Response Rate, N = 31 ....................91 
Table 14: 
Confidence Interval of Observed Response Rate, N = 50 ....................91 
Table 15: 
Confidence Interval of Observed Response Rate, N = 100 ..................92 
LIST OF FIGURES 
Figure 1: 
Efficacy of, and Body Weight Measurements for, BLU-285 in a KIT 
Exon 17 Mutant Driven P815 Xenograft Model ...................................33 
Figure 2: 
Efficacy of BLU-285 and Inhibition of KIT Exon 11/Exon 17 Mutant 
Signaling in a GIST Patient-Derived Xenograft Model .......................34 
Figure 3: 
Dose-escalation Schematic.......................................................................58 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 26 of 110
28 February 2018
LIST OF ABBREVIATIONS 
Abbreviation 
Definition 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
ANC 
Absolute neutrophil count 
AST 
Aspartate aminotransferase 
AUC0-24 
Area under the plasma concentration versus time curve from time 
0 to 24 hours postdose 
β-hCG 
Beta human chorionic gonadotropin 
BCRP 
Breast cancer resistance protein 
BID 
Twice daily 
C24 
Plasma drug concentration at 24 hours postdose 
Cmax 
Maximum plasma drug concentration 
CBR 
Clinical benefit rate 
CL/F 
Apparent oral clearance 
cm 
Centimeter 
CR 
Complete response 
CT 
Computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
ctDNA 
Circulating tumor deoxyribonucleic acid 
CxDx 
Cycle x Day x 
CYP 
Cytochrome P450 
DLT 
Dose-limiting toxicity 
DOR 
Duration of Response 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
Electronic case report form 
EEG 
Electroencephalogram 
EOT 
End-of-treatment 
18FDG-PET 
18Fluorodeoxyglucose positron emission tomography 
FIH 
First in human 
FSH 
Follicle stimulating hormone 
GCP 
Good Clinical Practice 
GI 
Gastrointestinal 
GIST 
Gastrointestinal stromal tumor 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 27 of 110
 
 
28 February 2018
 
GLP 
Good Laboratory Practice 
Hgb 
Hemoglobin 
HNSTD 
Highest non-severely toxic dose 
IB 
Investigator’s Brochure 
IC50 
Half-maximal inhibitory concentration 
ICH 
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
IUD 
Intrauterine device 
IUS 
Intrauterine/hormone-releasing system 
IV 
Intravenous 
Kd 
Dissociation constant 
KIT 
V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
mRECIST 
Response Evaluation Criteria in Solid Tumors modified for 
patients with gastrointestinal stromal tumors. 
MRI 
Magnetic resonance imaging 
MTD 
Maximum tolerated dose 
NCCN 
National Comprehensive Cancer Network  
NCI 
National Cancer Institute 
ORR 
Overall response rate 
OS 
Overall survival 
PD 
Pharmacodynamic(s) 
PDGFRα 
Platelet-derived growth factor receptor alpha 
PDX 
Patient derived xenograft 
PFS 
Progression-free survival 
PK 
Pharmacokinetic(s) 
PO 
Per os (by mouth; orally) 
PR 
Partial response  
PR (ECG interval) 
Time elapsed from the P wave to the R wave 
PS 
Performance status 
QD 
Once daily 
QRS 
time elapsed from the Q/R wave to the end of the S wave 
QT 
Interval between the Q/R wave and T wave 
QTc 
QT interval corrected for heart rate 
QTcF 
QT interval corrected using Fridericia’s formula 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 28 of 110
 
 
28 February 2018
 
R 
Accumulation ratio 
RP2D 
Recommended Phase 2 dose 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
STD10 
Severely toxic dose for 10% of animals 
t½  
Terminal half-life 
TKI 
Tyrosine kinase inhibitor 
Tmax 
Time to maximum plasma drug concentration 
Tlast 
Time of last quantifiable plasma drug concentration 
ULN 
Upper limit of normal 
Vz/F 
Apparent volume of distribution 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 29 of 110
28 February 2018
1 INTRODUCTION AND RATIONALE 
1.1 
Background 
Gastrointestinal Stromal Tumor 
Gastrointestinal stromal tumors (GIST) are thought to develop from the interstitial cells 
of Cajal or their stem cell precursors. They are the most common mesenchymal tumors 
occurring in the gastrointestinal (GI) tract, representing approximately 0.1% - 3.0% of all 
GI malignancies (Miettinen et al, 2006; Rammohan et al, 2013). GIST is most commonly 
diagnosed between the ages of 50 and 80 years, with a slight predilection for males 
(Nilsson et al, 2005).  
GISTs may develop at any point along the GI tract, with the stomach (60%) and small 
intestine (30%) being the most common locations; the remaining 10% of GIST arise from 
the esophagus, colon, rectum, or the mesentery (Nilsson et al, 2005). GIST most 
commonly presents with GI bleeding, with obstruction or acute tumor rupture occurring 
more rarely (Rammohan et al, 2013). Slightly fewer than half of patients with GIST 
present with high-risk characteristics, such as large size, local infiltration, and/or 
metastasis (Goettsch et al, 2005; Nilsson et al, 2005). GIST typically progresses by local 
extension from its site of origin, intra-peritoneal spread, and metastases to the hepatic 
parenchyma. Metastases to lymph nodes are rare. 
Surgery is the primary treatment for patients with resectable or potentially resectable 
GIST with the goal being to obtain histologically negative margins. GIST is not 
considered sensitive to either systemic cytotoxic chemotherapy or radiation therapy. 
Molecular Pathology of GIST 
Approximately 90% of patients with newly diagnosed GIST have a tumor that is 
dependent on a mutation in either V-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog (KIT) (75-80%) or the highly related protein platelet-derived growth 
factor receptor alpha (PDGFRα) (10-15%) (Antonescu et al, 2005; Barnett et al, 2012; 
Corless et al, 2005). A majority of mutations in PDGFRα occur at amino acid 842, with 
the most common mutation at this site being a substitution of valine for aspartic acid 
(D842V). The remaining cases, denoted as KIT and PDGFRα wild-type, are due to other 
abnormalities such as succinate dehydrogenase deficiency (Nannini et al, 2013). 
KIT-mutated GIST 
On a molecular level, the most common sites for mutations in KIT at the time of 
diagnosis are exon 11 (60-70%) and exon 9 (5-15%), though exon 17 mutations are 
identified in approximately 1% of patients (Heinrich et al, 2008; Debiec-Rychter et al, 
2006). Disease progression during treatment with a tyrosine kinase inhibitor (TKI) is 
most commonly due to the emergency of resistance mutations in KIT, including an 
increasing prevalence of those in exon 17, which are refractory to standard first and 
second line therapy, imatinib and sunitinib. At the time of progression on first-line TKI 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 30 of 110
 
 
28 February 2018
 
(imatinib) therapy approximately 20-25% of patients had GIST harboring a mutation in 
exon 17; this increased to 95-99% following second-line TKI therapy (Liegl et al, 2008; 
Wardelmann et al, 2006; Antonescu et al, 2005). No currently approved TKI selectively 
inhibits mutations in exon 17 of KIT.  
There are no agents approved to treat GIST after failure of regorafenib as no currently 
approved TKI selectively inhibits mutations in exon 17 of KIT, though other options, 
including sorafenib, nilotinib, dasatinib (for patients with the PDGFRα D824V mutation), 
and pazopanib are included in the National Comprehensive Cancer Network (NCCN) 
guidelines based on limited data (NCCN Soft Tissue Sarcoma Guidelines, 2015).  
Avapritinib (also known as BLU-285) has potent activity on the KIT activation loop 
mutants with biochemical half-maximal inhibitory concentration (IC50) against all 
activation-loop mutants (exons 17 and 18) of less than 2 nM. In context of primary KIT 
exon 11 mutations, the avapritinib biochemical IC50 against the predominant resistance 
mutation in exon 13 (V654A) is 11-nM. In addition, considerable avapritinib activity 
below 30 nM is retained in combinations of exons 11 14 mutations. Due to its high 
selectivity, avapritinib is well tolerated. Therefore, avapritinib can be dosed to cover a 
wide array of disease-relevant KIT mutants found in GIST patients. It is projected that 
the achieved RP2D of 300 mg avapritinib described in Section 1.4 will cover primary 
exon 11 mutants observed in imatinib-naïve GIST as well as combinations of exon 11 
with acquired resistance mutations in exons 13, 14, 17, or 18 in the post-imatinib setting. 
Pharmacokinetic data from the ongoing BLU-285-1101 Phase 1 dose escalation and 
expansion cohorts support these assumptions.  
Although imatinib is effective in many patients with GIST as first-line therapy, many 
patients do not respond and subsequent lines of therapy for those who respond are 
significantly less effective. Therapeutic failure appears linked to acquired resistance 
mutations, particularly those involving the ATP binding pocket (exons 13 and 14) and 
activation loop (exons 17 and 18) of KIT. (Heinrich MC et al, 2008). Post-imatinib, 
ATP-binding pocket mutations and activation-loop mutations occur at a rate of ~30% and 
~20%, respectively. Thirty-five percent of patients progress on imatinib without 
secondary mutations (mostly with KIT exon 9 mutations). The remainder of GIST 
patients who are unresponsive to imatinib harbor alterations in PDGFRα or SDH. In 
KIT-mutant GIST, the response rate for patients with tumors bearing ATP-binding pocket 
mutations to sunitinib is rather low (ORR 11%) and absent in activation-loop mutations 
(ORR 0%; Heinrich MC et al, 2008). Thus, patients failing imatinib due to either 
ATP-pocket or activation-loop mutations, represent an important medical need. The 
results observed thus far in this ongoing Phase 1 trial with avapritinib demonstrate 
important antitumor activity, including radiographic response with a disease-control rate 
of 56% based on central review (PR+SD) and prolonged PFS of 9.3 months in patients 
with heavily pretreated, KIT-mutant GIST. In this heavily pretreated population, imatinib 
rechallenge has shown a median PFS of 1.8 months (Kang et al, 2013). Based on these 
findings, an investigation of avapritinib, a potent and highly selective inhibitor of the 
post-imatinib mutants found in GIST, is warranted. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 31 of 110
28 February 2018
In the second-line GIST setting, sunitinib is the only approved TKI. A statistically 
significant improvement in PFS was demonstrated among patients treated with sunitinib 
compared with patients who received placebo (6.4 months vs 1.5 months; hazard ratio 
0.33). No patients in either group had a complete response (CR), while 14 of the 207 
patients in the sunitinib group and none of the 105 patients in the placebo group had a 
partial response (PR), giving ORRs of 6.8% and 0%, respectively. (Goodman et al, 
2007). The benefit of sunitinib in the second-line setting is considered modest 
post-imatinib progression, and treatment is associated with various severe toxicities. The 
most common adverse events (AEs) related to sunitinib included diarrhea, mucositis, skin 
abnormalities, and altered taste. Severe hypertension and reductions in left ventricular 
ejection fraction were also more common in sunitinib-treated patients. Even though 
sunitinib may be potent against the wild-type KIT kinase compared to first-line therapy, 
resistance to sunitinib usually evolves within 1 year of treatment.  
PDGFRα-mutated GIST 
Gastrointestinal stromal tumors dependent on mutations in PDGFRα occur more 
frequently in the stomach, are more commonly resectable, have a somewhat more 
indolent clinical course than KIT-dependent GIST, and are less 2-deoxy-2-[fluorine-
18]fluoro-D-glucose positron emission tomography (18FDG-PET) avid compared to
GIST dependent on a mutation in KIT (Matro, 2014). Despite the more indolent course
while localized, once metastatic, patients with GIST harboring the PDGFRα D842V
mutation have an extremely poor prognosis and respond poorly to imatinib and other
TKIs (Cassier et al, 2012; Yoo et al, 2015; Goodman et al, 2007; Heinrich et al, 2008).
In a retrospective study, Cassier et al identified 44 patients with PDGFRα-mutant GIST 
who had advanced disease from databases at 12 European institutions (N = 3,510 
genotyped GIST patients) and an additional 16 patients with advanced, PDGFRα-mutant 
GIST from the European Organisation for Research and Treatment of Cancer (EORTC) 
advanced GIST database (N = 465 genotyped GIST patients). Of 58 patients evaluable 
for efficacy post-imatinib, 32 patients (55%) had the PDGFRα D842V mutation and the 
remainder had mutations in PDGFRα Exon 4, 12, or 18 (non-D842V). The non-D842V 
patients had an overall response rate (ORR) of 36% with imatinib and median PFS > 1 
year. In contrast, patients with the D842V-mutation had no response (ORR = 0%). 
Median PFS with second-line treatment was short (2.1 months) and was not significantly 
different between imatinib, sunitinib, and other treatments. Similarly, in a small, 
retrospective Korean study (N = 18) PDGFRα-mutant GIST patients treated with 
imatinib reported a similar PDGFRα D842V prevalence (9/18; 50%) and poor outcome 
(median PFS 3.8 months and ORR 0% [0/5 evaluable patients]). Patients with the D842V 
substitution treated with sunitinib as second-line therapy reported median PFS 1.9 months 
and ORR 0% (Yoo et al, 2015). 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 32 of 110
28 February 2018
As there are no approved agents that target PDGFRα D842 mutations, unresectable 
PDGFRα-driven GIST represents a high, unmet medical need. 
1.1.1 
Preclinical Pharmacology 
BLU-285 was designed as a potent, selective, small molecule inhibitor of the KIT 
containing mutations in exon 17, and PDGFRα containing mutations at D842V, which 
mediate ligand independence. It has demonstrated biochemical in vitro activity on the 
KIT exon 17 mutant enzyme, KIT D816V (half-maximal inhibitory concentration 
[IC50 = 0.27 nM]) and the homologous mutant PDGFRα D842V (IC50 = 0.24 nM). These 
mutations result in resistance to the TKI used to treat GIST: imatinib, sunitinib, and 
regorafenib (Table 1). 
Table 1: 
Biochemical Activity of BLU-285 and GIST Agents against KIT 
Exon 17 D816V and PDGFRα D842V Mutants 
Compound 
PDGFRα D842V 
IC50 (nM) 
KIT D816V 
IC50 (nM) 
BLU-285 
0.24 
0.27 
Sunitinib 
118 
191 
Regorafenib 
825 
3619 
Imatinib 
656 
8481 
Abbreviations: GIST = gastrointestinal stromal tumors; IC50 = half-maximal inhibitory concentration of 
enzyme activity; KIT = V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog; 
PDGFRα = platelet-derived growth factor receptor alpha. 
The selectivity of BLU-285 was characterized across a panel of over 450 human kinases 
and disease-relevant kinase mutants. BLU-285 demonstrated the highest affinity for KIT 
exon 17 mutants (KIT D816V dissociation constant [Kd] = 0.3 nM; KIT D816H 
Kd = 0.6 nM), and also bound a small group of highly related class III receptor tyrosine 
kinases: KIT wild type (Kd = 17 nM), PDGFRα wild type (Kd = 1 nM), platelet-derived 
growth factor receptor beta wild type (Kd = 1 nM), colony stimulating factor 1 receptor 
(Kd = 6 nM), and FMS-like tyrosine kinase 3 (Kd = 25 nM). All other kinases 
demonstrated Kd values greater than 50 nM. These data demonstrated that BLU-285 is 
selective for the KIT exon 17 mutant proteins specifically and has limited potential for 
activity outside of the related class III receptor tyrosine kinases (Report BPM-0002). 
In vitro, BLU-285 was noted to inhibit the growth of the human mast cell leukemia cell 
line HMC1.2 (dependent on KIT D816V) and the mouse mastocytoma cell line P815 
(dependent on the mouse homolog of the human KIT D816Y mutant). Additionally, 
BLU-285 inhibited signaling of the oncogenic and ligand-independent PDGFRα D842V 
when expressed in an engineered cell line, a model against which imatinib is inactive. In 
each of these model systems, BLU-285 demonstrated dose-dependent inhibition of KIT 
exon 17 or PDGFRα D842V as well as inhibition of key downstream effector pathways 
known to be involved in tumorigenesis. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 33 of 110
28 February 2018
In vivo, anti-tumor efficacy of BLU-285 was demonstrated in a P815 mastocytoma 
xenograft and an imatinib-resistant mutant GIST patient-derived xenograft (PDX) tumor 
model, both of which are driven by exon 17 mutant KIT (Figure 1). In the P815 model, 
robust antitumor activity was demonstrated in animals treated with doses (10 or 
30 mg/kg) of BLU-285 that were well tolerated, as noted by a lack of impact on body 
weight. 
Figure 1: 
Efficacy of, and Body Weight Measurements for, BLU-285 in a 
KIT Exon 17 Mutant Driven P815 Xenograft Model 
Abbreviations: BID = twice daily; KIT = v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog; PO = per os (orally); QD = once daily. 
Mice bearing P815 xenograft tumors were dosed PO, QD with vehicle, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 
10 mg/kg, or 30 mg/kg BLU-285 or 25 mg/kg dasatinib BID.  
Left panel: A dose-dependent decrease in tumor growth was observed with PO, QD oral dosing of BLU-
285. 10 mg/kg and 30 mg/kg BLU-285 PO, QD dosing produced complete tumor growth inhibition with
several tumor regressions over the 10-day dosing period. Due to the aggressive disease course, all vehicle-
treated mice were euthanized after 10 days of dosing due to disease-related moribundity. Statistical
significance of tumor growth inhibition was determined with the 10 mg/kg or 30 mg/kg dose of BLU-285
and was highly statistically significant (P < 0.001 as measured by one-way analysis of variance).
Right panel: All doses of BLU-285 were well tolerated as indicated by body weight measurements. Data
points represent group mean and error bars represent standard error of the mean for 10 mice per cohort.
In the GIST PDX model, BLU-285 administered orally (PO) for 27 days resulted in 
antitumor activity sustained for 4 weeks after the completion of BLU-285 dosing, with 
demonstrated inhibition of both KIT activity and downstream signaling (Figure 2). 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 34 of 110
28 February 2018
Figure 2: 
Efficacy of BLU-285 and Inhibition of KIT Exon 11/Exon 17 
Mutant Signaling in a GIST Patient-Derived Xenograft Model 
Abbreviations: Akt = v-akt murine thymoma viral oncogene homolog; ERK = extracellular signal-regulated 
kinase; GIST = gastrointestinal stromal tumor; KIT = v-Kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog; p = phosphorylated; PDX = patient-derived xenograft; QD = once daily. 
Mice bearing KIT exon 11/exon 17 mutant GIST PDXs were dosed once daily, orally with vehicle, 
30 mg/kg, or 100 mg/kg BLU-285 for 27 days.  
Left panel: Tumor growth was measured twice weekly for the 27-day dosing period followed by a 28-day 
observation period. BLU-285 induced tumor regression and sustained tumor growth inhibition at both 
doses tested. BLU-285 antitumor activity was highly statistically significant (P < 0.0001 by one way 
analysis of variance). Data points represent group mean and error bars represent standard error of the mean 
for 9 mice per cohort.  
Right panel: After 7 days of once-daily dosing with vehicle, 30 mg/kg BLU-285, or 100 mg/kg BLU-285, 
tumors were harvested from 3 mice per group, 24 hours after the last dose. Tumor homogenates 
demonstrated inhibition of KIT signaling by analysis of KIT autophosphorylation and the downstream 
signaling markers p-ERK and p-AKT. 
Safety pharmacology studies revealed that BLU-285 inhibits the human ether-a-go-go 
related gene channel activity in vitro with an average IC50 of 2.4 µM by single cellular 
electrophysiologic recordings. BLU-285 was further evaluated in a cardiovascular safety 
pharmacology study in conscious radiotelemetry-instrumented male Beagle dogs to 
assess the effects of electrocardiogram (ECG) intervals, as well as blood pressure, body 
temperature, and respiratory parameters. Administration of BLU-285 at dose levels of 15, 
30, or 45 mg/kg did not result in BLU-285-related effects on any cardiovascular 
parameter, including ECG waveform morphology, duration of time elapsed from the P 
wave to the R wave (PR), time elapsed from the Q/R wave to the end of the S wave 
(QRS), time between consecutive R waves, interval between the Q/R wave and T wave 
(QT), and QT interval corrected using van de Water’s formula intervals, body 
temperature, or respiratory parameters. 
A Good Laboratory Practice (GLP)-compliant study performed to evaluate the effects of 
BLU-285 on the gross behavioral, physiological, and neurological state of female 
Sprague-Dawley rats (Irwin test) demonstrated, in a minority of animals, an increase in 
sensitivity to stimuli that are potentially underlying indicators of preconvulsive activity at 
the mid and high doses; no BLU-285 related effects were noted at the lowest dose level 
tested. In a separate study performed in conscious radiotelemetry-instrumented male 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 35 of 110
28 February 2018
Beagle dogs, no effects of BLU-285 were noted on any cardiovascular or respiratory 
parameter, or the clinical condition of the animals. 
1.1.2 
Toxicology 
Sprague-Dawley rats and Beagle dogs were chosen as the nonclinical test species for 
assessing chemical structure- and pharmacology-mediated toxicity of BLU-285 on the 
basis of the following criteria: a) these species are pharmacologically responsive to the 
effects of BLU-285; b) these species have historically been used to assess potential 
human adverse effects, and; c) these species are qualitatively similar in hepatocyte 
metabolism profiles to humans. 
Good Laboratory Practice-compliant 28-day repeated dose toxicology studies were 
conducted in Sprague-Dawley rats. The cause of morbidity and/or mortality was 
considered to be inanition and metabolic perturbations, as evidenced by body weight 
losses, decreased food consumption, serum and urine chemistry parameter alterations, 
and tissue effects. The severely toxic dose in 10% of animals (STD10) was 30 mg/kg/day 
(180 mg/m2/day). Convulsions were occasionally observed at doses above the STD10. 
Hematologic effects were observed, specifically depressed erythron, myeloid, and 
lymphoid parameters. Serum chemistry effects included increases in total bilirubin (likely 
secondary to impaired bile acid transport), mild to moderate increases in liver enzymes 
(without microscopic evidence of hepatic toxicity), and altered parameters suggesting 
impaired metabolism such as total cholesterol and serum cations. There were no 
morphologic brain alterations.  
An additional non-GLP-compliant study was conducted in female rats to determine if the 
oral administration of BLU-285 evokes changes in electroencephalographic (EEG) 
measures consistent with seizures or altered seizure threshold. Administration of 
BLU-285 at 15 mg/kg or 30 mg/kg for 9 consecutive days did not result in a frank seizure 
or consistent pattern of EEG suggestive of lowered seizure threshold. Increased 
sensitivity to BLU-285 at 50 mg/kg was noted in two rats, one that developed sharp 
waves after the first day of dosing and another that had a frank seizure on the ninth day of 
dosing. 
In a 28-day GLP-compliant toxicology study in male Beagle dogs, the dose-limiting 
effects were inanition and metabolic perturbations with vomiting, diarrhea, decreased 
food intake, body weight loss, hematologic and serum chemistry perturbations, and 
microscopic alterations in tissues. In addition, in the dog brain, a focal area of 
hemorrhage with vascular thrombus occurred at 30 mg/kg/day (reduced to 15 mg/kg/day) 
that may be associated with thrombocytosis and/or potential pharmacologic effects on the 
pericyte affecting vascular integrity. The highest non-severely toxic dose (HNSTD) was 
7.5 mg/kg/day (150 mg/m2/day). The microscopic effects in the brain had no effect on 
clinical examinations; specifically, no neurologic effects were observed during in-life 
observations. All findings reversed after the 2-week recovery period, except those in the 
gonad (hypospermatogenesis) and brain. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 36 of 110
28 February 2018
Subsequent 3-month GLP-compliant toxicology studies are currently ongoing in 
Sprague-Dawley rats and Beagle dogs to further characterize the dose-limiting toxicities 
(DLTs). Preliminary data are available from the study in dogs. At the high dose 
(30 mg/kg/day) tested in dogs, severe brain effects (including neurologic signs and brain 
and spinal cord hemorrhages) were noted in all animals. No neurologic signs or 
test-article related mortality occurred in dogs treated at the mid dose (15 mg/kg/day) or at 
the HNSTD (7.5 mg/kg/day). 
Additional information can be found in the Investigator’s Brochure (IB) for BLU-285. 
1.2 
Study Rationale 
Targeting KIT exon 17 and PDGFRα D842 mutants with small molecule inhibitors has 
had limited success due to difficulties in creating potent molecules with sufficient 
selectivity; there are currently no approved agents that selectively target these mutant 
kinases. BLU-285 is a potent, selective, small molecule inhibitor of the 
ligand-independent KIT exon 17 and PDGFRα D842 mutants, significantly more potent 
against these targets than imatinib, sunitinib and regorafenib (Table 1).  
BLU-285 has been shown to be tolerable at active doses in toxicology and safety 
pharmacology studies. Given the poor prognosis of patients with advanced GIST that has 
progressed after kinase-inhibitor therapy or that harbors a PDGFRα D842 mutation, 
along with the potential benefit/risk of BLU-285 in these patients, further development of 
this agent is warranted. The present clinical trial is a Phase 1, first-in-human (FIH) study 
of BLU-285 consisting of dose escalation (Part 1) and expansion (Part 2) parts. The 
objectives of Part 1 are to define the safety and tolerability of BLU-285, identify the 
maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), and to 
characterize the pharmacokinetics (PK) and pharmacodynamics (PD), and preliminary 
antineoplastic activity of BLU-285.  
Part 2 will begin once an MTD or RP2D has been determined in Part 1, and will permit a 
more complete assessment of safety, PK, PD, and antitumor activity in patients with 
GIST. Three groups of patients will be enrolled: 1) patients with GIST that has 
progressed following treatment with imatinib and at least 1 other kinase-inhibitor therapy 
(N~100); 2) patients with GIST harboring a D842V mutation in the PDGFRα gene, 
regardless of prior therapy (N~35); and 3) patients with GIST that has progressed and/or 
patients who experienced intolerance to imatinib and have not received additional kinase-
inhibitor therapy (N~50). This will permit assessment of antitumor activity in each of 
these populations of treatment-refractory GIST. Additionally, approximately 20 patients 
at selected sites will be evaluated with ECGs extracted from Holter monitoring to 
evaluate the effect of BLU-285 on ECG parameters in Groups 1 and 2. Analysis of 
safety, tolerability, PK, PD, and preliminary antitumor activity will help guide the future 
clinical development of BLU-285. In Part 2 of the study ORR, the primary measure of 
antitumor activity, will be evaluated for all patients, to determine if the observed ORR 
excludes a true ORR ≤ 10%, with 2-sided type I error of 0.05. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 37 of 110
 
 
28 February 2018
 
This study will be conducted in compliance with the protocol, Good Clinical Practice 
(GCP), and the applicable regulatory requirements. 
1.3 
Rationale for the Starting Dose and Dosing Regimen 
Selection of the safe starting dose in clinical trials for anticancer small molecules is based 
on either one-tenth the allometrically scaled STD10 in the most sensitive species (female 
rat) based on the administered dose, or one-sixth the allometrically scaled HNSTD in the 
other species (dogs) if they cannot tolerate one-tenth of the allometrically scaled rat 
STD10. The STD10 in the female rat is 30 mg/kg/day or 180 mg/m2/day, one-tenth of 
which equals 18 mg/m2/day. The HNSTD in the dog is 7.5 mg/kg/day or 150 mg/m2/day, 
indicating that the dog can tolerate one-tenth of the rat STD10. Therefore, the safe starting 
dose for this FIH Phase 1 trial will be 18 mg/m2/day, which equals a flat dose of 
30 mg/day based on a 1.7 m2 human body surface area. Based on a calculated elimination 
half-life of 22 hours, once daily (QD) dosing is appropriate. 
1.4 
BLU-285-1101 Study Update  
On 14 February 2017, the MTD for the BLU-285-1101 study was determined to be 
400 mg QD. Thirty-eight patients have initiated treatment in the dose expansion part 
(Part 2) of the study at 400 mg per day. However, based on a joint Investigator and 
Sponsor review of the available safety, PK, PD, and clinical activity data on 13 June 
2017, a new starting dose of 300 mg QD was selected as the initiation dose of avapritinib 
for the remainder of the expansion part of the study. There was an option of dose 
escalation to 400 mg after 2 consecutive treatment cycles in adherence with Section 6.4.3, 
Dose Modifications, if avapritinib was well tolerated. 
As of 11 October 2017, a total of 116 patients were treated with avapritinib at starting 
doses of 30 to 600 mg, including 46 patients enrolled in Part 1, dose escalation, and 
70 patients enrolled in Part 2, dose expansion. Thirty-seven (32%) patients had PDGFRα 
Exon 18 D842 mutation (34 D842V, 1 D842Y, 1 DI 842-843V, and 1 D842H845), 2 
(2%) patients had PDGFRα Exon 14 N659K mutation, 76 (66%) had KIT mutations, and 
1 patient was KIT and PDGFRα wild type.  
Response was assessed using Response Evaluation Criteria in Solid Tumors, version 1.1 
modified for patients with GIST (mRECIST version 1.1) based on blinded central review 
of CT/MRI scans. Of the 31 PDGFRα D842 patients with ≥ 1 radiographic assessment, 
1 (3%) patient had CR (pending confirmation), 21 (68%) patients had PR (18 confirmed 
and 3 pending confirmation). The ORR was 71% (95% CI: 52% - 86%). The remaining 
9 patients had stable disease (SD) as their best response, resulting in a disease control rate 
of 100% (Table 2). Median duration of response (DOR) among PDGFRα D842 
responders had not been reached, the estimated 1-year DOR rate was 65%. Of the 43 KIT 
patients with ≥ 1 radiographic assessment, 6 (14%) patients had PR (5 confirmed and 1 
pending confirmation). The ORR was 14% (95% CI: 5% - 28%). Twenty-three (53%) 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 38 of 110
 
 
28 February 2018
 
had SD, resulting in a DCR of 67% (Table 2). All 6 responders were still on treatment at 
the time of the data cut off, with DOR ongoing and ranging from 3 to 16 months. 
Table 2: 
Best Radiological Response with BLU-285 by Central 
Assessment per mRECIST Version 1.1 
Best Response a  
PDGFRα D842 
(N=31)  
n (%) 
KIT 
(N=43)  
n (%) 
CR 
1 (3)b 
0 
PR 
21 (68)c  
6 (14)d 
ORR (CR + PR) 
22 (71) 
6 (14) 
SD 
21 (68) 
23 (53) 
DCR (PR + SD)  
31 (100) 
29 (67) 
PD 
0 
14 (33) 
Abbreviations: DCR = disease control rate; KIT = v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog; mRECIST = Response Evaluation Criteria in Solid Tumors modified for patients with GIST; PD 
= progressive disease; PDGFRα = platelet-derived growth factor receptor alpha; PR = partial response; SD 
= stable disease. 
a  Per mRECIST 1.1 based on central radiology review with data cutoff of 11 October 2017. 
b  1 pending confirmation 
c  3 pending confirmation 
d  1 pending confirmation 
Eighty-three of the 116 patients started at a dose level of 300 mg QD (RP2D, n=33) or 
400 mg QD (MTD, n=50), including 18 PDGFRα D842 patients, 1 PDGFRα Exon 14 
patient, and 64 KIT patients. Twelve of the 18 PDGFRα D842 patients had ≥ 1 
radiographic assessment, 10 patients had PR, the ORR was 83%. Thirty of the KIT 
patients had ≥ 1 radiographic assessment, 5 patients had PR, the ORR was 17%. Median 
PFS among the 64 KIT patients was 11.5 months (95% CI: 9.3 months – not estimable). 
The estimated 6-month PFS rate was 69%.  
As of the 11 October 2017, 67 patients remained on treatment (31 PDGFRα patients and 
36 KIT patients). Forty-nine patients discontinued study treatment, including 6 patients 
due to adverse events, 40 patients due to disease progression, and 3 patients withdrew 
consent.  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 39 of 110
 
 
28 February 2018
 
Table 3: 
Overall Summary of Adverse Events by Severity and 
Relationship in ≥ 20% of Patients (BLU-285-1101, Safety 
Population, N=116)  
Safety Population 
N=116 
Severity 
n (%) 
Relationship 
n (%) 
Preferred Term 
Any Events 
n (%) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Related 
Patients with at least 1 AE 
112 (97) 
 
 
 
 
 
 
Nausea 
65 (56) 
41 (35) 
17 (15) 
7 (6) 
0 
0 
62 (53) 
Fatigue 
62 (53) 
23 (20) 
31 (27) 
8 (7) 
0 
0 
56 (48) 
Periorbital edema 
50 (43) 
42 (36) 
8 (7) 
0 
0 
0 
49 (42) 
Vomiting 
48 (41) 
36 (31) 
9 (8) 
3 (3) 
0 
0 
39 (34) 
Edema peripheral 
39 (34) 
28 (24) 
9 (8) 
2 (2) 
0 
0 
32 (28) 
Anemia 
36 (31) 
7 (6) 
10 (9) 
17 (15) 
2 (2) 
0 
23 (20) 
Diarrhea 
36 (31) 
26 (22) 
8 (7) 
2 (2) 
0 
0 
26 (22) 
Cognitive Effectsa 
35 (30) 
20 (17) 
10 (9) 
4 (3) 
1 (1) 
0 
32 (28) 
Lacrimation increased 
35 (30) 
29 (25) 
6 (5) 
0 
0 
0 
31 (27) 
Decreased appetite 
33 (28) 
24 (21) 
6 (5) 
3 (3) 
0 
0 
28 (24) 
Dizziness 
27 (23) 
21 (18) 
6 (5) 
0 
0 
0 
15 (13) 
Constipation 
25 (22) 
18 (16) 
6 (5) 
0 
1 (1) 
0 
8 (7) 
Hair color changes 
25 (22) 
24 (21) 
0 
0 
0 
0 
25 (22) 
Abbreviation: AE = adverse event. 
a Cognitive Effects include the following preferred terms: cognitive disorder, confusional state, disturbance 
in attention, memory impairment, mental impairment, personality change, and speech disorder. 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 40 of 110
28 February 2018
2 STUDY OBJECTIVES 
2.1 
Primary Objectives: 
2.1.1 
Part 1 
•
To determine the MTD and RP2D of avapritinib.
•
To determine the safety and tolerability of avapritinib.
2.1.2 
Part 2 
•
To determine the overall response rate (ORR) by mRECIST version 1.1 criteria at the
MTD/RP2D of avapritinib in patients with GIST who have a D842V mutation in
PDGFRα.
•
To determine the ORR by mRECIST version 1.1 criteria at the MTD/RP2D of
avapritinib in patients with GIST that has progressed following treatment with
imatinib and at least another kinase-inhibitor agent, and who are not known to have a
D842V mutation in PDGFRα.
•
To determine the ORR by mRECIST version 1.1 criteria at the MTD/R2PD of
avapritinib in patients with GIST who have progressed or who experienced
intolerance to imatinib, including in the adjuvant setting, and who have not received
additional kinase-inhibitor therapy and do not have a known D842V mutation in
PDGRα.
•
To determine the safety and tolerability of avapritinib.
2.2 
Secondary Objectives 
•
To characterize the PK profile of avapritinib, and correlate drug exposure with safety
assessments, including changes in ECG intervals.
•
To assess evidence of antineoplastic activity of BLU-285 as measured by DOR,
progression free survival (PFS), and clinical benefit rate (CBR).
•
To assess antitumor activity as measured by Choi Criteria.
•
To compare PFS on avapritinib with PFS on last prior anti-cancer therapy.
•
To assess mutations in KIT, PDGFRα, and other cancer-relevant genes in tumor
tissue at baseline and at the end of treatment (EOT).
•
To assess the KIT, PDGFRα and other cancer relevant gene mutant allele fractions
measured in circulating tumor deoxyribonucleic acid (ctDNA) at baseline, and the


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 41 of 110
28 February 2018
biologic activity of avapritinib based on changes in the mutant allele fractions 
measured in ctDNA. 
 
 
 
. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 42 of 110
28 February 2018
3 STUDY ENDPOINTS 
3.1 
Primary Endpoints 
3.1.1 
Part 1 
•
MTD and RP2D of avapritinib.
•
Overall safety profile of BLU-285, as assessed by the type, frequency, severity,
timing, and relationship to study drug of any AEs, serious AEs (SAEs), and changes
in vital signs, ECGs, and safety laboratory tests.
3.1.2 
Part 2 
•
ORR, defined as the rate of confirmed CR or PR by mRECIST version 1.1.
•
Overall safety profile of avapritinib, as assessed by the type, frequency, severity,
timing, and relationship to study drug of any AEs, SAEs, and changes in vital signs,
ECGs, and safety laboratory tests.
3.2 
Secondary Endpoints 
•
PK parameters of avapritinib: Maximum plasma drug concentration (Cmax), time to
maximum plasma drug concentration (Tmax), time of last quantifiable plasma drug
concentration (Tlast), area under the plasma concentration versus time curve from time
0 to 24 hours postdose (AUC0-24), plasma drug concentration at 24 hours postdose
(C24); apparent volume of distribution (Vz/F), terminal elimination half-life (t½),
apparent oral clearance (CL/F), accumulation ratio (R), and correlations between PK
parameters and safety findings of interest, including ECG intervals.
•
DOR, PFS, and CBR, as per mRECIST version 1.1 (Appendix 1).
•
Response rate as defined by Choi Criteria.
•
PFS on last prior anti-cancer therapy.
•
KIT, PDGFRα, and other cancer-relevant mutations present in tumor tissue at
baseline and EOT.
•
Change from baseline in the levels of KIT, PDGFRα, and other cancer-relevant
mutant allele fractions in peripheral blood.
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 43 of 110
28 February 2018
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 44 of 110
28 February 2018
4 STUDY PLAN 
4.1 
Study Design 
This is a Phase 1, open-label, FIH dose-escalation study designed to evaluate the safety, 
tolerability, PK, PD and preliminary antineoplastic activity of BLU-285, administered PO 
in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The 
study schematic is shown in Section 4.2. 
The study consists of 2 parts: dose-escalation part (Part 1) and expansion (Part 2). 
All study visits are intended to be conducted on an outpatient basis, but may be 
conducted on an inpatient basis as needed. After provision of written informed consent, 
patients will be evaluated for study eligibility during the Screening period within 56 days 
(8 weeks) before study drug administration on Day-3 for patients participating in Part 1 
or Cycle 1 Day 1 (C1D1) for patients participating in Part 2. 
A treatment cycle is 28 days in duration. In order to better evaluate the half-life of BLU-
285, which is predicted to be long, patients in Part 1 (Dose-Escalation) will participate in 
a 3-day PK-Lead in stage.  
In Part 1, patients will present to the study center on Day -3 for the first dose of study 
drug and serial PK sampling, PD sample collection, vital sign measurement, ECG 
monitoring, safety monitoring and AE recording. The dose received on D-3 will be the 
dose of the patient’s assigned cohort. Patients will return on days -2, -1, and 1 (24, 48, 
and 72 hours after study drug administration) for PK sampling and safety monitoring. 
Patients will not receive BLU-285 on Days -2 and -1. Immediately after the 72-hour PK 
sample is obtained, the C1D1 dose will be administered, and daily dosing will begin.  
Patients in Part 2 (Expansion) will present to the study center on C1D1 for the first dose 
of study drug and serial PK sampling (Groups 1 and 2), PD sample collection, vital sign 
measurement, ECG monitoring, safety monitoring and AE recording. Approximately 
20 patients in Groups 1 and 2, at selected sites will participate in continuous ECG 
(Holter) monitoring for extraction of ECGs at the times of PK sampling; Holter 
recordings will be collected in Cycle 1 on Days 1, 2, and 15. 
During Cycle 1 (C1), following the PK Lead-in (Part 1), patients are to attend study 
center visits on C1D1 (Parts 1 and 2), Days 8, 15, and 22 (Part 1), and Days 2 (Part 2, 
Groups 1 and 2) and 15 (Part 2). On C1D8 and C1D22, patients will undergo safety 
monitoring, and on C1D15 safety monitoring and dense PK sampling (Part 1). On Day 15 
(Part 2), patients will undergo simplified safety monitoring, and dense PK sampling 
(Groups 1 and 2), and sparse PK sampling (Group 3). 
During Cycle 2 (C2), all patients are to attend study center visits on Day 1 (D1) and 
Day 15 (Part 1), and on Day 1 only (Part 2) for safety monitoring and PK blood draws, 
and then on D1 of subsequent cycles. After C2, patients will return to the study center on 
Day 1 of each subsequent cycle to Cycle 13 for safety monitoring and (through Cycle 4 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 45 of 110
28 February 2018
Day 1) PK blood draws. After C2 (C3D1) and every 2 cycles thereafter, patient’s tumor 
status will be assessed by computed tomography (CT) or magnetic resonance imaging 
(MRI) through Cycle 13. After 13 cycles have been completed on trial, patients are to 
attend study center visits every 3 cycles on Day 1 for safety monitoring and a tumor 
status assessment (e.g., C16D1, C19D1, C22D1). This decreases the visit frequency and 
radiation exposure to the patient.  
It is anticipated that patients will receive at least 1 cycle of BLU-285; no maximum 
treatment duration has been set. After C1, patients may continue to receive BLU-285 
until precluded by toxicity, noncompliance, withdrawal of consent, physician decision, 
progressive disease, death, or closure of the study by the Sponsor. 
All patients will attend an EOT visit within 14 (±7) days after the last dose of study drug. 
A safety Follow-up (f/u) telephone contact for resolution of any residual AE will be made 
on Day 30 (+7 days) after the last dose of study drug, or at the time the patient initiates 
another antineoplastic therapy. Thereafter, patients are to be followed for disease 
assessment, subsequent antineoplastic therapy and survival approximately every 
3 months until death, withdrawal of consent, or closure of the study by the Sponsor.  
The study visits are listed in the Schedule of Assessments and Schedules for PK sample 
collection and ECG monitoring (Table 8, Table 9, and Table 10). 
Part 1 (Dose Escalation) 
The dose escalation part of the study will enroll patients with unresectable GIST or a 
relapsed or refractory solid tumor. Patients with GIST must have disease that has 
progressed following imatinib and at least 1 of the following: sunitinib, regorafenib, 
sorafenib, dasatinib, pazopanib or an experimental kinase-inhibitor agent, or disease with 
a D842 mutation in the PDGFRα gene. Patients with an advanced solid tumor other than 
GIST must have relapsed or refractory disease without an available effective therapy. A 
standard 3+3 dose-escalation design using cohorts of 3 patients will be employed.  
The first cohort of patients will receive BLU-285 at a starting dose of 30 mg QD. The 
dose escalation increment for the first escalation step will be a maximum of 100%; all 
subsequent dose escalation increments will be a maximum of 50%. 
Three patients will be enrolled initially in each cohort and an additional 3 patients (for a 
total of 6) will be enrolled should the cohort require expansion due to DLT. After the 
current escalation cohort is full, up to 3 additional patients, all of whom must have the 
diagnosis of GIST, may be enrolled into an enrichment cohort that included only 3 
patients evaluable for DLT, was reviewed at a dose-escalation meeting, and did not 
exceed the MTD. Enrollment of patients into an enrichment cohort requires written 
approval from the Sponsor. Data from these patients will allow for further exploration of 
PK, PD, and safety in patients with GIST. 
In cohorts in which the administered dose is < 100 mg QD, enrolled patients may have 
the diagnosis of either GIST or a relapsed/refractory solid tumor. To assure that the safety 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 46 of 110
28 February 2018
profile of BLU-285 is adequately described in patients with GIST, at least 2 of 3 patients 
in each cohort (4 of 6 patients if the cohort is expanded) dosed at ≥ 100 mg QD must 
have the diagnosis of GIST. 
The specific dose for each subsequent cohort will be determined at a dose-escalation 
meeting by teleconference that includes the Study Investigators and the Sponsor’s study 
team (including but not limited to the study physician and clinical study manager). The 
dose must be agreed to by the study investigator at each study center and the Sponsor 
Clinical Study Team. Dose-escalation meetings will occur after all patients in the current 
cohort have completed at least 28 days of observation after their first dose of BLU-285, 
or have experienced a DLT. Patients enrolled into enrichment cohorts at lower dose 
levels need not have completed 28 days of observation for a dose-escalation meeting to 
occur.  
Dose escalation will continue until the MTD or a RP2D below the MTD has been 
determined. In addition, based on evaluation of the data, alternative dosing regimens 
(e.g., twice daily [BID]) or schedules (e.g., 3 weeks on, 1 week rest) may be explored. 
Additional details on the dose-escalation process, estimation of the MTD/RP2D, and 
DLTs are provided in Section 6.4. 
Expansion (Part 2) 
Once the MTD or RP2D has been determined, 3 groups of patients with the following 
characteristics will be enrolled and treated with BLU-285:  
•
Group 1: Patients with unresectable GIST that has progressed following treatment
with imatinib and at least 1 of the following: sunitinib, regorafenib, sorafenib,
dasatinib, pazopanib, or an experimental kinase-inhibitor therapy and who do not
have a D842V mutation in PDGFRα (N~100).
•
Group 2: Patients with unresectable GIST harboring a D842V mutation in the
PDGFRα gene (N~35). The PDGFRα mutation will be identified by local and central
assessment, either in archival tissue or a new tumor biopsy obtained, prior to
treatment with BLU-285.
•
Group 3: Patients with unresectable GIST that has progressed and/or those who have
experienced intolerance following treatment with imatinib (including in the adjuvant
setting) and who have not received additional kinase-inhibitor therapy and do not
have a known D842V mutation in PDGFRα (N~50).
Patient safety will be reviewed on an ongoing basis (approximately every 1 – 2 months) 
at a safety review meeting that includes the Study Investigators and the Sponsor Clinical 
Study Team. All safety data collected to date will be reviewed to confirm that no 
unexpected, significant, or unacceptable risks have been discovered. Available tumor 
response, PK, and PD data will also be reviewed.  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 47 of 110
28 February 2018
4.2 
Study Schematic 
Abbreviations: GIST = gastrointestinal stromal tumor; PDGFRα = platelet-derived growth factor 
receptor alpha; R/R = relapsed/refractory; TKI = tyrosine kinase inhibitor. 
GIST (progressed following imatinib and ≥ 1 other TKI 
or a D842 mutation in PDGFRα gene) and R/R solid 
tumors (≥ 100 mg/d) 
 At least 2 (4 if cohort is expanded) patients with GIST 
per cohort 
N~30 
GIST (progressed following imatinib and ≥ 1 
other TKI or a D842 mutation in PDGFRα 
gene) and R/R solid tumors (< 100 mg/d) 
N~20 
GIST 
(progressed 
following imatinib 
and ≥ 1 other TKI) 
N~100 
GIST 
(PDGFRα D842V 
mutant) 
N~35 
Part 1: Dose-Escalation
Part 2:  Expansion 
GIST 
(progressed and/or 
imatinib-intolerant) 
N~50 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 48 of 110
28 February 2018
5 POPULATION 
5.1 
Number of Patients 
Approximately 235 patients will be enrolled in this study, including: 
•
Part 1 (Dose Escalation):
o
Approximately 50 patients with unresectable GIST or other advanced solid
tumors.
•
Part 2 (Expansion):
o
Group 1: Approximately 100 patients with unresectable GIST that has progressed
following treatment with imatinib and at least 1 of the following: sunitinib,
regorafenib, sorafenib, dasatinib, pazopanib, or an experimental kinase-inhibitor
therapy and who do not have a known D842V mutation in PDGFRα.
o
Group 2: Approximately 35 patients with unresectable GIST harboring a D842V
mutation in the PDGFRα gene. The PDGFRα mutation will be identified by local
and central assessment, either in archival tissue or a new tumor biopsy obtained,
prior to treatment with BLU-285.
o
Group 3: Approximately 50 patients with unresectable GIST that has progressed
and/or those who have experienced intolerance following treatment with imatinib
(including in the adjuvant setting) and have not received additional kinase-
inhibitor therapy and do not have a known D842V mutation in PDGFRα.
The total number of patients to be enrolled in Part 1 is dependent upon the observed 
safety profile, which will determine the number of patients per dose cohort, as well as the 
number of dose escalations required to identify the MTD, or a lower RP2D for further 
study in Part 2 if an MTD is not determined. 
5.2 
Inclusion Criteria 
Patients meeting the following criteria will be eligible for participation in the study: 
1. Patient is ≥ 18 years of age.
2. For Part 1: Histologically- or cytologically-confirmed diagnosis of unresectable GIST
or another advanced solid tumor. Patients with unresectable GIST must have disease
that has progressed following imatinib and at least 1 of the following: sunitinib,
regorafenib, sorafenib, dasatinib, pazopanib or an experimental kinase-inhibitor
agent, or disease with a D842 mutation in the PDGFRα gene. Patients with an
advanced solid tumor other than GIST must have relapsed or refractory disease
without an available effective therapy.


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 49 of 110
28 February 2018
o
At daily doses < 100 mg QD patients may have the diagnosis of either GIST or a
relapsed or refractory solid tumor.
o
At daily doses ≥ 100 mg QD, at least 2 patients in a cohort (4 patients if the
cohort is expanded) must have the diagnosis of GIST.
3. For Part 2:
o
Group 1: Patients must have a confirmed diagnosis of unresectable GIST that has
progressed following imatinib and at least 1 of the following: sunitinib,
regorafenib, sorafenib, dasatinib, pazopanib, or an experimental kinase-inhibitor
agent, and the patient does not have a D842V mutation in PDGFRα.
o
Group 2: Patients must have a confirmed diagnosis of unresectable GIST with a
D842V mutation in the PDGFRα gene. The PDGFRα mutation will be identified
by local or central assessment, either in an archival tissue sample or a new tumor
biopsy obtained prior to treatment with BLU-285.
o
Group 3: Patients must have a confirmed diagnosis of unresectable GIST that has
progressed and/or patients must have experienced intolerance to imatinib and not
received additional kinase-inhibitor therapy. Patients must not have a known
D842V mutation in PDGFRα.
o
Groups 1, 2, and 3: At least 1 measurable lesion defined by the mRECIST
version 1.1 for patients with GIST (Appendix 1).
o
Groups 1 and 2: A tumor sample (archival tissue or a new tumor biopsy) has been
submitted for mutational testing.
4. Patient has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
0-2.
5. Patient or legal guardian, if permitted by local regulatory authorities, provides
informed consent to participate in the study.
5.3 
Exclusion Criteria 
Patients meeting any of the following criteria will not be eligible for study participation: 
1. Patient has any of the following within 14 days prior to the first dose of study drug:
a.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 3 ×
upper limit of normal (ULN) if no hepatic metastases are present; > 5 × ULN
if hepatic metastases are present.
b. Total bilirubin > 1.5 × ULN; > 3 × ULN with direct bilirubin > 1.5 × ULN in
the presence of Gilbert’s Disease.


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 50 of 110
 
 
28 February 2018
 
c. Estimated (Cockcroft-Gault formula) or measured creatinine clearance 
< 40 mL/min. 
d. Platelet count < 90 × 109/L. 
e. Absolute neutrophil count (ANC) < 1.0 × 109/L. 
f. Hemoglobin (Hgb) < 9 g/dL. Transfusion and erythropoietin may be used to 
reach at least 9 g/dL, but must have been administered at least 2 weeks prior 
to the first dose of study drug. 
2. Patient received a prior anti-cancer drug less than 5 half-lives or 14 days (whichever 
is shorter) prior to the first dose of study drug. 
3. Patient has received neutrophil growth factor support within 14 days of the first dose 
of study drug. 
4. Group 3: Patients known to be KIT wild type. 
5. Patient requires therapy with a concomitant medication that is a strong inhibitor or 
strong inducer of cytochrome P450 (CYP) 3A4 (see Appendix 2).  
6. Patient has had a major surgical procedure (minor surgical procedures such as central 
venous catheter placement, tumor needle biopsy, and feeding tube placement are not 
considered major surgical procedures) within 14 days of the first dose of study drug. 
7. Patient has a history of another primary malignancy that has been diagnosed or 
required therapy within 1 year prior to the first dose of study drug. (The following are 
exempt from the 1-year limit:  completely resected basal cell and squamous cell skin 
cancer, curatively treated localized prostate cancer, and completely resected 
carcinoma in situ of any site.) 
8. Patient has a QT interval corrected using Fridericia’s formula (QTcF) 
> 450 milliseconds. 
9. Patient has a history of a seizure disorder (e.g., epilepsy) or requirement for anti-
seizure medication. 
10. Patient has a history of a cerebrovascular accident or transient ischemic attacks within 
1 year prior to the first dose of study drug.  
11. Patient has a known risk of intracranial bleeding, such as a brain aneurysm or history 
of subdural or subarachnoid bleeding. 
12. Patient has a primary brain malignancy or metastases to the brain. 
13. Patient has clinically significant, uncontrolled, cardiovascular disease, including 
congestive heart failure Grades II, III or IV according to the New York Heart 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 51 of 110
28 February 2018
Association classification, myocardial infarction or unstable angina within the 
previous 6 months, or poorly controlled hypertension. 
14. Patient has a known diagnosis of human immunodeficiency virus infection or active
viral hepatitis; viral testing is not required.
15. Patient is unwilling or unable to comply with scheduled visits, drug administration
plan, laboratory tests, or other study procedures and study restrictions.
16. Women who are unwilling, if not postmenopausal or surgically sterile, to abstain
from sexual intercourse or employ highly effective contraception during the study
drug administration period and for at least 30 days after the last dose of study drug.
Refer to Section 9.6 for acceptable methods of contraception.
17. Pregnant women as documented by a serum beta human chorionic gonadotropin
(β-hCG) pregnancy test consistent with pregnancy obtained within 7 days prior to the
first dose of study drug. Women with β-hCG values that are within the range for
pregnancy but are not pregnant (false-positives) may be enrolled with written consent
of the Sponsor after pregnancy has been excluded. Women of non-childbearing
potential (postmenopausal; hysterectomy; bilateral salpingectomy; or bilateral
oophorectomy) do not require a serum β-hCG pregnancy test.
18. Women who are breast feeding.
19. Patient has a prior or ongoing clinically significant illness, medical condition, surgical
history, physical finding, or laboratory abnormality that, in the Investigator’s opinion,
could affect the safety of the patient, alter the absorption, distribution, metabolism or
excretion of the study drug, or impair the assessment of study results.
5.4 
Patient Identification and Registration 
Patients who are candidates for enrollment into the study will be evaluated for eligibility 
by the Investigator to ensure that the inclusion and exclusion criteria (see Section 5.2 and 
Section 5.3) have been satisfied.  
During the dose-escalation part, upon identification of an eligible patient, study centers 
will submit a request to the Sponsor or designee to register each patient for enrollment. 
Enrollment will be granted based on availability in each dose-escalation cohort. Further 
instructions will be provided in the study manual. 
The Medical Monitor will confirm eligibility for all patients prior to receipt of the first 
dose of BLU-285. 
5.5 
Study Completion 
Patients will be considered to have completed the study if they withdraw from the study 
for any of the criteria listed in Section 5.6. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 52 of 110
28 February 2018
5.6 
Patient Withdrawal Criteria 
Patients have the right to withdraw from the study at any time for any reason. 
Patients may withdraw or be withdrawn from study treatments for any of the following 
reasons: 
•
Withdrawal of consent.
•
AE.
•
Disease progression.
•
Death.
•
Investigator decision.
•
Protocol deviation.
•
Pregnancy.
•
Lost to follow-up.
When a patient discontinues study drug or withdraws from the follow-up phase of the 
study, the primary reason(s) for discontinuation or withdrawal must be recorded in the 
appropriate sections of the electronic case report form (eCRF) and all efforts will be 
made to complete and report final study observations as thoroughly as possible. 
Following discontinuation of study drug, all efforts will be made to complete and report 
the protocol-defined study observations as completely as possible and to determine the 
reason for withdrawal. 
All AEs should be followed until resolution or for a period of 30 days from the last dose 
of study drug, whichever is shorter. If a patient withdraws from treatment because of an 
AE, every effort must be made to perform protocol-specified safety follow up procedures, 
as outlined in Section 7.6. 
In the event a patient is withdrawn from study drug or the follow-up phase of the study, 
the Medical Monitor must be informed. If there is a medical reason for withdrawal, the 
patient will remain under the supervision of the Investigator or designee until the 
condition has returned to baseline or stabilized. 
5.7 
Replacement of Patients 
Part 1: In order to be evaluable for DLT assessment, each patient in a cohort must have 
received at least 75% of their prescribed BLU-285 doses in C1 (i.e., ≥ 21 doses) and 
completed follow-up safety evaluations through C1D28 or experienced a DLT. Patients 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 53 of 110
28 February 2018
not evaluable for DLT assessment will be replaced to ensure that data are available from 
3 or 6 evaluable patients (as required for that cohort) prior to the dose-escalation meeting. 
Part 2: Patients may be added in order to have 100 antitumor assessment-evaluable 
patients in Group 1, 31 antitumor assessment-evaluable patients in Group 2, and 
50 antitumor assessment-evaluable patients in Group 3, as defined in Section 4.1. Safety 
data will be collected for all patients, whether or not they are evaluable for antitumor 
assessments.  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 54 of 110
28 February 2018
6 STUDY CONDUCT 
6.1 
General Conduct 
The study will be conducted at multiple study centers in the United States (US), 
European Union (EU), and Asia. 
The schedule of assessments for the study is provided in Table 8, Table 9, Table 10 and 
Table 11. 
The end of the study is defined as the time that the last patient completes his/her last visit, 
including assessments performed as a part of PSF follow-up, if the patient enters the PFS 
follow-up part of the study. See Table 8 for details of all study assessments.  
6.2 
Early Study Termination 
The study may be terminated early at the discretion of the Sponsor, if there is sufficiently 
reasonable cause. In the event of such action, written notification documenting the reason 
for study termination will be provided to each Investigator. 
Circumstances that may warrant early termination include, but are not limited to: 
•
Determination of unexpected, significant, or unacceptable risk to patients.
•
Failure to enter patients at an acceptable rate.
•
Insufficient adherence to protocol requirements.
•
Plans to modify, suspend, or discontinue the development of study drug.
•
Other administrative reasons.
Should the study be terminated prematurely, all study materials must be returned to the 
Sponsor or Sponsor’s designee. 
6.2.1 
Rules for Early Termination of Enrollment in Dose Expansion 
To help ensure patient safety, the study incorporates an enrollment stopping rule that 
terminates further enrollment in Part 2, Group 3 if there is an excess of permanent 
treatment discontinuations due to study drug-related AEs. 
After 10 patients in Group 3 of Part 2 have received at least 1 dose of BLU-285, the rate 
of permanent treatment discontinuations due to drug-related AEs will be assessed at least 
every 3 months. 
Adverse events meeting all of the following criteria will be included in the assessment: 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 55 of 110
28 February 2018
•
The AE is considered drug-related and is the reason for permanent discontinuation of
treatment;
•
The AE is Grade ≥3 or meets the criteria for DLT (including events that meet the
criteria for DLT but occur after C1);
•
The AE occurred after the first dose of study drug, but prior to initiation of a
subsequent anticancer therapy;
•
The AE occurred at a dose that does not exceed the MTD.
Further enrollment to Group 3 of Part 2 will be terminated if the lower bound of the 
1-sided 70% exact binomial confidence interval of the discontinuation rate due to AE is
>15%.
Table 4 below presents the operating characteristics for the early study termination 
assessment. 
Table 4: 
Examples of Implementing the Early Stopping Rule 
Number of Patients 
Discontinued due to 
Study Drug Related 
Adverse Events 
Number 
of 
Patients 
Treated 
70% Exact Binomial CI, 1-sided lower bound 
Action 
2 
10 
10.9% 
No stop 
3 
10 
19.26% 
Stop 
3 
15 
12.8% 
No stop 
4 
15 
18.6% 
Stop 
4 
20 
13.9% 
No stop 
5 
20 
18.36% 
Stop 
7 
40 
13.64% 
No stop 
8 
40 
15.93% 
Stop 
In addition, the study implements early stopping rules that terminate enrollment due to 
lack of treatment effect in Group 3 of Part 2. Early stopping due to lack of treatment 
effect will be assessed using mRECIST version 1.1 response (CR+PR) rate. For Group 3 
of Part 2, it is assumed that a true response rate ≥15% is clinically meaningful and that 
the probability of observing at least 2 responders among 20 patients is about 82%. If after 
20 patients have had at least one post baseline mRECIST version 1.1 response 
assessment, ≥2 responders (including an unconfirmed response in a patient who remains 
on treatment) are observed, the study will continue to the full enrollment of 50 patients, 
otherwise enrollment will be discontinued due to lack of efficacy. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 56 of 110
28 February 2018
6.3 
Dose and Administration 
BLU-285 will be administered PO, QD, in the morning, on D1 to 28 in 28-day cycles. In 
order to better evaluate the half-life of BLU-285, which is predicted to be long, patients 
in Part 1 (Dose Escalation) will participate in a 3-day PK-Lead in stage. For patients in 
Part 1, a single dose of BLU-285 will also be administered on Day-3 (the same dose as 
the patient’s assigned cohort dose). Patients will return on days -2, -1, and 1 (24, 48 and 
72 hours after study drug administration) for PK sampling, and will not receive BLU-285 
on days -2 and -1. Dosing will be continuous, with no inter-cycle rest periods. If 
warranted based on the emerging data, alternative dosing regimens (e.g., BID) or 
intermittent dosing (e.g., 3 weeks on, 1 week off) schedules may be explored. Patients 
will be dispensed the appropriate number of Sponsor-packaged, labeled bottles on D1 of 
each cycle to allow dosing for 28 days; alternatively, patients may be dispensed the 
appropriate bottle(s) until the next scheduled visit. Patients must return all unused 
capsules (or the empty bottles) at each scheduled visit. 
BLU-285 doses should be administered with a glass of water (at least 8 ounces or 
250 mL) in a fasted state, with no food intake from 2 hours before until 1 hour after study 
drug administration. Each dose should be administered at approximately the same time 
each day. Patients should be instructed to swallow capsules whole and to not chew the 
capsules. Patients should be instructed to avoid proton pump inhibitors and H2-receptor 
antagonists. Furthermore, antacids should not be taken within 3-4 hours before or after 
BLU-285 administration.   
On study day clinic visits, patients will take their dose of BLU-285 in the study clinic 
under observation. 
If the patient forgets to take their morning dose, he/she should take BLU-285 by 4 pm 
that day (the BLU-285 dose should be administered with a glass of water in a fasted state, 
with no food intake from 2 hours before until 1 hour after study drug administration). If 
the dose has not been taken by 4 pm, then that dose should be omitted and the patient 
should resume treatment with the next scheduled dose, the following morning. If a patient 
vomits during or after taking their BLU-285, re-dosing is not permitted until the next 
scheduled dose. 
A temporary discontinuation (up to 2 weeks) in BLU-285 dosing is allowed for patients 
who require an interruption (e.g., for surgery or other procedure) during the treatment 
period. BLU-285 should be discontinued 48 hours before the procedure and resumed 48 
hours after the procedure is completed.  
6.4 
Guidelines for Dose Escalation 
Dose-escalation decisions will be made by the Study Investigators and Clinical Study 
Team. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 57 of 110
28 February 2018
The dose escalation part of the study (Part 1) will enroll patients with GIST or a relapsed 
or refractory solid tumor. A 3+3 dose-escalation design using cohorts of 3 patients will be 
employed. 
The first cohort of patients will receive BLU-285 at a starting dose of 30 mg QD. The 
dose escalation increment for the first escalation step will be a maximum of 100%. 
However, if ≥ 1 patient treated at the starting dose level has a ≥ Grade 2 non-hematologic 
AE or a ≥ Grade 3 hematologic AE and the AE (non-hematologic or hematologic) is not 
clearly attributable to a cause other than BLU-285, then the maximum dose escalation 
increment for the first escalation step will be 50%. All subsequent dose escalation 
increments will be a maximum of 50%. 
Three patients will be enrolled initially in each cohort and an additional 3 patients (for a 
total of 6) will be enrolled should the cohort require expansion due to a DLT. After the 
current escalation cohort is full, up to 3 additional patients, all of whom must have the 
diagnosis of GIST, may be enrolled into an enrichment cohort that included only 3 
patients evaluable for DLT, was reviewed at a dose-escalation meeting, and did not 
exceed the MTD. Enrollment of patients into an enrichment cohort requires written 
approval from the Sponsor. Data from these patients will allow for further exploration of 
PK, PD, and safety in patients with GIST. Dose-limiting toxicities occurring in patients 
enrolled into enrichment cohorts will be included in the assessment of the MTD as 
described in Table 5. 
If the second or third patients enrolled in the first cohort of the study are enrolled at a site 
in the UK, those patients may only be dosed if there is no safety concern at least 24 hours 
after the first patient was dosed. 
In cohorts in which the administered dose is < 100 mg QD, enrolled patients may have 
the diagnosis of either GIST or a relapsed/refractory solid tumor. To assure that the safety 
profile of BLU-285 is adequately described in patients with GIST, at least 2 of 3 patients 
in each cohort (4 of 6 patients if the cohort is expanded) dosed at ≥ 100 mg QD must 
have the diagnosis of GIST. 
Dose escalation will continue until the MTD or a RP2D below the MTD has been 
determined. In addition, based on evaluation of the data, alternative dosing regimens 
(e.g., BID) or schedules (e.g., 3 weeks on, 1 week rest) may be explored. 
A summary of the dose-escalation scheme is presented Table 5 and Figure 3. Provisional 
dose-escalation levels are presented in Table 6. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 58 of 110
28 February 2018
Table 5: 
Dose-escalation Scheme 
No DLT 
Escalate by ≤ 50% to next dose level (≤ 100% for 
the first escalation step) 
1 DLT in 3 patients 
Expand cohort up to 6 patients 
1 DLT in 6 patients 
Escalate by ≤ 50% to next dose level (≤ 100% for 
the first escalation step) 
> 1 DLT in ≤ 6 patients (including patients
enrolled into enrichment cohorts)a 
Stop dose escalation 
Expand highest prior dose level to 6 evaluable 
patients, if 6 evaluable patients not already treated 
Highest prior dose with ≤ 1 DLT in 6 patients is 
MTD 
Possibly explore lower doses to determine RP2D 
Abbreviations: DLT = dose-limiting toxicity, MTD = maximum tolerated dose, RP2D = recommended 
Phase 2 dose.  
a If a DLT in an enrichment patient results in a second DLT in 6 patients at a prior dose level, escalation 
will stop and the dose level with > 1 DLT will have exceeded the MTD.  
Figure 3: 
Dose-escalation Schematic 
Abbreviations: di = initial dose, di+1= 1 level above the initial dose, DLT = dose-limiting toxicity, 
MTD = maximum tolerated dose. 
Table 6: 
Provisional Dose-escalation levels 
Dose Level Cohort 
Dose (mg) 
% Change from Previous Dose Level 
-2
10 
-50%
-1
20 
-33%
1 (starting Dose Level) 
30 
- 
2a 
60 
100% 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 59 of 110
 
 
28 February 2018
 
Dose Level Cohort 
Dose (mg) 
% Change from Previous Dose Level 
3 
90 
50% 
4 
135 
50% 
5b 
200 
48% 
a Dose level 2 is limited to ≤ 1.5 times dose level 1 if ≥ 1 patient treated at dose level 1 has a ≥ Grade 2 
non-hematologic AE or a ≥ Grade 3 hematologic AE and the AE (non-hematologic or hematologic) is not 
clearly attributable to a cause other than BLU-285. 
b Subsequent escalations are ≤ 1.5 times the prior dose.  
6.4.1 
Intra-patient Dose Modification 
To minimize the number of patients treated at potentially inactive doses, intra-patient 
dose escalation may be permitted after a patient has completed ≥ 2 cycles of treatment 
without experiencing Grade ≥ 3 toxicity. The patient’s dose may then be escalated to a 
dose that has been reviewed at a dose-escalation meeting and does not exceed the MTD. 
Intra-patient dose escalation requires written approval from the Sponsor. 
6.4.2 
Dose Limiting Toxicity 
Dose-limiting toxicity is defined as any treatment-emergent AE of Grade ≥ 3 occurring 
during C1 and not clearly attributable to a cause other than BLU-285, with the following 
exceptions:  
• Thrombocytopenia is a DLT only if it is Grade 4 and persists > 3 days or Grade 3 and 
associated with bleeding.  
• Neutropenia is a DLT only if it is Grade 4 and either persists > 3 days or is of any 
duration and requires growth factor support. 
• Anemia is a DLT only if it is Grade 4. 
• Lymphopenia is a DLT only if it is Grade 4 and persists > 7 days. 
• Nausea is a DLT only if it is Grade 3 and persists > 3 days despite therapy. 
• Vomiting is a DLT if it is Grade 4, or Grade 3 and persists > 3 days despite therapy. 
• Diarrhea is a DLT only if it is Grade 4, or Grade 3 and persists > 3 days despite 
therapy. 
• Total bilirubin Grade ≥ 2 is a DLT if associated with ALT ≥ Grade 2.  
• Infection is a DLT if it is Grade 4 or if it is Grade 3 and persist > 7 days. 
• Fever in the absence of neutropenia is a DLT if it is Grade 4 despite antipyretic 
therapy. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 60 of 110
 
 
28 February 2018
 
• Abnormalities of serum calcium, magnesium, and phosphate are DLTs only if they 
are Grade 4, or Grade 3 and the patient is clinically symptomatic, requires 
hospitalization, or if the specific abnormality is not able to be corrected to Grade ≤ 2 
within 3 days. 
• Fatigue is a DLT only if it is Grade 3 and persists > 7 days.  
• Other clinically important AEs that do not meet the specified DLT criteria may be 
considered to be a DLT upon review at a Dose-escalation meeting. 
6.4.3 
Dose Modifications 
BLU-285 will be administered PO at a starting dose of 300 mg QD in continuous 28-day 
cycles. If the treating investigator considers it to be in the patient’s best medical interest. 
the dose may be increased to 400 mg QD under the following circumstances:  
• The patient has received two or more cycles of BLU-285 without any treatment-
related AEs ≥ Grade 3 (unless the AE has resolved to Grade 1 or less), and 
without any cognitive, mood or intracranial bleeding AEs ≥ Grade 2 (regardless 
of resolution), and there is evidence of tumor increase. 
• The patient has received four or more cycles of BLU-285 without any treatment-
related AEs ≥ Grade 3 (unless the AE has resolved to Grade 1 or less), and 
without any cognitive, mood or intracranial bleeding AEs ≥ Grade 2 (regardless 
of resolution), and the patient has not had a PR or CR. 
Dose reduction guidelines for BLU-285-related toxicity are summarized in Table 7. 
These guidelines for dose reductions should be followed by clinical investigators; 
however, for an individual patient, dose interruptions, reductions, and treatment 
discontinuation should also be based on clinical circumstances. Adverse events should be 
graded according to NCI CTCAE, v4.03. Deviation from these guidelines must be 
documented and communicated with the Sponsor. 
It is recommended that patients with hematologic AEs (neutropenia, thrombocytopenia 
and anemia) of Grade 4 be evaluated at least twice-weekly and those with 
non-hematologic toxicity of Grade 3 or worse be evaluated at least once-weekly until 
resolution of the AE(s). 
A maximum of 3 dose reductions are permitted; no dose reductions are permitted below 
the 100 mg daily dose level. 
In case of dose re-escalation due to resistance or loss of response, the Sponsor must be 
contacted and must provide written approval for the patient to continue on treatment and 
to be escalated to the next dose level. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 61 of 110
 
 
28 February 2018
 
Table 7: 
Dose Modification Guidelines for BLU-285-related Toxicity 
Toxicity 
Modification 
General 
Grade 1 or Grade 2 
• 
No dose modification required 
Grade 3 or Grade 4 
of any duration 
• 
Hold until event is Grade 2 or less, or has returned to baseline, and then 
resume by reducing the dose by 100 mg less than the current dose 
• 
If the patient is already receiving a dose of 100 mg QD, and continued 
treatment is considered in the best interest of the patient due to the underlying 
GIST, treatment may be resumed at 100 mg, after the adverse event has 
improved to Grade 2 or less 
Cognitive or mood effectsa 
Grade 1 with only 
mild impairment 
• 
No dose modification required 
Grade 1, other than 
mild impairment 
• 
Interrupt dosing for 7 days, and resume dosing without dose reduction.  
• 
The dosing interruption may be repeated if the impairment continues to 
worsen after resuming dosing; however, repeated dosing interruption is not 
required, and should be balanced with the need to treat the underlying GIST  
Grade 2 
• 
Interrupt dosing for a minimum of 7 days 
• 
Resume dosing with a dose reduction of 100 mg when the cognitive effect has 
improved to Grade 1 or less, or while still at Grade 2, if continued treatment is 
considered in the best interest of the patient due to the underlying GIST 
• 
If the patient is already receiving a dose of 100 mg QD, and continued 
treatment is considered in the best interest of the patient due to the underlying 
GIST, treatment may be resumed at 100 mg   
Grade 3-4 
• 
Interrupt dosing for a minimum of 14 days 
• 
Resume dosing with a dose reduction of 100 mg when the cognitive effect has 
improved to Grade 1 or less, or when it has improved to Grade 2, if continued 
treatment is considered in the best interest of the patient due to the underlying 
GIST 
• 
If the patient is already receiving a dose of 100 mg QD, and continued 
treatment is considered in the best interest of the patient due to the underlying 
GIST, treatment may be resumed at 100 mg, after the cognitive effect has 
improved to Grade 2 or less  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 62 of 110
 
 
28 February 2018
 
Toxicity 
Modification 
Intracranial Bleeding 
Grade 1 
• 
Interrupt dosing for a minimum of 7 days, and re-image brain.  
• 
Resume dosing without dose reduction, if the bleed is stable or improving, 
and continued treatment is considered in the best interest of the patient due to 
the underlying GIST.  
Grade 2 
• 
Interrupt dosing for a minimum of 14 days and re-image brain.  
• 
Resume dosing with a dose reduction of 100 mg when the intercranial 
bleeding has improved to Grade 1 or less, or while still at Grade 2, if 
continued treatment is considered in the best interest of the patient due to the 
underlying GIST 
• 
If the patient is already receiving a dose of 100 mg QD, and continued 
treatment is considered in the best interest of the patient due to the underlying 
GIST, treatment may be resumed at 100 mg   
Grade 3-4 
• 
Permanently discontinue BLU-285 treatment.  
Abbreviations: GIST = gastrointestinal stromal tumor; QD = once daily 
a Changes in cognition, memory, attention, mood, or speech (thought to originate in the central nervous 
system). 
6.4.4 
Maximum Tolerated Dose 
The MTD is defined as the highest dose level at which ≤ 1 patient experiences DLTs in 
C1 during Part 1 of the study. At least 6 patients must be treated at this dose in order to 
determine that it is the MTD. 
6.4.5 
Recommended Phase 2 Dose 
The RP2D will not exceed the MTD and will be determined at a dose-escalation meeting 
during Part 1 of the study. Additionally, observations related to PK, PD, and any 
cumulative toxicity observed after multiple cycles may be included in the rationale 
supporting the RP2D below the MTD. If an MTD is not identified, then PK, PD, and 
safety data, along with pertinent non-clinical data suggestive of a dose-effect relationship, 
will be used to define a RP2D. Six patients must be treated at this dose in order to 
confirm that it is the RP2D. 
6.4.6 
Alternate Dosing Schedule 
Alternate dosing schedules, such as BID and intermittent dosing may be evaluated if 
supported by PK, PD, safety, or efficacy data. A decision to change the treatment 
schedule, including the choice of a starting dose for the new schedule, will only occur 
after agreement has been reached among the study Investigators at each study center and 
the Sponsor Clinical Study Team; should any of these people not have attended the 
meeting, approval will be obtained in writing. The protocol will be amended prior to 
evaluating new dosing schedules.  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 63 of 110
 
 
28 February 2018
 
6.5 
Prior and Concomitant Therapy 
All medications administered and procedures within 28 days of the first dose of study 
drug should be recorded on the eCRF. In addition, all prior treatments for the underlying 
malignancy should be recorded. 
6.5.1 
Prohibited Concomitant Therapy 
• In vitro studies with recombinant human CYP enzymes demonstrated that BLU-285 
phase I metabolism is predominantly mediated by CYP3A4, with CYP2C9 playing a 
minor role. Therefore, concomitant treatment with drugs that are strong CYP3A4 
inhibitors or strong CYP3A4 inducers is prohibited (refer to Appendix 2 for a list of 
strong CYP3A4 inhibitors and inducers). 
• Any investigational agent or device other than BLU-285. 
• Any antineoplastic agent other than study drug. 
• Neutrophil growth factor support is prohibited within 14 days prior to the first dose of 
study drug and throughout C1, unless the patient experiences a DLT of neutropenia. 
Radiation therapy to target lesions or surgical removal of target lesions is considered 
indicative of progressive disease. 
6.5.2 
Concomitant Therapy to be used with Caution 
In vitro, BLU-285 is a reversible inhibitor of CYP2C8, CYPC9, and CYP3A4/5 at 
clinically relevant concentrations ([I]/Ki > 0.1). BLU-285 also has demonstrated 
time-dependent inhibition of CYP3A4/5 in vitro with an estimated Kinact and KI of 
0.0301 min-1 and 12.3 μM, respectively. Therefore, clinical drug-drug interactions with 
comedications for which CYP2C8, CYP2C9, or CYP3A-mediated metabolism 
constitutes the primary mechanism of clearance is likely. In vitro, BLU-285, at 
concentrations of 0.3 to 3 μM, induced CYP3A4 mRNA expression with a maximal 
3.25-fold induction observed at 3 μM. 
In vitro, BLU-285 is an inhibitor of P-glycoprotein (P-gp), breast cancer resistance 
protein (BCRP), bile salt export pump (BSEP), and multidrug and toxin extrusion protein 
(MATE1, MATE2K). Therefore, BLU-285 may have the potential to increase plasma 
concentrations of co-administered substrates of these transporters. Medications that are 
CYP2C9, CYP3A4, or BCRP substrates with a narrow therapeutic index should be used 
with caution (refer to Appendix 3 for a list of these medications). 
Investigators should ensure patients avoid proton pump inhibitors and H2-receptor 
antagonist during the dose escalation part of the study. Furthermore, antacids should be 
taken at a time point that is not proximal to study drug administration (at least 3-4 hours 
before or after study drug administration).  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 64 of 110
 
 
28 February 2018
 
In addition, medications that are known to increase the risk of seizures should be used 
with caution. 
6.5.3 
Permitted Concomitant Therapy 
Medications and treatments other than those specified in Section 6.5.1 and Section 6.5.2, 
including palliative and supportive care for disease-related symptoms are permitted 
during the study.  
Patients should be closely monitored, and treatment is to be instituted for disease-related 
symptoms as appropriate. Supportive care measures for treating AEs should be instituted 
as soon as they are recognized. 
Antiemetic treatments may be used at the Investigator’s discretion and in accordance with 
the American Society of Clinical Oncology guidelines or equivalent after documented 
nausea or vomiting has occurred without medications having been used. The choice of 
anti-emetic treatment, if required, will be made at the Investigator’s discretion. During 
Part 1 of the study prophylaxis for nausea or vomiting may be instituted beginning on 
C2D1 in patients who experience these toxicities during C1, and during C1 for patients 
who experienced a DLT of nausea or vomiting. During Part 2 of the study, prophylaxis 
for nausea and vomiting may be instituted at the Investigator’s discretion. Anti-diarrhea 
medications may also be used at the Investigator’s discretion. 
6.6 
Additional Precautions 
The light absorption characteristics of BLU-285 suggest the possibility the BLU-285 
treatment will be associated with phototoxicity. Therefore, patients should use clothing 
and sunscreen to avoid direct sun exposure.  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 65 of 110
 
 
28 February 2018
 
Table 8: 
Schedule of Assessments 
Study Activitiesa 
Screening 
Study Treatment 
EOTc 
Safety 
Follow-
up 
PFS 
Follow-
upd 
Cycle 
 
PK Lead-inb 
C1 
C2 
≥ C3 
Study Day 
-59 to -4e 
-56 to -1 
D-3 
D-2 
D-1 
D1 
D2 
D8f 
D15 
D22f 
D1 
D15f 
D1 
14 days 
post last 
dose 
30 days 
post last 
doseg 
Every 3 
months 
after 
Safety 
F/U 
Window (Days) 
 
 
 
 
 
 
±1 
±2 
±2 
+3h 
±3 
±7 
±7 
±7 
±14 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical historyi 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical 
examinationj 
X 
Xk 
 
 
Xl 
 
X 
X 
X 
X 
X 
X 
X 
 
 
Vital signsm 
X 
Xk 
 
 
Xl 
Xl 
X 
X 
X 
X 
X 
X 
X 
 
 
Serum Pregnancy 
(β-hCG) testn 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Performance status 
(ECOG)dd 
X 
Xk 
 
 
Xl 
 
X 
X 
X 
X 
X 
X 
X 
 
 
12-lead ECG/ECG 
extraction from 
Holter monitor 
X 
Refer to Table 9, Table 10, and Table 11 for ECG schedule. 
 
 
 
Hematologyo 
X 
Xk,p 
 
 
Xl,p 
 
X 
Xq 
X 
X 
X 
X 
X 
 
 
Coagulationr 
X 
Xk,p 
 
 
Xl,p 
 
X 
Xq 
X 
X 
X 
X 
X 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 66 of 110
 
 
28 February 2018
 
Study Activitiesa 
Screening 
Study Treatment 
EOTc 
Safety 
Follow-
up 
PFS 
Follow-
upd 
Cycle 
 
PK Lead-inb 
C1 
C2 
≥ C3 
Study Day 
-59 to -4e 
-56 to -1 
D-3 
D-2 
D-1 
D1 
D2 
D8f 
D15 
D22f 
D1 
D15f 
D1 
14 days 
post last 
dose 
30 days 
post last 
doseg 
Every 3 
months 
after 
Safety 
F/U 
Window (Days) 
 
 
 
 
 
 
±1 
±2 
±2 
+3h 
±3 
±7 
±7 
±7 
±14 
Serum chemistrys 
X 
Xk,p 
 
 
Xl,p 
 
X 
Xq 
X 
X 
X 
X 
X 
 
 
Urinalysis 
X 
Xk,p 
 
 
Xl,p 
 
 
 
 
 
 
 
X 
 
 
BLU-285 
administrationt 
 
X 
 
 
X 
 
 
 
PK Blood Samplesu 
 
X 
X 
X 
Xcc 
Xl 
 
X 
 
X 
 
X 
 
 
 
Plasma Sample for 
Biomarkersv 
 
Xp 
 
 
Xp 
 
 
Xcc 
 
X 
 
X 
X 
 
 
Tumor samplew 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Tumor Imagingx 
X 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
Xy; 
MRI or CT of the 
brainz 
X 
 
 
 
 
 
 
 
 
X 
 
Xz 
 
 
 
AE Monitoringaa 
 
X 
 
SAE Monitoringbb 
X 
 
Concomitant 
medicationsbb 
X 
 
Abbreviations: AE = adverse event, ALT = alanine aminotransferase; AST = aspartate aminotransferase; β-hCG = beta human chorionic gonadotropin; 
C = cycle, CT = computed tomography, D = day, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology Group, EOT = end-of-treatment, 
F/U = follow-up; GIST = gastrointestinal stromal tumor; Hgb = hemoglobin; mRECIST = Response Evaluation Criteria in Solid Tumors modified for patients 
with GIST; MRI = magnetic resonance imaging, PFS = progression-free survival, PD = pharmacodynamic(s), PK = pharmacokinetic(s), QD = once daily; 
RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event; ULN = upper limit of normal. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 67 of 110
 
 
28 February 2018
 
Note: Every effort should be made to keep the schedule of assessments on time for each patient. 
a On days when study drug is to be administered in the clinic, all tests or procedures must be completed pre-dose at each study visit unless otherwise indicated. 
Additional safety tests (e.g., hematology, ECG) may be performed whenever clinically indicated, at the Investigator’s discretion. Whenever a test result is 
questionable, it should be repeated immediately.  
b The PK lead-in stage will occur during Part 1.  
c If an alternate treatment is to be started within 14 days after the last study drug dose, the EOT visit should be conducted prior to the first dose of alternate 
therapy. End-of-treatment procedures do not need to be repeated if they were completed within 7 days (or within 28 days for disease response assessments). 
d After completing the Safety Follow-up, patients are to be followed every 3 months (±14 days) until death, withdrawal of consent, or closure of the study by 
the Sponsor. 
e Screening will occur from D-59 through D-4 for patients in Part 1 and from D-56 through D-1 for patients in Part 2. 
f Only Part 1. These visits are not required for patients enrolled in Part 2 of the study. 
g The 30-day Safety Follow-up may be performed by phone. 
h In the event that a patient requires a delay up to 14 days (e.g., for toxicity), this visit can be delayed for up to 14 days. 
i 
A complete medical history will be obtained at the Screening visit, including a history of GIST and/or other malignancies, prior treatments, response to each 
treatment (if available), and concurrent illnesses. 
j 
A complete physical examination including weight, height, evaluation of the skin, head and neck, lymph nodes, heart, lungs, breasts, abdomen, pelvis (if 
indicated based on symptoms), musculoskeletal system, neurologic system, and a basic assessment of mental status and mood will be performed at the 
Screening visit. Subsequent physical examinations will focus on weight, signs of the GIST (or relapsed or refractory solid tumor), changes from previous 
physical examinations, neurologic, mental status, and mood examinations, and AEs. Complete physical examinations should be completed by all patients on 
Day 1 of each cycle through and including Cycle 13. After Cycle 13, physical examinations will be performed every 3 cycles (C16D1, C19D1, etc.), and at 
EOT. 
k Only Part 1; these values will be considered “Baseline” and do not need to be repeated on D1. 
l 
Only Part 2 Group 1 and 2 patients. 
m Vital signs include temperature, pulse, and systolic/diastolic blood pressure. Vital signs should be completed by all patients on Day 1 of each cycle through 
and including Cycle 13. After Cycle 13, vital signs will be performed every 3 cycles (C16D1, C19D1, etc.), and at EOT.  
n To be performed for women of child-bearing potential. Baseline is to be obtained within 7 days of the first dose of study drug (D -3 for patients in Part 1; 
C1D1 for patients in Part 2) and on D1 of every odd numbered cycle (e.g., C3, C5) through and including Cycle 13. After Cycle 13, pregnancy test will be 
performed every 3 cycles (C16D1, C19D1, etc.), and at EOT. For Belgium and Poland only, pregnancy test will be performed on D1 of every cycle.  
o Hematology parameters to be measured include Hgb, white blood cell (WBC) with differential count, and platelet count. On days when safety ECGs are to be 
obtained in the clinic, the ECG will be acquired within 2 hours prior to the collection of the blood sample. Hematology testing should be completed by all 
patients on Day 1 of every cycle through and including Cycle 13. After Cycle 13, hematology testing will be completed every 3 cycles (C16D1, C19D1, etc.), 
and at EOT. 
p Baseline (D-3 for patients in Part 1; C1D1 for patients in Part 2) safety laboratory tests and samples for PD markers are to be obtained within 7 days before 
the first study drug dose. Should Screening tests occur within 7 days of D-3 (Part 1) or C1D1 (Part 2), they do not need to be repeated. 
q Only Part 1. These assessments are not required for patients enrolled in Part 2. 
r Coagulation studies include international normalized ratio (INR) and activated partial thromboplastin time (aPTT). If they are within the normal range 
through C3D1 then they can be discontinued and obtained only as clinically indicated. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 68 of 110
 
 
28 February 2018
 
s The comprehensive serum chemistry panel includes sodium, potassium, blood urea nitrogen (BUN) or urea, bicarbonate (venous), creatinine, calcium, 
chloride, magnesium, phosphorus, albumin, AST, ALT, alkaline phosphatase (ALP), and total bilirubin (direct bilirubin if total bilirubin is > ULN). 
Comprehensive serum chemistry panel should be completed by all patients on Day 1 of every cycle through and including Cycle 13. After Cycle 13, serum 
chemistry testing will be completed every 3 cycles (C16D1, C19D1, etc.), and at EOT. 
t 
BLU-285 will be administered QD in the morning at least 2 hours after and 1 hour before eating. On study visit days when PK samples are collected, patients 
will take their dose of BLU-285 under observation at the study clinic after the pre-dose (trough) PK sample has been obtained. 
u PK sampling will be performed as specified in Table 9 (Part 1), Table 10, and Table 11 (Part 2). Additionally, Investigators may obtain blood samples for PK 
analysis at the time(s) that significant drug-related AEs and SAEs occur. 
v Plasma samples for biomarkers are drawn at baseline, C1D15, C2D1, C3D1, every odd cycle post C3 until and including C11 and EOT for Groups 1 and 2 
(Part 2). Plasma samples for biomarkers are drawn at baseline, C2D1, C3D1, every odd cycle post C3 until and including C11 and EOT for Group 3 (Part 2). 
See Table 12 for further details regarding schedule of PD sample acquisition. 
w Archival or new tumor biopsy samples required for Part 2 Group 1 and 2 patients. Archival or new tumor biopsy samples optional for Part 2 Group 3 patients. 
For further details refer to Table 12. 
x Disease response assessment (per mRECIST version 1.1) will be based on local assessments of computed tomography (CT) / magnetic resonance imaging 
(MRI) scans. Computed tomography with intravenous (IV) contrast of the chest and CT or MRI with IV contrast of the abdomen and pelvis will be performed 
at Screening. Imaging of body regions containing sites of disease (target or non-target) will be repeated in all patients on C3D1 and then after every 2 cycles 
through and including Cycle 13. After Cycle 13, tumor assessment will be performed every 3 cycles (C16D1, C19D1, etc), and at EOT. If a patient is not 
tolerant of IV contrast, non-contrast scans may be performed. For each patient, the same method of tumor imaging used at baseline should be used throughout 
the study. 
y Patients are to be seen in follow-up every up every 3 months to assess their disease status by imaging. Patients will not be required to participate in these 
visits once they either start a new antineoplastic therapy, or their tumor demonstrates progressive disease. 
z MRI or CT of the brain to be performed at screening, C2D1, C3D1, and C4D1. 
aa AEs are to be collected from the start of study drug administration through the Safety Follow-up. 
bb SAEs and concomitant medications are to be collected from the date of the informed consent signature through the Safety Follow-up. 
cc Only Part 1 and Part 2 Group 1 and 2 patients. 
dd Performance status will be assessed for all patients on Day 1 of each cycle through and including Cycle 13. After Cycle 13, performance status will be 
assessed every 3 cycles (C16D1, C19D1, etc.), and at EOT.  
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 69 of 110
 
 
28 February 2018
 
Table 9: 
Pharmacokinetics Sample Collection and ECG Schedule – Part 1 
Cycle 
Lead-in 
C1 
C2-4 
EOT 
Day 
D-3 
D-2 
D-1 
D1 
D15 
D1 
 
Time 
(hours) 
Pre-
dose 
0.5 
1 
2 
4 
8 
10 
24 
48 
72 
Pre-
dose 
0.5 
1 
2 
4 
8 
Pre-
dosea 
 
Window 
 
±5 
min 
±5 
min 
±5 
min 
±10 
min 
±10 
min 
±15 
min 
± 2 
hours 
± 2 
hours 
± 2 
hours 
 
±5 
min 
±5 
min 
±5 
min 
±10 
min 
±10 
min 
 
 
PK 
Sampling 
Xa 
X 
X 
X 
X 
X 
X 
X 
X 
Xa 
Xa 
X 
X 
X 
X 
X 
X 
 
Standard 
12-Lead 
ECG 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
X 
Abbreviations: C = cycle; D = day; ECG = electrocardiogram; EOT = End-of-treatment; min = minutes; PK = pharmacokinetics. 
a Sample to be obtained just prior to BLU-285 administration. 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 70 of 110
 
 
28 February 2018
 
Table 10: 
Pharmacokinetics Sample Collection and Holter Monitoring/ECG Schedule - Part 2 (Groups 1 and 2) 
Cycle 
C1  
C2 –
C4 
EOT 
Day 
D1 
D2 
D15 
D1 
≤ 14 days post 
last dose 
Time (hours) 
Pre-
dosea 
0.5 
1 
2 
4 
8 
24 
Pre-dosea 
0.5 
1 
2 
4 
8 
Pre-
dosea 
 
Window 
 
±5 
min 
±5 
min 
±5 
min 
±10 
min 
±10 
min 
± 2 
hours 
 
±5 
min 
±5 
min 
±5 
min 
±10 
min 
±10 
min 
 
 
PK Sampling 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Holter monitoring 
(for ECG 
extractions)b 
Xc 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Standard 12-lead 
ECG 
Xd 
 
 
 
 
 
 
Xd 
 
 
 
 
 
X 
X 
Abbreviations: C = cycle; D = day; ECG = electrocardiogram; EOT = End-of-Treatment; min = minutes; PK = pharmacokinetics. 
a PK sample to be obtained just prior to BLU-285 administration but after ECG acquisition in patients undergoing 12-lead Holter recordings. 
b At selected sites ECGs will be extracted in replicates from 12-lead Holter monitor recordings. Instructions for placement of the 12-lead Holter monitors will 
be provided in a separate manual. 
c Three time points will be extracted within 1 hour prior to dosing (e.g., -45 minutes, -30 minutes, -15 minutes). 
d Patients not participating in Holter monitoring will have a single standard 12-lead ECG obtained, ≤ 1 hour prior to the blood draw for PK sampling. 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 71 of 110
 
 
28 February 2018
 
Table 11: 
Pharmacokinetics Sample Collection and ECG Schedule - Part 2 (Group 3)  
Cycle 
C1 
C2 –C4 
EOT 
Day 
D1 
D15 
D1 
≤ 14 days post 
last dose 
Time (hours) 
Pre-dose 
Pre-dose 
1 
4 
6-8 
Pre-dose 
 
Window 
 
 
±5 min 
±10 min 
±10 min 
 
 
PK Sampling 
 
X 
X 
X 
X 
X 
 
Standard 12-lead 
ECG 
Xa 
X 
 
 
 
X 
X 
Abbreviations: C = cycle; D = day; ECG = electrocardiogram; EOT = End-of-Treatment; min = minutes; PK = pharmacokinetics 
a 
Patients will have a single standard 12-lead ECG obtained, ≤ 1 hour prior to the blood draw for PK sampling. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 72 of 110
 
 
 
28 February 2018
 
7 DESCRIPTION OF STUDY PROCEDURES 
7.1 
Screening 
Following informed consent, all patients will participate in screening procedures to 
determine eligibility within 56 days (8 weeks) prior to dosing on D -3 (for patients 
participating in the PK lead-in stage [Part 1]) or C1D1 (for patients not participating in 
the PK lead-in stage [Part 2]). 
During Part 2 of the study, all patients must submit a formalin-fixed, paraffin-embedded 
tumor sample for PDGFRα mutational testing at a central laboratory prior to beginning 
treatment with BLU-285. The tumor sample may be archival or from a new tumor biopsy. 
The tumor sample should be submitted as two tissue blocks (preferred) or as 20 unstained 
slides. Additional details on the sample requirements are described in the laboratory 
manual. The tumor samples may be submitted under the Tissue Screening ICF, before the 
Study ICF has been completed, or it may be submitted under the Study ICF. 
The following procedures will also be performed at the Screening visit: 
• Obtain Informed Consent 
• Obtain demographic data, including gender, date of birth/age, race, and ethnicity; 
• Complete medical history, including a history of GIST and other malignancies, prior 
treatments, response to each treatment (if available), and concurrent illnesses.  
• Obtain list of concomitant medications  
• Complete physical examination, including height, weight, evaluation of the skin, head 
and neck, lymph nodes, heart, lungs, breasts, abdomen, pelvis (if indicated based on 
symptoms), musculoskeletal system, neurologic system, and a basic assessment of 
mental status and mood. 
• ECOG PS 
• Obtain tumor samples (mandatory for Part 2, Group 1 and 2 patients only) and send 
for central laboratory assessment as described above, and in Section 7.4.2. 
• Tumor imaging: CT with intravenous (IV) contrast of the chest; MRI with IV contrast 
or CT with IV contrast of the abdomen and pelvis. If a patient is not tolerant of IV 
contrast, non-contrast scans may be performed. 
• Vital signs including temperature, pulse, and systolic/diastolic blood pressure; 
• Single 12-lead ECG. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 73 of 110
 
 
 
28 February 2018
 
• Clinical laboratory assessment (hematology, coagulation, serum chemistry, 
urinalysis). 
• Serum pregnancy test (for women of childbearing potential only) within 7 days prior 
to dosing on D -3 for patients participating in the PK lead-in stage or C1D1 for 
patients not participating in the PK lead-in stage.  
• CT scan or MRI of the brain is required for all patients. 
7.2 
Safety Assessments 
The schedule of safety assessments is described in Table 8. Additional safety assessments 
may be performed when clinically indicated, at the Investigator’s discretion. 
7.2.1 
Physical Examination 
A complete physical examination will be performed at the Screening visit. Subsequent 
physical examinations will be performed as outlined in Table 8 and will focus on signs 
and symptoms of GIST (or other solid tumors), AEs, and changes from previous physical 
examinations. 
7.2.2 
Eastern Cooperative Oncology Group Performance Status 
Determination of ECOG PS will be performed at the time points outlined in Table 8. 
Please refer to Appendix 4 for ECOG PS scoring. 
7.2.3 
Vital Signs 
Vital sign measurement will include temperature, systolic/diastolic blood pressure, and 
pulse, and will be performed at the time points outlined in Table 8. 
Assessments should be conducted while the patient is seated or supine. Blood pressure is 
to be obtained in the same position at each visit. 
7.2.4 
ECGs 
A single 12-lead ECG will be obtained for all patients at the time points outlined in 
Table 9, Table 10, and Table 11.  
Twelve-lead ECGs are to be conducted/extracted after at least 5 minutes of recumbency 
or semi-recumbency.  
In Part 2 of the study only, continuous ECG Holter monitoring will be performed in 
approximately 20 patients at select study centers. Replicate 12-lead ECGs will be 
extracted from the continuous recording at the time points outlined in Table 10. 
Instructions for acquisition of ECG data will be provided in a separate ECG manual. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 74 of 110
 
 
 
28 February 2018
 
7.2.5 
Clinical Laboratory Tests 
Clinical laboratory evaluations will be performed at the local laboratory. Prior to starting 
the study, the Investigator will provide the Sponsor (or its designee) copies of all 
laboratory certifications and normal ranges for all laboratory parameters to be performed 
by that laboratory. 
Clinical laboratory evaluations will be conducted at the time points outlined in Table 8. 
In addition, all clinically significant laboratory abnormalities noted on testing will be 
followed by repeat testing and further investigated according to the judgment of the 
Investigator.  
The following safety laboratory parameters are to be evaluated by the Investigator: 
Hematologya: 
Hgb, white blood cell with percent differential count, platelet 
count 
Coagulationa,b: 
International normalized ratio and activated partial 
thromboplastin time 
Serum chemistrya: 
Sodium, potassium, blood urea nitrogen or urea, bicarbonate 
(venous), creatinine, calcium, chloride, magnesium, 
phosphorus, albumin, AST, ALT, alkaline phosphatase, total 
bilirubin (direct bilirubin if total bilirubin is > ULN) 
Urinalysis (dipstick): 
pH, specific gravity, bilirubin, blood, glucose, ketones, 
leukocyte esterase, nitrite, protein, urobilinogen 
Serum pregnancyc: 
β-hCG 
a On days when study drug is to be administered in the clinic, blood must be drawn prior to study drug 
administration. 
b If coagulation tests are within the normal range through C3D1, then beginning in C4 they can be 
discontinued and obtained only as clinically indicated. 
c For women of childbearing potential only, as defined in Section 9.6. 
7.2.6 
Imaging of the Brain 
Imaging of the brain by CT scan or MRI will be performed at screening, C2D1, C3D1 
and C4D1, as outlined in Table 8. 
7.2.7 
Adverse Events and Concomitant Medications 
Each patient must be carefully monitored for the development of any AEs throughout the 
study from the start of study drug administration (or from the time of signing informed 
consent, for SAEs that are assessed as possibly or probably related to study related 
procedures) to 30 days after the last dose. In addition, SAEs that are assessed as possibly 
or probably related to study treatment that occur 30 days post-treatment are also to be 
reported. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 75 of 110
 
 
 
28 February 2018
 
Complete details on AE and SAE monitoring are provided in Section 9 and Section 10. 
Concomitant medications will be recorded from the time of signing informed consent to 
30 days after the last dose. 
7.3 
Pharmacokinetic Assessment 
Serial blood samples will be collected at the time points outlined in Table 9 (Part 1) and 
Table 10 (Part 2, Groups 1 and 2) to determine systemic concentrations of BLU-285, 
including metabolites when relevant. Sparse blood samples will be collected at the time 
points outlined in Table 11 (Part 2, Group 3). Additionally, Investigators may obtain 
blood samples for PK analysis at the time(s) that significant drug-related AEs and SAEs 
occur. 
When the timing of a blood sample coincides with the timing of an ECG measurement or 
extraction, the ECG will be completed within 1 hour prior to the collection of the blood 
sample. 
The timing of blood samples drawn for BLU-285 concentration determination may be 
changed if the emerging data indicates that an alternate sampling scheme is needed for 
better characterization of the BLU-285 PK profile. Moreover, the total number of 
samples may be decreased if the initial sampling scheme is considered unnecessarily 
intensive. Should the number of required samples increase, the protocol and informed 
consent form will be amended. 
7.4 
Pharmacodynamic / Biomarker Assessment 
7.4.1 
Blood Samples for Pharmacodynamic / Biomarker Assessment 
Blood samples will be collected at the time points outlined in Table 12 to characterize the 
mutant allele fraction in plasma ctDNA of KIT or PDGFRα at baseline and during 
treatment with BLU-285, and to measure changes from baseline in the levels of KIT, 
PDGFRα, and other cancer-relevant mutant allele fractions. 
The timing of blood samples drawn for PD/biomarker assessments may be changed based 
on emerging data. Should the number of required samples increase, a protocol 
amendment and updated informed consent form will be created and distributed. 
Additional details will be provided in a laboratory manual. 
7.4.2 
Tumor Samples for Biomarker Assessment 
To meet the secondary objectives, tumor tissue will be obtained at the time points 
detailed in Table 12. During Part 2, tumor mutation analysis of an archival tumor sample 
or new tumor biopsy will be performed by a central laboratory, and a sample must be 
submitted for PDGFRα D842V testing prior to initiating treatment with BLU-285 for 
Group 1 and 2 patients only.  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 76 of 110
 
 
 
28 February 2018
 
For new biopsies, efforts should be made to obtain biopsies from progressing lesions. If a 
new tumor biopsy is obtained, it should be by core needle biopsy according to local 
institutional practices and fixed in formalin. If feasible, tumor biopsies will also be 
obtained at the EOT in patients who discontinue for progression, ideally from progressive 
lesions. 
In addition to the screening central laboratory testing for PDGFRα D842V, tumor tissue 
will be analyzed centrally for assessment of KIT, PDGFRα and other cancer relevant 
mutations in a retrospective manner.  
Additional exploratory biomarker research may be performed using the plasma sample 
for exploratory biomarkers, as well as residual tumor tissue samples and material derived 
from these samples in view of developing new genetic and mechanistic biomarkers to 
assess the effects of BLU-285 in patients with cancer. 
Additional details will be provided in a laboratory manual.  
Table 12: 
Schedule for Pharmacodynamic Biomarker Sample Collection 
 
Screening 
Study Treatment 
EOT 
Cycle 
PK Lead-In 
1 
2 
≥ 3 
Day 
Day -3 
1 
15 
1 
1 
Tumor Tissue 
Samplea 
Xa 
 
 
 
 
 
Xb 
Plasma Sample 
for Biomarkersc 
 
Xd 
Xe 
Xf 
X 
X 
X 
Abbreviations: PK = Pharmacokinetic; EOT = End-of-Treatment. 
a 
Mandatory submission of a tumor tissue sample at Screening except for Group 3 patients. Archival or 
new tumor tissue samples are to be collected for patients with GIST to identify the specific KIT or 
PDGFRα mutations. For patients with KIT mutated GIST, attempt should be made to obtain a new 
biopsy from a progressing lesion at study entry. Formalin-fixed, paraffin-embedded blocks should be of 
adequate size to obtain ≥ 10 5 micron sections. If blocks are not available ≥ 10 slides of 5 micron 
thickness are acceptable.  
b 
For patients who have progressive disease at the EOT, additional tumor tissue should be obtained; if 
feasible, this biopsy should be from a progressing lesion.  
c 
Plasma sample for biomarkers are drawn at baseline, C1D15, C2D1, C3D1, every odd cycle post C3 
until and including C11, and EOT for Groups 1 and 2 (Part 2). Plasma sample for biomarkers are drawn 
at baseline, C2D1, C3D1, every odd cycle post C3 until and including C11 and EOT for Group 3 
(Part 2). 
d Only for patients participating in the PK Lead-In (Part 1). 
e 
Only for patients not participating in the PK Lead-In (Part 2). 
f 
Only for patients participating in Part 1 and Groups 1 and 2 (Part 2). 
7.5 
Disease Response Assessment 
Investigator-assessed disease response in patients with GIST according to mRECIST 
version 1.1 for GIST will be based on local MRI or CT scans performed at the time 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 77 of 110
28 February 2018
points outlined in Table 8. Computed tomography with IV contrast of the chest, and CT 
or MRI with IV contrast of the abdomen and pelvis will be performed at screening. At 
subsequent time points all body regions that contained sites of disease (target or 
non-target) at screening will be imaged. If a patient is not tolerant of IV contrast, 
non-contrast CT or MRI may be performed. For each patient, the same method of tumor 
imaging used at baseline should be used throughout the study. 
Magnetic resonance imaging and CT scans will be reviewed locally at the study center, 
ideally by the same individual for each patient at each time point. Magnetic resonance 
imaging and CT scans will also be collected and reviewed centrally to provide a central 
assessment of response and progression.  
7.6 
End-of-treatment, Safety Follow-up, and PFS Follow-up 
All patients will attend an EOT visit 14 (±7) days after the last dose of study drug (see 
Table 8 for a list of EOT assessments). If an alternate treatment is started within 14 days 
of the last dose of study drug, the EOT visit should be conducted prior to the first dose of 
alternate therapy. End-of-treatment procedures do not need to be repeated if they were 
completed within 7 days (or within 28 days for disease response [imaging] assessments). 
A Safety Follow-up telephone contact to inquire about resolution of any residual AE(s) 
will be made 30 (+7) days after the last dose of study drug, or at the time the patient 
initiates another antineoplastic therapy for GIST or solid tumor. Thereafter, patients will 
be followed approximately every 3 months until death, withdrawal of consent or closure 
of the study by the Sponsor. 
7.7 
Sample Processing, Storage, and Shipment 
Instructions for the processing, storage, and shipment of all study samples for central 
analysis will be provided in a separate study manual. 
Samples will be stored until analysis and remaining samples and/or tissue may be 
retained until 10 years after the completion of the study, or until the research is 
discontinued, whichever occurs first. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 78 of 110
 
 
 
28 February 2018
 
8 STUDY DRUG MANAGEMENT 
8.1 
Description 
8.1.1 
Formulation 
BLU-285 will be administered as a drug in capsule formulation or an immediate release 
tablet for oral administration. The drug substance and drug product are manufactured and 
formulated following current Good Manufacturing Practices.  
Each BLU-285 hard-gelatin capsule contains 5 mg (size 4 dark green opaque), 10 mg 
(size 3 white opaque), 30 mg (size 2 gray opaque), or 100 mg (size 1 light blue opaque) 
of the active drug substance. 
Each BLU-285 tablet is blended with compendial excipients. The formulation blend is 
roller compacted, compressed into white round tablets and aesthetically film coated. 
BLU-285 tablets are prepared as 100 mg in strength.   
All study drugs are for investigational use only and should only be used within the 
context of this study. 
8.1.2 
Storage 
BLU-285 capsules and tablets must be stored at room temperature in their original 
container, according to the package label. 
All study drug products must be stored in a secure, limited-access location and may be 
dispensed only by the Investigator or by a member of the staff specifically authorized by 
the Investigator. 
8.2 
Packaging and Shipment 
BLU-285 capsules and tablets will be supplied in to the study center packaged in 60 cc 
Wide Mouth Round high-density polyethylene bottles. Each bottle will be induction-
sealed and capped with a 33 mm child-resistant closure. 
Packaging will meet all regulatory requirements. 
8.3 
Accountability 
Accountability for the study drug at the study site is the responsibility of the Investigator. 
The Investigator will ensure that the study drug is used only in accordance with this 
protocol. Where allowed, the Investigator may choose to assign drug accountability 
responsibilities to a pharmacist or other appropriate individual. 
The Investigator or delegate will maintain accurate drug accountability records indicating 
the drug’s delivery date to the site, inventory at the site, use by each patient, and return to 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 79 of 110
 
 
 
28 February 2018
 
the Sponsor or its designee (or disposal of the drug, if approved by the Sponsor). These 
records will adequately document that the patients were provided the doses as specified 
in the protocol and should reconcile all study drug received from the Sponsor. 
Accountability records will include dates, quantities, batch/serial numbers, expiration 
dates (if applicable), and patient numbers. The Sponsor or its designee will review drug 
accountability at the site on an ongoing basis during monitoring visits. 
Study drug must not be used for any purpose other than the present study. Study drug that 
has been dispensed to a patient and returned unused must not be re-dispensed to a 
different patient. 
Patients will receive instructions for home administration of BLU-285. 
All study drug that is either unused or dispensed and returned should be retained at the 
site until it is inventoried by the study monitor. All used, unused, or expired study drug 
will be returned to the Sponsor or its designee, or if authorized, disposed of at the study 
site per the site’s Standard Operating Procedures and documented. All material 
containing BLU-285 will be treated and disposed of as hazardous waste in accordance 
with governing regulations. 
8.4 
Compliance 
Patients will be dispensed the appropriate number of study drug bottles to allow for 
dosing for a full cycle, or until the next scheduled visit. Patients are to return all unused 
capsules and tablets (or the empty bottles) on D1 of each treatment cycle or at the next 
scheduled visit. Compliance with the dosing regimen will be assessed based on return of 
unused drug (or empty bottles). 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 80 of 110
 
 
 
28 February 2018
 
9 ADVERSE EVENTS 
Monitoring of AEs will be conducted throughout the study. Adverse events will be 
recorded in the eCRF from the time of first study drug dose through 30 days after the last 
dose of study drug. SAEs and serious pretreatment events (see Section 10) will be 
recorded in the eCRF from the time of signing informed consent through 30 days after 
the last dose of study drug. In addition, SAEs that are assessed as possibly or probably 
related to study treatment that occur > 30 days post-treatment will also be reported. All 
AEs should be monitored until they are resolved or are clearly determined to be due to a 
patient’s stable or chronic condition or intercurrent illness(es). 
9.1 
Definitions 
9.1.1 
Definition of Adverse Event 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE (also referred to as an adverse experience) 
can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a drug, without any judgment 
about causality. An AE can arise from any use of the drug (e.g., off-label use, use in 
combination with another drug) and from any route of administration, formulation, or 
dose, including an overdose. Overdose includes only clinically symptomatic doses that 
are at least twice the intended dose.  
An abnormal laboratory value will not be assessed as an AE unless that value leads to 
discontinuation or delay in treatment, dose modification, therapeutic intervention, or is 
considered by the Investigator to be clinically significant. 
In general, disease progression should not be reported as an AE (or an SAE), or cause of 
death in this study. Instead the AEs (or SAEs) considered as complications of disease 
progression should be reported. However, if no specific complications of disease 
progression can be identified that explain the clinical observations, “disease progression” 
may be reported as an AE, SAE or cause of death.  
9.1.2 
Suspected Adverse Reaction 
A suspected adverse reaction is any treatment-emergent AE that is not clearly attributable 
to a cause other than BLU-285. 
9.1.3 
Unexpected Adverse Event 
An unexpected AE is one for which the nature or severity of the event is not consistent 
with the applicable product information, e.g., the IB. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 81 of 110
 
 
 
28 February 2018
 
9.2 
Documenting Adverse Events 
Each patient must be carefully monitored for the development of any AEs. This 
information should be obtained in the form of non-leading questions (e.g., “How are you 
feeling?”) and from signs and symptoms detected during each examination, observations 
of study personnel, and spontaneous reports from patients. 
All AEs (serious and non-serious) spontaneously reported by the patient and/or in 
response to an open question from study personnel or revealed by observation, physical 
examination, or other diagnostic procedures will be recorded in the appropriate section of 
the eCRF. Any clinically significant value in laboratory assessments or other clinical 
findings is considered an AE and must be recorded on the appropriate pages of the eCRF. 
A laboratory value may also be considered an AE when it qualifies as a SAE, when it 
requires medical intervention, or when it affects dosing with study drug. When possible, 
signs and symptoms indicating a common underlying pathology should be noted as one 
comprehensive event. 
9.3 
Assessment of Intensity 
Intensity of all AEs, including clinically significant treatment-emergent laboratory 
abnormalities, will be graded according to the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE), version 4.03. Adverse events not 
listed in the CTCAE will be graded as follows: 
• Grade 1: Mild, the event is noticeable to the patient but does not interfere with routine 
activity. 
• Grade 2: Moderate, the event interferes with routine activity but responds to 
symptomatic therapy or rest. 
• Grade 3: Severe, the event significantly limits the patient’s ability to perform routine 
activities despite symptomatic therapy. 
• Grade 4: Life-threatening, an event in which the patient was at risk of death at the 
time of the event. 
• Grade 5: Fatal, an event that results in the death of the patient. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 82 of 110
 
 
 
28 February 2018
 
9.4 
Assessment of Causality 
Relationship to study drug administration will be determined by the Investigator 
according to the following criteria: 
• Not Related: Exposure to the study treatment did not occur, or the occurrence of the 
AE is not reasonably related in time, or the AE is considered unlikely to be related to 
the study treatment. 
• Possibly Related: The study treatment and the AE were reasonably related in time, 
and the AE could be explained equally well by causes other than exposure to the 
study treatment. 
• Probably Related: The study treatment and the AE were reasonably related in time, 
and the AE was more likely explained by exposure to the study treatment than by 
other causes, or the study treatment was the most likely cause of the AE. 
9.5 
Pretreatment Events 
A pretreatment event is any untoward occurrence in a patient who has signed informed 
consent to participate in a study but before administration of any study drug. It does not 
necessarily have a causal relationship with study participation. A serious pretreatment 
event meets the criterion of a pretreatment event and satisfies any of the 6 criteria 
specified for an SAE as described in Section 10. 
9.6 
Pregnancy Reporting 
Pregnancy is neither an AE nor an SAE, unless a complication relating to the pregnancy 
occurs (e.g., spontaneous abortion, which may qualify as an SAE). 
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of 
age or disease state) of a female patient or partner of a male patient occurring while the 
patient is on study drug, or within 30 days of the patient’s last dose of study drug, are 
considered immediately reportable events. If a female partner of a male patient taking 
investigational product becomes pregnant, the male patient taking BLU-285 should notify 
the Investigator, and the pregnant female partner should be advised to call her healthcare 
provider immediately. In pregnant female patients, study drug is to be discontinued 
immediately and the patient instructed to return any unused BLU-285 to the Investigator. 
The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
immediately using the Pregnancy Report Form. The Investigator must follow up and 
document the course and outcome of all pregnancies even if the patient was discontinued 
from the study or if the study has finished. The female patient or partner of a male patient 
should receive any necessary counseling regarding the risks of continuing the pregnancy 
and the possible effects on the fetus. Monitoring should continue until conclusion of the 
pregnancy. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 83 of 110
 
 
 
28 February 2018
 
All outcomes of pregnancy must be reported by the Investigator to the Sponsor or 
Medical Monitor on a Pregnancy Outcome Report form within 30 days after he/she has 
gained knowledge of the delivery or elective abortion.  
Any SAE that occurs during pregnancy must be recorded on the SAE report form (e.g., 
maternal serious complications, spontaneous or therapeutic abortion, ectopic pregnancy, 
stillbirth, neonatal death, congenital anomaly, or birth defect) and reported within 
24 hours in accordance with the procedure for reporting SAEs. 
9.6.1 
Contraception Requirements 
Women of childbearing potential must agree to use a highly effective method of 
contraception (Clinical Trial Facilitation Group, 2014) throughout the study drug 
administration period until at least 30 days after the last dose of BLU-285. Women are 
considered to be of childbearing potential following menarche and until becoming post-
menopausal (defined as no menses for at least 12 months without an alternative medical 
cause) unless permanently sterile. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a post-menopausal state in women not 
using hormonal contraception or hormonal replacement therapy. However, in the absence 
of 12 months of amenorrhea, a single FSH measurement is insufficient. Permanent 
sterilization methods include hysterectomy, bilateral salpingectomy and bilateral 
oophorectomy (Clinical Trial Facilitation Group, 2014). Because BLU-285 is a potential 
CYP3A4 inducer, women should use hormonal contraception with caution and 
supplement with other highly effective methods.  
Men with partners who are women of reproductive potential must agree that they will use 
condoms and their partners will use highly effective contraceptive methods throughout 
the study drug administration period until at least 90 days after the last dose of BLU-285. 
Highly effective forms of contraception are defined as the following (Clinical Trial 
Facilitation Group, 2014):  
• Combined (estrogen and progestogen containing) hormonal contraceptives that 
inhibit ovulation, including oral, intravaginal and transdermal products. 
• Progestogen-only hormonal contraceptives that inhibit ovulation, including oral, 
injectable and implanted products.  
• Intrauterine devices (IUD) and intrauterine hormone-releasing system (IUS).  
• Bilateral tubal occlusion (women).  
• Male partner vasectomy or other method of surgical sterilization provided that the 
partner is the sole sexual partner of the trial participant and the vasectomized 
partner has received medical assessment of surgical success.  


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 84 of 110
 
 
 
28 February 2018
 
• Sexual abstinence (men and women), when this is the preferred and usual lifestyle 
of the patient. Periodic abstinence (such as a calendar, symptothermal and post- 
ovulation methods, withdrawal (coitus interruptus), and the lactational 
amenorrhea method are not acceptable methods of contraception.  
The following methods of contraception are not considered highly effective (Clinical 
Trials Facilitation Group, 2014): 
• Progestogen-only oral hormonal contraception that do not inhibit ovulation.  
• Barrier methods with or without spermicide, or spermicide alone. 
9.6.2 
Gamete and Embryo Banking 
Hypospermatogenesis was observed in the testis and epididymis of rats and dogs and did 
not recover after 2-week recovery. Patients should be informed of the possibility of 
gamete and embryo banking. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 85 of 110
 
 
 
28 February 2018
 
10 SERIOUS ADVERSE EVENT 
10.1 Definition of Serious Adverse Event 
An SAE is any event that meets any of the following criteria: 
• Death. 
• Life-threatening. 
An AE is life threatening if the patient was at immediate risk of death from the event 
as it occurred; i.e., it does not include a reaction that if it had occurred in a more 
serious form might have caused death. For example, drug-induced hepatitis that 
resolved without evidence of hepatic failure would not be considered life threatening 
even though drug induced hepatitis can be fatal. 
• Inpatient hospitalization or prolongation of existing hospitalization. 
Adverse events requiring hospitalization should be considered SAEs. Hospitalization 
for elective surgery or routine clinical procedures that are not the result of AE (e.g., 
elective surgery for a pre-existing condition that has not worsened) need not be 
considered AEs or SAEs. If anything untoward is reported during the procedure, that 
occurrence must be reported as an AE, either 'serious' or 'non-serious' according to the 
usual criteria. 
In general, hospitalization signifies that the patient has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician's 
office or outpatient setting. When in doubt as to whether 'hospitalization' occurred or 
was necessary, the AE should be considered serious. 
• Persistent or significant disability/incapacity. 
An AE is incapacitating or disabling if the experience results in a substantial and/or 
permanent disruption of the patient's ability to carry out normal life functions. 
• Congenital anomaly/birth defect in the offspring of a subject who received BLU-285. 
• Other: Important medical events that may not result in death, be life-threatening, or 
require hospitalization, may be considered an SAE when, based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 86 of 110
28 February 2018
surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such events are: 
o
Intensive treatment in an emergency room or at home for allergic bronchospasm.
o
Blood abnormalities or convulsions that do not result in inpatient hospitalization.
o
Development of drug dependency or drug abuse.
10.2 Reporting Serious Adverse Events 
All SAEs or serious pretreatment events that occur during the course of the study must be 
promptly reported by the Investigator to Chiltern International. Deaths and AEs assessed 
as life-threatening are to be reported immediately and SAEs that meet other criteria are to 
be reported within 24 hours from the point in time when the Investigator becomes aware 
of the SAE. All SAEs must be reported whether or not they are considered causally 
related to BLU-285. Serious AE forms will be completed and the information collected 
will include patient number, a narrative description of the event, and an assessment by the 
Investigator as to the severity of the event and relatedness to study drug. Follow-up 
information on the SAE may be requested by the Sponsor or Medical Monitor. 
 
 
 
  
 
 
If there are serious, unexpected adverse drug reactions associated with the use of 
BLU-285, the Sponsor will notify the appropriate regulatory agency(ies) and all 
participating Investigators on an expedited basis. The local Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) will be promptly notified based on local 
regulations where required by the IRB/IEC of all serious, unexpected adverse drug 
reactions involving risk to human patients. 
All AEs, whether serious or not, will be described in the source documents and in the 
appropriate section of the eCRF. All new events, as well as those that worsen in intensity 
or frequency relative to baseline, which occur after signing the informed consent through 
30 days following the last dose of study drug, must be recorded. Adverse events that are 
ongoing at the time of treatment discontinuation should be followed through the 30-day 
follow up assessment. Serious AEs felt by the Investigator to be related to BLU-285, 
however, must be reported any time the Investigator becomes aware of such an event, 
even if this occurrence is more than 30 days after the last dose of study drug. 
Information to be reported in the description of each AE includes: 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 87 of 110
 
 
 
28 February 2018
 
• A medical diagnosis of the event (if a medical diagnosis cannot be determined, a 
description of each sign or symptom characterizing the event should be recorded). 
• The date of onset of the event. 
• The date of resolution of the event. 
• Whether the event is serious or not. 
• Intensity of the event (see Section 9.3 for definitions). 
• Relationship of the event to study treatment (see Section 9.4 for definitions). 
• Action taken: none; change in the study drug administration (e.g., temporary 
interruption in dosing); drug treatment required; non-drug treatment required; 
hospitalization or prolongation of hospitalization required (complete SAE page); 
diagnostic procedure performed; patient discontinued from the study (complete End 
of Study visit). 
• Outcome: patient recovered without sequelae; patient recovered with sequelae; event 
ongoing; patient died (notify the Medical Monitor immediately, and complete the 
SAE form).  
10.2.1 
Overdose 
Overdose includes only clinically symptomatic doses that are at least twice the intended 
dose. Any instance of overdose (suspected or confirmed and irrespective of whether or 
not it involved BLU-285) must be communicated to Blueprint Medicines or a specified 
designee within 24 hours and be fully documented as an SAE. Details of any signs or 
symptoms and their management should be recorded including details of any antidote(s) 
administered. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 88 of 110
28 February 2018
11 STATISTICS 
11.1 General Procedures 
Continuous variables will be summarized using descriptive statistics (n, mean, standard 
deviation, median, minimum, and maximum). 
Categorical variables will be summarized showing the number and percentage (n, %) of 
patients within each classification. Appropriate confidence intervals will also be 
presented. Time to event data will be summarized using Kaplan-Meier methods, which 
will include the estimated median with 95% CIs and 25th and 75th percentiles. 
Safety, efficacy, PK, and PD evaluations will be assessed in the appropriate populations. 
These data will be summarized descriptively by dose level, dose groups, and overall as 
appropriate. Statistical hypothesis testing will be applied to the analysis of ORR in 
patients with starting dose of 300 or 400 mg QD (RP2D and MTD, respectively) in the 
following groups of patients: patients with PDGFRα D842V mutation, patients with no 
PDGFRα D842V mutation in second line treatment, and patients with no PDGFRα 
D842V mutation in 3+ line treatment. 
The primary analysis for patients with PDGFRα D842V and patients with no PDGFRα 
D842V mutation in 3+ line treatment will occur after the number of patients specified in 
the sample size calculations for each group have enrolled and had the opportunity for 
8 months of treatment or have ended treatment earlier. A clinical study report will be 
written using this analysis. The final database lock will occur after all patients enrolled in 
Part 2 have had an opportunity for 8 months of treatment or have ended treatment earlier. 
A clinical study report addendum will be written to include the primary efficacy analysis 
for patients with no PDGFRα D842V mutation in second line treatment and update 
clinical study report analyses with further follow up data from all patients. 
All data will be provided in by-patient listings. 
A separate Statistical Analysis Plan (SAP) will be finalized prior to locking the database. 
11.2 Analysis Populations 
The following analysis populations will be used for presentation of the data: 
•
Safety Population: The safety population includes all patients who have received at
least 1 dose of study drug. Patients will be analyzed based on the dose they receive.
The safety population will be the primary population for efficacy and safety analysis
unless otherwise specified.
•
Dose Determining (DD) Population: The DD population includes all patients in Part 1
who have received at least 75% of their prescribed doses (i.e., ≥ 21 doses) of the
study drug in C1 and completed follow-up through C1D28 or experienced a DLT
regardless of extent of study drug exposure. The DD population will be the default


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 89 of 110
28 February 2018
analysis population for the dose escalation phase for all MTD related analyses. 
Patients will be analyzed according to the dose they receive. 
•
Response-Evaluable (RE) Population: The RE population includes all patients in the
safety population who have at least 1 target lesion per mRECIST version 1.1, at
baseline, have at least 1 postbaseline disease assessment by central radiology per
mRECIST version 1.1, and have experienced no major protocol violations. Subjects
will be analyzed according to the dose they receive. Selected efficacy analyses may
be performed using the RE population.
Within each of the safety, DD, and RE populations, selected analyses may be conducted 
based on subpopulations such as PDGFRα D842V, PDGFRα Exon 18, PDGFRα, and 
non- PDGFRα D842V. 
•
PK Population: The PK population includes patients who have sufficient plasma
concentration-time data to reliably estimate the PK parameters of BLU-285.
•
ECG Population: The ECG population includes patients who undergo continuous
Holter monitoring and have sufficient ECG tracings so that the QT interval corrected
for heart rate (QTc) parameter can be evaluated.
11.3 Sample Size 
The total number of patients to be enrolled in the Part 1 is dependent upon the observed 
safety profile, which will determine the number of patients per dose cohort, as well as the 
number of dose escalations required to achieve the MTD or identify the RP2D. It is 
expected that approximately 50 patients who meet the criteria for the DD Population will 
be enrolled in Part 1.  
Sample size calculation for Part 2 takes into consideration patients treated at the RP2Ds 
in Part 1.  
For patients with PDGFRα D842V mutation, a sample size of 31 patients will allow 
testing the null hypothesis of ORR ≤ 10% versus the alternative hypothesis of ORR ≥ 
35% using Fisher’s exact test with 90% power assuming a 2-sided type I error rate of 
0.05. 
For patients with no PDGFRα D842V mutation in second line treatment, a sample size of 
50 patients will allow testing the null hypothesis of ORR ≤ 10% versus the alternative 
hypothesis of ORR ≥ 25% using Fisher’s exact test with 83% power assuming a 2-sided 
type I error rate of 0.05. 
For patients with no PDGFRα D842V mutation in 3+ line treatment, a sample size of 
100 patients will allow testing the null hypothesis of ORR ≤ 5% versus the alternative 
hypothesis of ORR ≥ 15% using Fisher’s exact test with 90% power assuming a 2-sided 
type I error rate of 0.05. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 90 of 110
28 February 2018
11.4 Procedures for Handling Missing, Unused, and Spurious Data 
No imputation will be performed for missing data elements. Dates that are partially 
missing or impossible will be imputed using the method described in the SAP. 
11.5 Statistical Methods 
11.5.1 
Disposition 
A tabulation of the disposition of patients will be presented, including the number 
enrolled, the number treated, and the reasons for study discontinuation. Entry criteria and 
protocol deviations will be listed. 
11.5.2 
Demographic and Baseline Characteristics 
Demographic and baseline disease characteristic data will be summarized descriptively. 
11.5.3 
Exposure Analysis 
A summary of study drug exposure, including number of doses administered, total dose, 
duration of treatment, dose intensity, and the proportion of patients with dose 
modifications will be produced. 
11.5.4 
Primary Endpoint(s) 
Parts 1 and 2:  
Safety evaluations will be based on the incidence, severity, and type of AEs, and changes 
in the patient’s vital signs, clinical laboratory results, and ECG findings. Summarization 
will focus on incidence of any SAEs, AEs, drug-related AEs, and AEs leading to 
discontinuation or death, and will be presented in tabular form by system organ class and 
preferred term. Tabulations of the incidence of DLTs at each dose level will be provided. 
Adverse events will be assessed for severity according to the NCI CTCAE, version 4.03, 
and the verbatim AE terms will be coded using the Medical Dictionary for Regulatory 
Activities for purposes of summarization. 
Treatment-emergent AEs will be tabulated, where treatment-emergent is defined as any 
AE that occurs during or after administration of the first dose of study drug through 
30 days after the last dose of study drug, any event that is considered study drug-related 
regardless of the start date of the event, or any event that is present at baseline but 
worsens in intensity or is subsequently considered study drug-related by the Investigator. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 91 of 110
28 February 2018
Part 2: 
Overall response rate is defined as the proportion of patients with a confirmed best 
response of CR or PR. Overall response rate will be estimated and 95% CI based on the 
exact binomial distribution will be presented.  
An observed ORR of ≥ 26% in 31 patients in Group 2 will result in an exact binomial 
95% CI with a lower bound greater than 10% (Table 13), which is clinically meaningful, 
and exceeds the ORR expected with available therapies Cassier et al, 2012; Yoo et al, 
2015). 
An observed ORR of ≥ 20% in 50 patients in Group 3 will result in an exact binomial 
95% CI with a lower bound greater than 10% (Table 14), which is clinically meaningful, 
and exceeds the ORR expected with available therapies (Goodman et al, 2007; Sutent 
[package insert]). 
An observed ORR of ≥ 11% in 100 patients in Group 1 will result in an exact binomial 
95% CI with a lower bound greater than 5% (Kang et al, 2013; Stivarga [package insert]). 
An observed ORR of ≥ 17% in 100 patients will result in an exact binomial 95% CI with 
a lower bound greater than 10% (Table 15). 
Table 13: 
Confidence Interval of Observed Response Rate, N = 31 
Observed ORR 
Number of Confirmed 
CR/PR 
Exact 95% CI 
23% 
7 
(9.59; 41.10) 
26% 
8 
(11.86; 44.61) 
52% 
16 
(33.06; 69.85) 
55% 
17 
(36.03; 72.68) 
Abbreviations: ORR = overall response rate; CR = complete response; PR = partial response; 
CI = confidence interval. 
Table 14: 
Confidence Interval of Observed Response Rate, N = 50 
Observed ORR 
Number of Confirmed 
CR/PR 
Exact 95% CI 
18% 
9 
(8.58; 31.44) 
20% 
10 
(10.03; 33.72) 
28% 
14 
(16.23; 42.49) 
34% 
17 
(21.21; 48.77) 
40% 
20 
(26.41; 54.82) 
Abbreviations: ORR = overall response rate; CR = complete response; PR = partial response; 
CI = confidence interval. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 92 of 110
28 February 2018
Table 15: 
Confidence Interval of Observed Response Rate, N = 100 
Observed ORR 
Number of Confirmed 
CR/PR 
Exact 95% CI 
10% 
10 
(4.90; 17.62) 
11% 
11 
(5.62; 18.83) 
15% 
15 
(8.65; 23.53) 
16% 
16 
(9.43; 24.68) 
17% 
17 
(10.23; 25.82) 
Abbreviations: ORR = overall response rate; CR = complete response; PR = partial response; 
CI = confidence interval. 
ECG Assessment: 
In Part 2, the effects of BLU-285 on ECG parameters will be evaluated for approximately 
20 patients using 12-lead ECGs extracted from continuous recordings (12-lead Holter) on 
C1D1 and C1D15. Individual ECGs will be extracted in replicate from the 12-lead Holter 
recordings at specified time points and will be evaluated by a central laboratory. QT 
intervals will be measured from Lead II and will be corrected for heart rate (QTc) using 
Fridericia’s correction factors. The primary QTc parameter will be QTcF. Secondary 
parameters (heart rate, PR, and QRS, and T-wave morphology) will also be evaluated. 
Potential effects of BLU-285 will be evaluated as change-from predose baseline heart 
rate, PR, QRS, and QTcF by post-dosing time point. For the purpose of QT assessment, 
exposure-response analysis will be performed on the relationship between BLU-285 
systemic levels and change in QTcF. 
11.5.5 
Secondary Endpoint(s) 
Pharmacokinetics:  
Pharmacokinetic parameters will be calculated from the plasma concentration-time data 
using standard non-compartmental methods and/or by suitable models that describe BLU-
285 disposition. Descriptive statistics (i.e., n, mean, standard deviation, geometric mean, 
coefficient of variation, median, minimum, maximum, and 95% CIs) will be used to 
summarize PK parameters for each dose level. The dose versus systemic exposure 
relationships will be assessed graphically. Pharmacokinetic parameters of interest will 
include maximum plasma drug concentration (Cmax), time to maximum plasma drug 
concentration (Tmax), time of last quantifiable plasma drug concentration (Tlast), area 
under the plasma concentration versus time curve from time 0 to 24 hours postdose 
(AUC0-24), plasma drug concentration at 24 hours postdose (C24); apparent volume of 
distribution (Vz/F), terminal elimination half-life (t½), apparent oral clearance (CL/F), and 
accumulation ratio (R). Additional details of the PK analyses, including combined 
analyses of the ECG and PK parameters, will be contained in the statistical analysis plan 
(SAP). 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 93 of 110
28 February 2018
Efficacy: 
Progression free survival is defined as the time from the start of treatment to the date of 
first documented disease progression or death. Progression free survival will be described 
using Kaplan-Meier methods and will include the estimated median with 95% CIs and 
25th and 75th percentiles. Estimated PFS rate at 3-, 6-, and 12-month landmarks will also 
be presented. If a patient has not had an event, PFS is censored at the date of last response 
assessment that is stable or better. 
Duration of response is defined as the time from first documented response (CR/PR) to 
the date of first documented disease progression or death; and is limited to the subset of 
patients with confirmed CR or PR. Duration of response will be described using 
Kaplan-Meier methods and will include the estimated median with 95% CIs and 25th and 
75th percentiles. Censoring rules for DOR will be the same as those for PFS. 
Clinical benefit rate is defined as the proportion of patients with a confirmed CR/PR, or 
stable disease lasting for 4 cycles from the start of treatment. Clinical benefit rate will be 
summarized similarly as ORR.  
Response rate per Choi criteria will be summarized descriptively. 
Progression free survival on last prior anticancer therapy will be summarized. Estimated 
PFS rate at 3-, 6-, and 12-month landmarks will also be presented. Statistical testing such 
as log-rank test; and z-test for PFS rate at 3-, 6-, and 12-month landmarks maybe 
performed to further understand the differences between PFS on avapritinib versus PFS 
on last prior anticancer therapy.  
KIT, PDGFRα, and other cancer-relevant mutations present in tumor tissue at baseline: 
Mutation analysis results will be presented descriptively including those reported on the 
case report form and central assessment of the KIT, PDGFRα and other cancer-relevant 
mutations. 
Biologic Activity: 
Change in KIT, PDGFRα and other cancer relevant mutant allele fractions in ctDNA will 
be presented descriptively. 
 
 
 
 
 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 94 of 110
28 February 2018
 
 
 
 
11.6 Procedures for Reporting Deviations to Original Statistical Analysis 
Plan 
All deviations from the original SAP will be provided in the final clinical study report. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 95 of 110
 
 
 
28 February 2018
 
12 ETHICS AND RESPONSIBILITIES 
12.1 Good Clinical Practice 
The study will be conducted in accordance with the International Conference on 
Harmonization (ICH) for GCP and the appropriate regulatory requirement(s). The 
Investigator will be thoroughly familiar with the appropriate use of the study drug as 
described in the protocol and IB. Essential clinical documents will be maintained to 
demonstrate the validity of the study and the integrity of the data collected. Master files 
should be established at the beginning of the study, maintained for the duration of the 
study, and retained according to the appropriate regulations. 
12.2 Data and Safety Monitoring Committee 
A formal independent data monitoring committee will not be used for this study. This is 
an open-label, Phase 1 study in which all patients receive single-agent BLU-285. The 
Sponsor will have access to the safety data on a regular basis. The Sponsor Clinical Study 
Team will host Investigator teleconferences on a regular basis during the study. During 
the Part 1 of the study, the Sponsor Clinical Study Team and the Investigators will meet 
at the end of each treatment cohort to discuss and evaluate all of the gathered safety data. 
At the dose-escalation teleconference, safety information, including DLTs and all 
Grade 2 or worse AEs reported during C1, and all available PK data will be described 
and reviewed for each patient in the current dose cohort. Updated safety, PK and other 
data for all other ongoing patients, including data from later cycles, will also be 
discussed.  
Dose-escalation decisions will be based on an evaluation of all relevant, available data, 
and not solely on DLT information. The selection of the dose for the next cohort of 
patients will be limited to a 100% increase for the first escalation and 50% thereafter, or 
to the addition of 3 patients with no dose increase, as described in Section 6.4. However, 
the actual dose level chosen may be less than the maximum permitted, and will be based 
on a medical review of relevant clinical and available PK data. The Sponsor Clinical 
Study Team and the Investigators must reach agreement on whether to determine that the 
MTD has been achieved, to escalate the dose further, or to de-escalate to a lower dose. 
12.3 Institutional Review Board/Independent Ethics Committee 
The study will be conducted in accordance with ethical principles founded in the 
Declaration of Helsinki. 
The Investigator must obtain IRB/IEC approval for the investigation and must submit 
written documentation of the approval to the Sponsor before he or she can enroll any 
patient into the study. The IRB/IEC will review all appropriate study documentation in 
order to safeguard the rights, safety, and well-being of the patients. The study will only 
be conducted at sites where IRB/IEC approval has been obtained. The protocol, IB, 
informed consent, advertisements (if applicable), written information given to the 
patients, safety updates, annual progress reports, and any revisions to these documents 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 96 of 110
 
 
 
28 February 2018
 
will be provided to the IRB/IEC. The IRB/IEC is to be notified of any amendment to the 
protocol in accordance with local requirements. Progress reports and notifications of 
serious unexpected adverse drug reactions will be provided to the IRB/IEC according to 
local regulations and guidelines. 
12.4 Informed Consent 
The Investigator at each center will ensure that the patient is given full and adequate oral 
and written information about the nature, purpose, possible risk, and benefit of the study. 
Patients must also be notified that they are free to discontinue from the study at any time. 
The patient should be given the opportunity to ask questions and allowed time to consider 
the information provided. 
After the study has been fully explained, written informed consent, including separate 
consent for exploratory biomarker research to be conducted on biological samples 
collected during the study, will be obtained from either the patient or his/her guardian or 
legal representative prior to study participation. 
The patient’s signed and dated informed consent must be obtained before conducting any 
study-related procedures. The Investigator must maintain the original, signed consent 
form. A copy of the signed form must be given to the patient. 
The method of obtaining and documenting the informed consent and the contents of the 
consent will comply with ICH-GCP and all applicable regulatory requirement(s). 
12.5 Records Management 
All data for the patients recruited for the study will be entered onto the eCRFs via an 
Electronic Data Capture system provided by the Sponsor or designee. Only authorized 
staff may enter data into the eCRFs. If an entry error is made, the corrections to the 
eCRFs will be made according to eCRF guidelines by an authorized member of the site 
staff. 
Electronic case report forms will be checked for correctness against source document 
data by the Sponsor’s monitor. If any entries into the eCRF are incorrect or incomplete, 
the monitor will ask the Investigator or the study site staff to make appropriate 
corrections, and the corrected eCRF will again be reviewed for completeness and 
consistency. Any discrepancies will be noted in the eCRF system by means of electronic 
data queries. Authorized site staff will be asked to respond to all electronic queries 
according to the eCRF guidelines. 
12.6 Source Documentation 
Source documents/eCRFs will be completed for each study patient. It is the Investigator’s 
responsibility to ensure the accuracy, completeness, and timeliness of the data reported in 
the patient’s source document/eCRF. The source document/eCRF should indicate the 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 97 of 110
 
 
 
28 February 2018
 
patient’s participation in the study and should document the dates and details of study 
procedures, AEs, and patient status. 
The Investigator, or designated representative, should complete the source 
document/eCRF as soon as possible after information is collected, preferably on the same 
day that a study patient is seen for an examination, treatment, or any other study 
procedure. Any outstanding entries must be completed immediately after the final 
examination. An explanation should be given for all missing data. 
The Investigator must sign and date the Investigator’s Statement at the end of the source 
document/eCRF to endorse the recorded data.  
The Investigator will retain all completed source documents. 
12.7 Study Files and Record Retention 
The Investigator will maintain all study records according to ICH-GCP and applicable 
regulatory requirement(s). Records will be retained for at least 2 years after the last 
marketing application approval or 2 years after formal discontinuation of the clinical 
development of the investigational product or according to applicable regulatory 
requirement(s). If the Investigator withdraws from the responsibility of keeping the study 
records, custody must be transferred to a person willing to accept the responsibility. The 
Sponsor must be notified in writing if a custodial change occurs. 
12.8 Liability and Insurance 
The Sponsor has subscribed to an insurance policy covering, in its terms and provisions, 
its legal liability for injuries caused to participating persons and arising out of this 
research performed strictly in accordance with the scientific protocol as well as with 
applicable law and professional standards. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 98 of 110
28 February 2018
13 AUDITING AND MONITORING 
The study will be monitored by the Sponsor or its designee. Monitoring will be done by 
personal visits from a representative of the Sponsor (site monitor) and will include on-site 
review of the source documents/eCRFs for completeness and clarity, cross-checking with 
source documents, and clarification of administrative matters will be performed. The 
review of medical records will be performed in a manner to ensure that patient 
confidentiality is maintained. 
The site monitor will ensure that the investigation is conducted according to protocol 
design and regulatory requirements by frequent communications. 
All unused study drug and other study materials should be destroyed or returned to the 
Sponsor or designee after the study has been completed, as directed by the Sponsor. 
Regulatory authorities, the IEC/IRB, and/or the Sponsor’s clinical quality assurance 
group or designee may request access to all source documents, eCRFs, and other study 
documentation for an on-site audit or inspection. Direct access to these documents must 
be guaranteed by the Investigator, who must provide support at all times for these 
activities. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 99 of 110
28 February 2018
14 AMENDMENTS 
Protocol modifications, except those intended to reduce immediate risk to study patients, 
may be made only by Blueprint Medicines. A protocol change intended to eliminate an 
apparent immediate hazard to patients may be implemented immediately, provided the 
IRB/IEC is notified within 5 days. 
Any permanent change to the protocol must be handled as a protocol amendment. The 
written amendment must be submitted to the IRB/IEC and the Investigator must await 
approval before implementing the changes. Blueprint Medicines will submit protocol 
amendments to the appropriate regulatory authorities for approval. 
If in the judgment of the IRB/IEC, the Investigator, and/or Blueprint Medicines, the 
amendment to the protocol substantially changes the study design and/or increases the 
potential risk to the patient and/or has an impact on the patient's involvement as a study 
participant, the currently approved written informed consent form will require similar 
modification. In such cases, informed consent will be renewed for patients enrolled in the 
study before continued participation. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 100 of 110
28 February 2018
15 STUDY REPORT AND PUBLICATIONS 
Blueprint Medicines is responsible for preparing and providing the appropriate regulatory 
authorities with clinical study reports according to the applicable regulatory 
requirements. 
The publication policy of Blueprint Medicines is discussed in the Investigator's Clinical 
Research Agreement. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 101 of 110
28 February 2018
16 STUDY DISCONTINUATION 
Both Blueprint Medicines and the Investigator reserve the right to terminate the study at 
the Investigator’s site at any time. Should this be necessary, Blueprint Medicines or a 
specified designee will inform the appropriate regulatory authorities of the termination of 
the study and the reasons for its termination, and the Investigator will inform the 
IRB/IEC of the same. In terminating the study, Blueprint Medicines and the Principal 
Investigator will assure that adequate consideration is given to the protection of the 
patients’ interests. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 102 of 110
28 February 2018
17 CONFIDENTIALITY 
All information generated in this study is considered confidential and must not be 
disclosed to any person or entity not directly involved with the study unless prior written 
consent is gained from Blueprint Medicines. However, authorized regulatory officials, 
IRB/IEC personnel, Blueprint Medicines and its authorized representatives are allowed 
full access to the records. 
Identification of patients and eCRFs shall be by initials and screening and treatment 
numbers only. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 103 of 110
28 February 2018
18 REFERENCES 
Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired 
resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene 
mutation. Clin Cancer Res. 2005 Jun 1;11(11):4182-90. 
Barnett CM, Heinrich MC. Management of tyrosine kinase inhibitor-resistant 
gastrointestinal stromal tumors. Am Soc Clin Oncol Educ Book. 2012:663-8. 
Cassier PA, Fumagalli E, Rutkowski P, Schoffski P, Van Glabbeke M, Debiec-Rychter 
M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated 
gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012 
Aug 15;18(16):4458-64. 
Clinical Trial Facilitation Group. Recommendations related to contraception and 
pregnancy testing in clinical trials [Online]. Available at: 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf. 
Accessed 06 May 2015. 
Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA 
mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity 
to imatinib. J Clin Oncol. 2005 Aug 10;23(23):5357-64. 
Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom 
AT, et al. KIT mutations and dose selection for imatinib in patients with advanced 
gastrointestinal stromal tumours. Eur J Cancer. 2006 May;42(8):1093-103. 
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. 
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after 
failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, 
placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302. 
U.S. Food and Drug Administration (FDA). Drug Development and Drug Interactions: 
Table of Substrates, Inhibitors, and Inducers [Online]. Available at: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIn
teractionsLabeling/ucm093664.htm#4. Updated 27 October 2014. Accessed 22 April 
2015. 
Gleevec [prescribing information]. East Hanover, NJ: Novartis; 2015 [Online]. Available 
at: http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf. Updated January 
2015. Accessed 22 April 2015. 
Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RMC, and 
Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results 
of a nation-wide study. Eur J Cancer. 2005 Dec;41(18):2868-72. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 104 of 110
 
 
 
28 February 2018
 
Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, et al. 
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant 
gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 
2007 Mar 1;13(5):1367-73. 
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary 
and secondary kinase genotypes correlate with the biological and clinical activity of 
sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 
20;26(33):5352-9. 
Kang YK, Ryu MH, Yoo, C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of Imatinib 
dosing to control metastatic gastrointestinal stromal tumors (GIST) after failure of 
imatinib and sunitinib: results of a randomised, placebo-controlled, phase 3 trial 
(RIGHT). Lancet Oncol. 2013 Nov; 14(12): 1175-1182. 
Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of 
kinase inhibitor resistant mechanisms in GIST. J Pathol. 2008 Sep;216(1):64-74. 
Matro JM, Yu JQ, Heinrich MC, Ramachandran A, Ku N, and von Mehren M. 
Correlation of PET/CT and CT RECIST response in GIST patients with PDGFRA 
D842V gene mutations treated with crenolanib. J Clin Oncol [Online] 32:5s, 2014 (suppl; 
abstr 10546). Available at: http:// meetinglibrary.asco.org/content/129852-144. Accessed 
22 April 2015. 
Miettinen M and Lasota J. Gastrointestinal Stromal Tumors: Review on Morphology, 
Molecular Pathology, Prognosis, and Differential Diagnosis. Arch Pathol Lab Med 2006; 
130: 1466-78. 
Nannini M, Biasco G, Astolfi A, and Pantaleo MA. An overview on molecular biology of 
KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genet. 
2013 Oct;50(10):653-61. 
National Comprehensive Cancer Network. Soft Tissue Sarcoma (Version 1. 2015) 
[Online]. Available at: http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. 
Accessed 22 April 2015. (Available upon request) 
Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. 
Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and 
prognostication in the preimatinib mesylate era--a population-based study in western 
Sweden. Cancer. 2005 Feb 15;103(4):821-9. 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 
1982 Dec;5(6):649-55. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 105 of 110
 
 
 
28 February 2018
 
Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, 
et al. A gist of gastrointestinal tumors: A review. World J Gastrointest Oncol. 2013 Jun 
15;5(6):102-12. 
Stivarga [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2017 
[Online]. Available at: http://labeling.bayerhealthcare.com/html/products/pi/ 
Stivarga_PI.pdf. Accessed 31 August 2017. 
Sutent [package insert]. New York, NY: Pfizer Labs; 2014 [Online]. Available at: 
http://labeling.pfizer.com/ShowLabeling.aspx?id=607. Accessed 09 March 2015. 
Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, et 
al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal 
tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006 Mar 
15;12(6):1743-9. 
Yoo C, Ryu MH, Jo J, Park I, Ryoo BY, Kang YK. Efficacy of Imatinib in Patients with 
Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal 
Tumors. Cancer Res and Treat. 2015;48(2):546-52. 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 106 of 110
 
 
 
28 February 2018
 
19 APPENDICES 
19.1 Appendix 1 
MODIFICATIONS TO RESPONSE EVALUATION CRITERIA IN 
SOLID TUMORS VERSION 1.1 (RECIST 1.1), FOR PATIENTS 
WITH GIST 
1. No lymph nodes to be chosen as target lesions. Enlarged lymph nodes are to be 
followed up as non-target lesions 
2. No bone lesions to be chosen as target lesions 
3. 18Fluorodeoxyglucose positron emission tomography (18FDG-PET) is not acceptable 
for radiological assessment 
4. A progressively growing new tumor nodule within a pre-existing tumor mass must 
meet the following criteria in order to be regarded as unequivocal evidence of 
progressive disease according to the aforementioned GIST-specific modifications to 
RECIST 1.1: 
a. The lesion must be ≥ 2 cm in size and definitely be a new active GIST lesions 
(e.g., enhanced with contrast or other criteria to rule out artifact); or 
b. The lesion must be expanding on at least 2 sequential imaging studies. 
Source: (Demetri et al, 2013). 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 107 of 110
 
 
 
28 February 2018
 
19.2 Appendix 2 
STRONG INHIBITORS AND INDUCERS OF CYP3A4 
Inhibitors 
Inducers 
Boceprevir 
Carbamazepine 
Clarithromycin 
Phenytoin 
Conivaptan 
Rifampin 
Cobicistat 
St. John’s Wort 
Grapefruit, Grapefruit juice 
Phenobarbital 
Indinavir 
 
Itraconazole 
 
Ketoconazole 
 
Lopinavir 
 
Nefazodone 
 
Nelfinavir 
 
Posaconazole 
 
Ritonavir 
 
Saquinavir 
 
Telaprevir 
 
Telithromycin 
 
Voriconazole 
 
 
Source: (FDA, 2016). 
This list is not intended to be exhaustive. A similar restriction will apply to other drugs that are known to 
strongly modulate CYP3A4; appropriate medical judgement is required. Please contact Blueprint 
Medicines with any queries relating to this issue. 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 108 of 110
28 February 2018
19.3 Appendix 3 
SUBSTRATES OF CYP3A4, CYP2C9 OR BCRP WITH A NARROW 
THERAPEUTIC RANGE 
CYP3A4 Substrates 
CYP2C9 Substrates 
BCRP Substrates 
Alfentanil 
Warfarin 
Rosuvastatin 
Cyclosporine 
Lapatinib 
Dihydroergotamine 
Methotrexate 
Ergotamine 
Fentanyl 
Midazolam 
Pimozide 
Quinidine 
Sirolimus 
Simvastatin 
Tacrolimus 
Terfenadine 
Source:  (FDA, 2016). 
This list is not intended to be exhaustive. A similar restriction will apply to other drugs that are sensitive 
substrates; appropriate medical judgement is required. Please contact Blueprint Medicines with any queries 
relating to this issue.


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 109 of 110
 
 
 
28 February 2018
 
19.4 Appendix 4 
EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE 
STATUS 
Grade 
Symptomatology 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work 
2 
Ambulatory and capable of all self-care but unable to carry out any work activities. 
Up and about more than 50% of waking hours 
3 
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours 
4 
Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 
Dead 
Source: (Oken et al, 1982). 
 


Protocol BLU-285-1101 Amendment 8 
Confidential
Avapritinib 
Page 110 of 110
28 February 2018
19.5 Appendix 5 
BLU-285-1101 
A PHASE 1 STUDY OF BLU-285 IN PATIENTS WITH 
GASTROINTESTINAL STROMAL TUMORS (GIST) AND OTHER 
RELAPSED AND REFRACTORY SOLID TUMORS  
CONFIDENTIALITY AND INVESTIGATOR STATEMENT 
The information contained in this protocol and all other information relevant to BLU-285 
are the confidential and proprietary information of Blueprint Medicines, and except as 
may be required by federal, state or local laws or regulation, may not be disclosed to 
others without prior written permission of Blueprint Medicines. 
I have read the protocol, including all appendices, and I agree that it contains all of the 
necessary information for me and my staff to conduct this study as described. I will 
conduct this study as outlined herein, in accordance with the regulations stated in the 
Federal Code of Regulations for Good Clinical Practices and International Conference on 
Harmonization guidelines, and will make a reasonable effort to complete the study within 
the time designated. 
I will provide all study personnel under my supervision copies of the protocol and any 
amendments, and access to all information provided by Blueprint Medicines or specified 
designees. I will discuss the material with them to ensure that they are fully informed 
about avapritinib and the study. 
Principal Investigator Name (printed) 
Signature 
Date 

SAP_001.pdf: 
Statistical Analysis Plan BLU-285-1101  
Avapritinib 
 
ClinicalTrials.gov Document Cover Page 
 
Statistical Analysis Plan 
 
Study BLU-285-1101 
 
Study Title: A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) 
and other Relapsed and Refractory Solid Tumors 
 
Document Date: 26 October 2018 
 
NCT Number: 02508532 




Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
2 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS...........................................6 
1. INTRODUCTION ................................................................................................................8 
1.1 Study Design ...................................................................................................................8 
1.2 Study Objectives ...........................................................................................................11 
 Primary Objectives ................................................................................................11 
 Secondary Objectives ............................................................................................11 
 Exploratory Objectives ..........................................................................................11 
1.3 Sample Size Justification ..............................................................................................12 
2. POPULATIONS FOR ANALYSIS ...................................................................................13 
2.1 Safety Population ..........................................................................................................13 
2.2 Dose-Determining Population ......................................................................................13 
2.3 Response-Evaluable Population ...................................................................................13 
2.4 Sub-Populations ............................................................................................................13 
3. GENERAL STATISTICAL CONSIDERATIONS ............................................................15 
3.1 Randomization, Stratification and Blinding .................................................................15 
3.2 Data Analysis General Information and Definition ......................................................15 
 Study Drug .............................................................................................................15 
 Day 1 and Other Days ............................................................................................15 
 Calculation Using Dates ........................................................................................15 
 Duration Derivation ...............................................................................................16 
 Baseline Values......................................................................................................16 
 Last Contact ...........................................................................................................16 
3.3 Methods for Handling Missing Data ............................................................................16 
3.4 Windowing of Visits .....................................................................................................16 
3.5 Withdrawals, Dropouts, Lost to Follow-Up .................................................................17 
3.6 Protocol Deviations ......................................................................................................18 
4. STATISTICAL METHODOLOGY ...................................................................................19 
4.1 Analysis Populations ....................................................................................................19 
4.2 Patient Disposition ........................................................................................................19 
4.3 Demographics and Baseline Disease Characteristics ...................................................20 
 Demographics ........................................................................................................20 
 Baseline Disease Characteristics ...........................................................................20 
 Medical History .....................................................................................................21 
4.4 Prior and Concomitant Medications and Prior Therapies ............................................21 
 Prior and Concomitant Medications ......................................................................21 
 Prior Therapies for the Underlying Malignancy ....................................................21 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
3 
4.5 Study Treatments and Extent of Exposure ...................................................................22 
 Treatment Duration and Exposure .........................................................................22 
 Cumulative Dose....................................................................................................23 
 Average Daily Dose ...............................................................................................23 
 Dose Intensity ........................................................................................................23 
 Relative Dose Intensity ..........................................................................................23 
 Dose Modification .................................................................................................23 
4.6 Efficacy Analyses .........................................................................................................24 
 Analysis of Primary Efficacy Endpoint .................................................................24 
 Analysis of Secondary Efficacy Endpoints ...........................................................25 
 Analysis of Exploratory Efficacy Endpoints .........................................................28 
 Subgroup Analysis .................................................................................................29 
4.7 Safety Analyses ............................................................................................................29 
 Adverse Events ......................................................................................................30 
 Adverse Events of Special Interest ........................................................................31 
 Deaths ....................................................................................................................33 
 Clinical Laboratory Evaluations ............................................................................33 
4.8 Vital Signs ....................................................................................................................33 
4.9 Electrocardiograms .......................................................................................................33 
4.10 ECOG Performance Status .........................................................................................34 
5. INTERIM ANALYSES ......................................................................................................35 
6. CHANGES TO PLANNED ANALYSES FROM THE PROTOCOL ..............................36 
7. APPENDICES ....................................................................................................................37 
7.1 Data Imputation Guidelines ..........................................................................................37 
 Adverse Event Date Imputation .............................................................................37 
 Concomitant Medication Date Imputation ............................................................38 
 Prior Therapies Date Imputation............................................................................38 
 Death Date Imputation ...........................................................................................39 
 Post-Therapies Date Imputation ............................................................................39 
 Other Imputations ..................................................................................................39 
7.2 Table, Listing, and Figure Format ................................................................................39 
7.3 Conventions ..................................................................................................................40 
8. REFERENCES ...................................................................................................................41 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
4 
LIST OF TABLES 
Table 1: 
Sample Size for Part 2 by Group ........................................................................ 12 
Table 2: 
Visit 
Windows 
for 
Patients 
Who 
Participate 
in 
a 
3-Day 
Pharmacokinetic-Lead in Stage .......................................................................... 17 
Table 3: 
Visit Windows for Other Patients ....................................................................... 17 
Table 4: 
Duration of Response and Progression Free Survival Censoring Rules ............ 26 
Table 5 
Summary of Adverse Event Tables: ................................................................... 32 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
5 
LIST OF FIGURES 
Figure 1: 
Study Schematic ................................................................................................. 10 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
6 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Term 
2L 
Second-line 
3L+ 
Third-line or later 
4L+ 
Fourth-line or later 
AE 
Adverse event 
AESI 
Adverse event of special interest 
BMI 
Body mass index 
BP 
Blood pressure 
C3D1 
Cycle 3 Day 1 
CBR 
Clinical benefit rate 
CI 
Confidence interval  
CR 
Complete response 
CS 
Clinically significant 
CSR 
Clinical study report 
CTCAE 
Common Terminology Criteria for Adverse Events 
ctDNA 
Circulating tumor deoxyribonucleic acid 
CXDX 
Cycle X Day X 
D842V 
Aspartic acid to valine at amino acid 842 
DD 
Dose-determining 
DE 
Dose escalation 
DOR 
Duration of response 
DLT 
Dose limiting toxicity 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
Electronic case report form 
EMA 
European Medicines Agency 
EOT 
End-of-treatment 
FDA 
Food and Drug Administration 
GIST 
Gastrointestinal stromal tumors 
KIT 
V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
KM 
Kaplan-Meier 
MAF 
Mutant allele fractions 
MedDRA 
Medical Dictionary for Regulatory Activities 
mRECIST 1.1 
Modified Response Evaluation Criteria in Solid Tumors version 1.1 
MTD 
Maximum tolerated dose 
NCI 
National Cancer Institute 
NCS 
Not clinically significant 
NE 
Not evaluable 
ORR 
Overall response rate 
OS 
Overall survival 
PD 
Progressive Disease 
PFS 
Progression free survival 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
7 
Abbreviation 
Term 
PDGFRα 
Platelet-derived growth factor receptor alpha 
PK 
Pharmacokinetic 
PGDx 
Personal Genome Diagnostics 
PR 
Partial response 
PT 
Preferred term 
QD 
Once daily 
RDI 
Relative dose intensity 
RE 
Response-evaluable 
R/R 
Relapsed or refractory  
RP2D 
Recommended phase 2 dose 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SD 
Stable disease 
SOC 
System organ class 
StdDev 
Standard deviation 
TEAE 
Treatment-emergent adverse event 
TKI 
Tyrosine kinase inhibitor 
TNM 
Tumor/lymph nodes/metastasis 
TTR 
Time to response 
US 
United States (of America) 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
8 
1. INTRODUCTION 
This statistical analysis plan (SAP) describes the statistical analysis and data presentations to 
be performed for Blueprint Medicines Corporation, Protocol Number. BLU-285-1101 
(amendment 8 dated 28 Feb 2018) “A Phase 1 Study of BLU-285 in Patients with 
Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors.” 
It contains definitions of analysis populations, derived variables, and statistical methods for 
the analysis of efficacy and safety. 
This Phase 1 study consists of Dose Escalation (DE) (Part 1) and Expansion (Part 2).  
The Part 2 further breaks down into 3 groups:  
• Group 1: Patients who have received treatment with imatinib and at least one other 
tyrosine kinase inhibitor (TKI) for the treatment of GIST (third-line or later [3L+]), 
and whose tumor lacks an aspartic acid to valine at amino acid 842 (D842V) mutation 
in platelet-derived growth factor receptor alpha (PDGFRα)  
• Group 2: Patients whose tumor contains a PDGFRα D842V mutation  
• Group 3: Patients who have received imatinib and no other TKI for the treatment of 
GIST (second-line [2L]), and whose tumor lacks a PDGFRα D842V mutation. 
The study data will be analyzed and reported based on all patients’ data from the Part 1 DE, 
and the combined Part 1 and Part 2 data by mutation type and/or line of therapy and dose 
levels with a data cutoff date of 16 Nov 2018 for the clinical study report (CSR). The database 
will be locked after the completion of the medical review of the data, and identification of 
protocol deviations, and the data cleaning. The SAP will be finalized and approved prior to 
the clinical database lock.  
At the time of the data cutoff date, the planned enrollment in Part 2 Groups 1 and 2 will be 
complete, however enrollment to Part 2 Group 3 might be ongoing. An addendum to the CSR 
analysis will therefore be conducted when all patients in the study have been enrolled and had 
sufficient treatment duration.  
All statistical analyses will be conducted using SAS version 9.3 or higher. 
Pharmacokinetic (PK), pharmacodynamic, and analyses of patients who undergo continuous 
Holter monitoring are not within the scope of this SAP and will be addressed separately. 
1.1 Study Design 
This is a Phase 1, open-label, first-in-human dose escalation (DE) /dose expansion study  
designed to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary 
antineoplastic activity of avapritinib (also known as BLU-285), administered orally, once 
daily (QD) in patients with unresectable GIST or other relapsed or refractory (R/R) solid 
tumors.  


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
9 
The study includes a DE part to determine the maximum tolerated dose (MTD) and 
recommended Phase 2 dose (RP2D); and an expansion part to further evaluate the safety and 
tolerability, and to assess the clinical efficacy of avapritinib at the MTD/RP2D (Figure 1). 
Dose Escalation (Part 1) 
The DE part of the study will enroll patients with unresectable GIST or a R/R solid tumor. 
Patients with GIST must have disease that has progressed following imatinib and at least 1 of 
the following: sunitinib, regorafenib, sorafenib, dasatinib, pazopanib or an experimental 
kinase-inhibitor agent, or disease with an D842V mutation in the PDGFRα gene. Patients with 
an advanced solid tumor other than GIST must have R/R disease without an available effective 
therapy. A standard 3+3 DE design using cohorts of 3 patients will be employed.  
The first cohort of patients will receive avapritinib at a starting dose of 30 mg QD. The DE 
increment for the first escalation step will be a maximum of 100%; all subsequent DE 
increments will be a maximum of 50%. 
Three patients will be enrolled initially in each cohort and an additional 3 patients (for a total 
of 6) will be enrolled should the cohort require expansion due to dose limiting toxicity (DLT). 
After the current escalation cohort is full, up to 3 additional patients, all of whom must have 
the diagnosis of GIST, may be enrolled into an enrichment cohort that included only 3 patients 
evaluable for DLT, was reviewed at a DE meeting, and did not exceed the MTD. Enrollment 
of patients into an enrichment cohort requires written approval from the Sponsor. Data from 
these patients will allow for further exploration of PK, pharmacodynamic, safety, , and anit-
tumor activity in patients with GIST. 
In cohorts in which the administered dose is <100 mg QD, enrolled patients may have the 
diagnosis of either GIST or a R/R solid tumor. To assure that the safety profile of avapritinib 
is adequately described in patients with GIST, at least 2 of 3 patients in each cohort (4 of 
6 patients if the cohort is expanded) dosed at ≥100 mg QD must have the diagnosis of GIST. 
Dose escalation will continue until the MTD or a RP2D below the MTD has been determined.  
Additional details on the DE process, estimation of the MTD/RP2D, and DLTs are provided 
in Section 6.4 of the protocol. 
Expansion (Part 2) 
Once the MTD or RP2D has been determined, 3 groups of patients with the following 
characteristics will be enrolled and treated with avapritinib:  
• Group 1: Patients with unresectable GIST that has progressed following treatment with 
imatinib and at least 1 of the following: sunitinib, regorafenib, sorafenib, dasatinib, 
pazopanib, or an experimental kinase-inhibitor therapy and who do not have a D842V 
mutation in PDGFRα (N~100) 
• Group 2: Patients with unresectable GIST harboring a D842V mutation in the 
PDGFRα gene (N~35). The PDGFRα mutation will be identified by local and central 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
10 
assessment, either in archival tissue or a new tumor biopsy obtained, prior to treatment 
with avapritinib 
• Group 3: Patients with unresectable GIST that has progressed and/or those who have 
experienced intolerance following treatment with imatinib (including in the adjuvant 
setting) and who have not received additional kinase-inhibitor therapy and do not have 
a known D842V mutation in PDGFRα (N~50). 
Figure 1: 
Study Schematic 
 
Abbreviations: D842V = aspartic acid to valine at amino acid 842; GIST = gastrointestinal stromal tumor; 
N = Approximate number of patients to be enrolled; PDGFRα = platelet-derived growth factor receptor alpha; 
R/R = relapsed/refractory; TKI = tyrosine kinase inhibitor. 
 
 
GIST (progressed following imatinib and ≥1 other TKI or a 
D842V mutation in PDGFRα gene) and R/R solid tumors 
(≥100 mg/day) 
At least 2 (4 if cohort is expanded) patients with GIST per 
cohort 
N~30 
GIST (progressed following imatinib and ≥ 1 other 
TKI or a D842V mutation in PDGFRα gene) and 
R/R solid tumors (<100 mg/day) 
N~20 
Group 1 
(progressed following 
imatinib and ≥1 other 
TKI) 
N~100 
Group 2 
(PDGFRα D842V 
mutant) 
N~35 
Part 1: Dose-Escalation
Part 2:  Expansion
Group 3 
(progressed and/or 
imatinib-intolerant) 
N~50 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
11 
1.2 Study Objectives 
 Primary Objectives 
Part 1: 
• To determine the MTD and RP2D of avapritinib 
• To determine the safety and tolerability of avapritinib. 
Part 2: 
• To determine the overall response rate (ORR) per modified Response Evaluation 
Criteria in Solid Tumors version 1.1 (mRECIST 1.1) (Eisenhauer, 2009) at the 
MTD/RP2D of avapritinib in patients with GIST who have a D842V mutation in 
PDGFRα 
• To determine the ORR by mRECIST 1.1 at the MTD/RP2D of avapritinib in patients 
with GIST that has progressed following treatment with imatinib and at least another 
kinase-inhibitor agent, and who are not known to have a D842V mutation in PDGFRα 
• To determine the ORR by mRECIST 1.1 at the MTD/R2PD of avapritinib in patients 
with GIST who have progressed or who experienced intolerance to imatinib, including 
in the adjuvant setting, and who have not received additional kinase-inhibitor therapy 
and do not have a known D842V mutation in PDGFRα 
• To determine the safety and tolerability of avapritinib. 
 Secondary Objectives 
• To characterize the PK profile of avapritinib, and correlate drug exposure with safety 
assessments, including changes in electrocardiogram (ECG) intervals 
• To assess evidence of antineoplastic activity of avapritinib as measured by duration of 
response (DOR), progression free survival (PFS), and clinical benefit rate (CBR) 
• To assess antitumor activity as measured by Choi criteria 
• To compare PFS on avapritinib with PFS on last prior anticancer therapy 
• To assess mutations in v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (KIT) and PDGFRα in tumor tissue at baseline and at Cycle 3 Day 1 (C3D1) 
• To assess the KIT and PDGFRα gene mutant allele fractions (MAF) measured in 
circulating tumor deoxyribonucleic acid (ctDNA) at baseline, and changes in the MAF 
measured in ctDNA after treatment with avapritinib 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
12 
1.3 Sample Size Justification 
The total number of patients to be enrolled in Part 1 depends upon the observed safety profile, 
which will determine the number of patients per dose cohort, as well as the number of DEs 
required to achieve the MTD or identify the RP2D. It is expected that approximately 50 
patients who meet the criteria for the Dose-Determining (DD) Population (defined in 
Section 2) will be enrolled in Part 1.  
In Part 2 Group 1, a sample size of 100 non-D842V 3L+ patients will allow testing the null 
hypothesis of ORR ≤5% versus the alternative hypothesis of ORR ≥15% using exact binomial 
test with 90% power assuming a 2-sided type I error rate of 0.05. An observed ORR of ≥11% 
in 100 patients will result in an exact binomial 95% confidence interval (CI) with a lower 
bound greater than 5%) (Table 1), which is clinically meaningful and exceeds the ORR 
expected with available therapies (Kang, 2013; Stivarga®, 2017). 
Table 1: 
Sample Size for Part 2 by Group 
Part 2 
Sample 
Size 
Null ORR 
Alternative 
ORR 
Observed ORR Needed to Reject Null 
(95% CI) 
Group 1 
100 
≤5% 
≥15% 
11% (5.62%, 18.83%) 
Group 2 
31 
≤10% 
≥35% 
26% (11.86%, 44.61%) 
Group 3 
50 
≤10% 
≥25% 
20% (10.03%, 33.72%) 
Abbreviations: CI = confidence interval; ORR = overall response rate. 
In Part 2 Group 2, a sample size of 31 D842V patients will allow testing the null hypothesis 
of ORR ≤10% versus the alternative hypothesis of ORR ≥35% using exact binomial test with 
90% power assuming a 2-sided type I error rate of 0.05. An observed ORR of ≥26% in 
31 patients will result in an exact binomial 95% CI with a lower bound greater than 10% 
(Table 1), which is clinically meaningful, and exceeds the ORR expected with available 
therapies (Cassier, 2012; Yoo, 2016). We target to enroll up to 35 D842V patients. 
In Part 2 Group 3, a sample size of 50 non-D842V 2L patients will allow testing the null 
hypothesis of ORR ≤10% versus the alternative hypothesis of ORR ≥25% using exact 
binomial test with 83% power assuming a 2-sided type I error rate of 0.05. An observed ORR 
of >20% in 50 patients will result in an exact binomial 95% CI with a lower bound greater 
than 10% (Table 1), which is clinically meaningful, and exceeds the ORR expected with 
available therapies (Goodman, 2007; Sutent®, 2014). 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
13 
2. POPULATIONS FOR ANALYSIS 
2.1 Safety Population 
The Safety Population includes all patients who have received at least 1 dose of study drug. 
The Safety Population will be the primary population for efficacy and safety analysis unless 
otherwise specified. Patients will be analyzed based on the dose they receive on Day 1. 
2.2 Dose-Determining Population  
The DD Population includes all patients in Part 1 who have received at least 75% of their 
prescribed doses (i.e. ≥21 doses) of the study drug in cycle 1 (C1) and completed follow-up 
through C1 Day 28 (C1D28) or experienced a DLT regardless of the extent of study drug 
exposure. The DD Population will be the default analysis population for the DE phase for all 
MTD related analyses. Patients will be analyzed according to the dose they receive on Day 1. 
2.3 Response-Evaluable Population 
The Response-Evaluable (RE) Population included all patients in the Safety Population who 
have at least 1 target lesion at baseline by central radiology review per mRECIST 1.1, have at 
least 1 post-baseline disease assessment by central radiology per mRECIST 1.1, and have 
experienced no major protocol deviations. Selected efficacy analysis may be performed using 
the RE Population. Patients will be analyzed according to the dose they receive.  
Major protocol deviations leading to exclusion from the RE Population include: 
• Patient has history of another primary malignancy within 1 year 
• Patient received concomitant treatment for the underlying malignancy while taking 
avapritinib prior to the efficacy assessment of interest. 
2.4 Sub-Populations 
Selected analyses may be conducted on sub-populations of safety or RE based on line of TKI 
therapy and GIST mutation types, which are determined in the order of Qiagen, Sysmex or 
Personal Genome Diagnostics [PGDx], and local when available. 
• Qiagen D842V: PDGFRα D842V patients determined by the Qiagen assay  
• D842V: PDGFRα D842V patients  
• Exon 18: PDGFRα exon 18 patients  
• 4L+: all patients regardless of mutation type, who received 3 or more prior lines of 
TKI 
• Non-D842V 4L+: non-PDGFRα D842V 4L+ patients  


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
14 
• Non-D842V 3L+: non-PDGFRα D842V patients, who received 2 or more prior lines 
of TKI  
• 
Non-D842V 2L: non-PDGFRα D842V patients, who received imatinib as the only 
prior TKI therapy.  
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
15 
3. GENERAL STATISTICAL CONSIDERATIONS 
3.1 Randomization, Stratification and Blinding 
This is an open label, single arm study with no randomization or stratification. 
3.2 Data Analysis General Information and Definition 
Summary statistics for continuous variables will include n (non-missing observations), mean, 
standard deviation (StdDev), minimum, median, and maximum. Summary statistics for 
categorical variables will be presented in terms of frequencies and percentages. Time to event 
data will be summarized using Kaplan-Meier (KM) method, which will include the estimated 
median with 95% CIs and 25th and 75th percentiles. 
 Study Drug 
Study drug or study treatment used in the rest of the document refers to avapritinib (BLU-285).  
 Day 1 and Other Days  
Date of first dose of avapritinib (or Day 1) is defined as the day of the first administration 
of study drug in the study, i.e. after enrollment. First dose refers to first dose in study unless 
specified otherwise. 
Date of last dose of avapritinib is defined as the date of last administration of study drug 
(last dose) in the study. For patients who have not end treatment and last dose date is missing, 
the cutoff date will be used.  
 Calculation Using Dates 
Calculations using dates will adhere to the following conventions: 
• Study day for a date of interest (TARGET DATE) is calculated as 
STUDY DAY = TARGET DATE – Day 1 + 1 if TARGET DATE is on or after Day 1; 
STUDY DAY = TARGET DATE – Day 1 otherwise. 
Note that negative study days are reflective of observations obtained during the 
screening period. Partial dates for the first study drug administration are not imputed 
in general.  
• Age (in days) is calculated as 
AGE = CONSENT DATE – BIRTH DATE (DOB) + 1.  
Age (in years) = (year of consent) - (year of DOB) if passed Birthday;  
Age (in years) = (year of consent) - (year of DOB) - 1 if otherwise. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
16 
This is equivalent to the following:  
[(year of consent) - (year of DOB)] – [(month of consent) ≤ (month of DOB)] + 
[(month of consent) = (month of DOB) and (day of consent) ≥ (day of DOB)] 
 Duration Derivation 
Unless otherwise specified for a specific panel or variable, duration variables will be derived 
according to the following rules: 
• Duration (in days) = [end date – start date +1] 
• Duration (in weeks) = [end date – start date +1]/ 7  
• Duration (in months) = [end date – start date +1]/ 30.4375  
• Duration (in years) = [end date – start date +1]/ 365.25. 
Duration variables which are to be expressed in units greater than day will be rounded to 
1 decimal place. 
 Baseline Values 
Baseline is defined as the last observation prior to first dose of study drug, i.e. Day 1 pre-dose 
value or the last available (including unscheduled) value before Day 1 if Day 1 pre-dose value 
is unavailable. 
 Last Contact 
Last contact is the date of last measurement or assessment upon the patient. 
3.3 Methods for Handling Missing Data  
Refer to Section 7.1 for detailed date imputation guidelines.  
3.4 Windowing of Visits 
Visits will be windowed. Data are summarized by visit following the visit windows reported 
in Table 2 and Table 3 when appropriate (e.g. lab parameters). If multiple assessments occur 
within a visit window, the assessment closest to the target day will be used. In case of ties, 
with equal number of days on either side of target day, the value from the day before target 
day shall be used. 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
17 
Table 2: 
Visit 
Windows 
for 
Patients 
Who 
Participate 
in 
a 
3-Day 
Pharmacokinetic-Lead in Stage 
Visit 
Start Day (time) 
Target Day (time) 
End Day (time) 
Week 1 (C1D8) 
1 
11 ± 1 
14 
Week 2 (C1D15) 
15 
18 ± 2 
21 
Week 3 (C1D22) 
22 
25 ± 2 
28 
Week 4 (C2D1) 
29 
32 ± 3 
39 
Week 6 (C2D15) 
40 
46 ± 3 
51 
Week 8 (C3D1) 
52 
60 ± 7 
74 
Week 12 (C4D1) 
75 
88 ± 7 
102 
Week 16 (C5D1) 
103 
116 ± 7 
130 
Week 4*X (C(X+1)D1) 
28*X-9 
(28*X+4) ± 7 
28*X+18 
Note: Visit window for Week 1 will not consider Day 1 if Day 1 observation is marked as baseline; X can be 4, 
5, 6… until cover all visit windows.  
Table 3: 
Visit Windows for Other Patients 
Visit  
Start day (time) 
Target Day (time) 
End day (time) 
Week 1 (C1D8) 
1 
8 ± 1 
11 
Week 2 (C1D15) 
12 
15 ± 2 
18 
Week 3 (C1D22) 
19 
22 ± 2 
25 
Week 4 (C2D1) 
26 
29 ± 3 
36 
Week 6 (C2D15) 
37 
43 ± 3 
48 
Week 8 (C3D1) 
49 
57 ± 7 
71 
Week 12 (C4D1) 
72 
85 ± 7 
99 
Week 16 (C5D1) 
100 
113 ± 7 
127 
Week 4*X (C(X+1)D1) 
28*X-12 
28*X+1 ± 7 
28*X+15 
Note: Visit window for Week 4 will not consider Day 1 if Day 1 observation is marked as baseline; X can be 4, 
5, 6… until cover all visit windows. 
3.5 Withdrawals, Dropouts, Lost to Follow-Up 
Patients may withdraw or be withdrawn from study treatments at any time for any of the 
following reasons:  
• Withdrawal of consent 
• Adverse event (AE) 
• Disease progression 
• Death 
• Investigator decision 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
18 
• Protocol deviation 
• Pregnancy 
• Lost to follow-up. 
3.6 Protocol Deviations 
Deviations from the protocol, as defined in the protocol and protocol deviation plan, will be 
documented in Insight on an ongoing basis by the study monitors and project manager 
throughout the study period.  
Prior to database lock, protocol deviations will be reviewed and categorized as major or minor 
for summarization.  
Major protocol deviations will be summarized descriptively for the Safety Population.  
A by-patient listing of patients with protocol deviations in the Safety Population will be 
provided. A separate listing of patients with major protocol deviations that lead to exclusion 
from the RE Population will also be provided. 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
19 
4. STATISTICAL METHODOLOGY 
All primary analyses in this section will be conducted and presented by starting daily dose 
(grouped as ‘<300 mg’, ‘300 mg’, ‘400 mg’, ‘300/400 mg’, and ‘all doses’) for the Safety 
Population and/or its sub-populations which refer to those specified in Section 2.4. Selected 
sensitivity analyses will be conducted for the RE sub-populations by the same starting dose 
grouping.   
Analyses based on the DD Population, e.g. MTD, DLT analyses, will be presented by starting 
daily dose without grouping, and ‘all doses’. 
4.1 Analysis Populations  
A summary of analysis populations by starting dose will be presented for the following: 
• Safety Population and its sub-populations 
• RE Population and its sub-populations 
• DD Population. 
4.2 Patient Disposition 
The number of patients treated, discontinued from treatment and study and the reasons for 
discontinuations, will be summarized by starting dose for the Safety Population. 
Reasons for treatment discontinuation and study discontinuation will be summarized with the 
following categories collected on the electronic case report form (eCRF): 
• Disease progression 
• AE 
• Death 
• Lost to follow-up 
• Protocol deviation 
• Withdrew consent 
• Pregnancy 
• Investigator decision 
• Administrative/other 
• Sponsor decision. 
Listings will be provided for discontinued patients with reason for treatment discontinuation, 
study discontinuation. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
20 
4.3 Demographics and Baseline Disease Characteristics  
Demographic and baseline disease characteristic data will be summarized by starting dose 
based on the Safety Population and its sub-populations, and the DD Population when 
appropriate. Medical history data will be summarized similarly. 
 Demographics 
The number and percentage of patients in each of the following categories will be presented: 
• Age group (<65 years or ≥65 years) 
• Sex 
• Ethnicity 
• Race. 
Patients’ age (years), height (cm), weight (kg), body mass index (BMI) (kg/m2), and other 
continuous demographic variables will be summarized descriptively.  
BMI will be calculated as: BMI (kg/m2) = (weight in kg) / (height in m)2. 
 Baseline Disease Characteristics 
The number and percentage of patients in each of the following categories will be presented: 
• The Eastern Cooperative Oncology Group (ECOG) performance status (0, 1, 2, 3...) 
• GIST subtype: 
o KIT mutant (all, exon 13 or 14, exon 17 or 18, V654 and T670) 
o PDGFRα exon 18 mutants (all, D842V, non- D842V) 
o PDGFRα exon 14 mutants (all, N659K) 
o KIT & PDGFRα wild type 
• Metastatic disease (Yes, No) 
• Largest target lesion size (≤5 cm, >5 to ≤10 cm, >10 cm) by central radiographic 
assessment 
• Patient staged at screening by tumor/lymph nodes/metastasis (TNM) system (Yes, No) 
• Current stage at screening by TNM 
• Prior imatinib (Yes, No) 
• Prior sunitinib (Yes, No) 
• Prior regorafenib (Yes, No) 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
21 
• Primary tumor site of GIST at the time of diagnosis 
• Site of metastatic disease 
• Prior surgical resection (Yes, No), and type of resection (total, partial, other). 
Continuous baseline disease characteristics will be summarized using descriptive statistics.  
 Medical History 
Ongoing medical history data will be summarized by system organ class (SOC) and preferred 
term (PT) per Medical Dictionary for Regulatory Activities (MedDRA) version 18.1. All 
medical history data will be listed. 
4.4 Prior and Concomitant Medications and Prior Therapies 
 Prior and Concomitant Medications 
Prior medications are those that started and stopped before exposure to study drug. 
Concomitant medications are all medications taken at any time from first dose date of study 
drug to last dose date of study drug + 30 days. If the last dose date of study drug is not 
available, the cutoff date is used in place of the last dose date. 
The number and percentage of patients taking concomitant medications and significant non-
drug therapies will be summarized and listed by therapeutic area (ATCText3) and preferred 
drug name for the Safety Population. A patient taking the same medication multiple times is 
counted only once under that preferred drug name. 
Prior (with clear flag) and concomitant medications will be listed for the Safety Population. 
Medications are coded using the World Health Organization Drug dictionary B2 enhanced, 
version Mar 2017. 
 Prior Therapies for the Underlying Malignancy 
Prior therapy is defined as all treatment that started and ended on or before first dose date of 
avapritinib.  
The number and percentage of patients for each category below will be summarized by PT: 
• Prior antineoplastic therapy (Yes, No) 
• Prior chemotherapy (Yes, No) 
• Prior Lines of TKI (0, 1, 2, 3, 4+)  
• Prior Distinct TKI(s) (0, 1, 2, 3, 4+)  
• Prior radiation therapy (Yes, No) 
• Prior cancer related surgery-procedures (Yes, No) 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
22 
• Best response to any prior TKI (CR, PR, SD, progressive disease, NE) 
• Best response to last prior TKI (CR, PR, SD, progressive disease, NE).  
Continuous variables to be summarized include: 
• Time between diagnosis to first dose of avapritinib 
• Time between end of last prior line of antineoplastic therapy to the first dose date of 
avapritinib  
• Duration of previous exposure to TKI. 
The duration of previous exposure to TKI will be the sum of exposure from each prior TKI 
therapy, which is number of days from start date to end date captured on the prior cancer 
therapy eCRF page. 
No overlap between the exposure to prior therapies and avapritinib will be allowed and any 
overlap of exposure will be queried at data review stage. The end date of the last prior therapy 
will be imputed to ‘first dose date of avapritinib – 15’ if the imputation of partial dates is 
within 14 days of Day 1. However, if Day 1 of study drug is within the first half of the month, 
and last prior therapy ended on the same month as study drug start, the day component of last 
prior therapy end date will be imputed as 1.  
4.5 Study Treatments and Extent of Exposure 
A summary of study drug exposure, including number of doses administered, cumulative 
dose, dose intensity, relative dose intensity (RDI), duration of treatment, and the proportion 
of patients with dose modifications will be produced. 
Exposure data will be summarized descriptively by time (every 4 weeks and entire duration) 
and by starting dose in the safety, and the DD Population when appropriate.  
Duration in every 4 weeks is defined as the time from first day of the 4 weeks to the day prior 
to the first day of the subsequent 4 weeks; for the last 4 weeks, the end date is the date of last 
dose. 
 Treatment Duration and Exposure 
Duration of treatment (days) = (treatment end date– treatment start date + 1).  
Duration of treatment (weeks) = (treatment end date– treatment start date + 1) / 7.  
The treatment start date is the first dose date of study drug, and the treatment end date is the 
last dose date of study drug or data cutoff date, whichever is earlier. 
Descriptive statistics will be provided for treatment duration in weeks. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
23 
 Cumulative Dose  
Cumulative dose (mg) is defined as sum of all dose taken. The dosage will be counted as 0 for 
days when the study drug is not taken. 
 Average Daily Dose  
Average daily dose (mg) is defined as the cumulative dose divided by the number of days 
dosed. Each patient has an average daily dose.  
 Dose Intensity  
Dose intensity (mg/day) is defined as the cumulative dose divided by the treatment duration 
(in days).  
 Relative Dose Intensity 
Relative dose intensity is defined as the ratio: dose intensity / planned dose intensity. Planned 
dose intensity is based on initial assigned daily dose.  
Relative dose intensity will be summarized descriptively as a continuous variable and be 
categorized into <75%, 75% to <90%, 90% to 120%, 120 to 150%, and ≥150%. 
A by-patient listing of study drug including treatment duration, cumulative dose, average daily 
dose, dose intensity, planned initial dose, RDI will be provided. 
 Dose Modification 
Frequency of dose modification will be summarized as follows:  
Dose reduction due to AE will be summarized using the number and percent of patients with 
0, 1, 2, or >2 dose reduction during the entire treatment period.  
Dose increase will be summarized using the number and percent of patients with 0, 1, 2, or 
>2 dose increase during the entire treatment period.  
A bivariate table will summarize (number and percentage) both dose reduction and increase.  
The number of patients whose dose escalates from total daily dose of 300 mg to 400 mg, and 
the number of patients who have dose modification and types of dose modification after the 
DE will be summarized. 
The number of patients whose dose reduces from total daily dose of 400 mg or 300 mg, and 
the number of patients who have dose modification and types of dose modification after the 
dose reduction will be summarized. 
Time to first dose reduction among patients with at least one dose reduction, is the time in 
weeks elapsed from the date of first dose of study drug to the date when the first dose reduction 
occurred. It will be summarized as a continuous variable. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
24 
Dose interruption/missing due to AE will be summarized using the number and percentage 
of patients who have 0, 1, 2, or >2 dose interruptions/missing, by starting dose and the dose 
the patient was on at the time of interruption.  
Details of dose modifications will be provided in listings. 
4.6 Efficacy Analyses 
All efficacy analyses will be conducted by daily starting dose (‘<300 mg’, ‘300 mg’, ‘400 mg’, 
‘300/400 mg’, and ‘all doses) for the safety sub-populations primarily. Supportive analyses 
may be conducted in the RE sub-populations. Endpoints involving response assessment will 
be primarily based on central radiology per mRECIST 1.1. Investigator assessment per 
mRECIST 1.1, or central radiology assessment per Choi criteria will only be supportive. 
Logistic regression and Cox proportional hazards model may be based on the overall Safety 
Population. 
 Analysis of Primary Efficacy Endpoint 
The primary efficacy endpoint of ORR is defined as the proportion of patients with a 
confirmed (CR/PR for at least two assessments with no progression in between) best response 
of complete response (CR) or partial response (PR).  
The primary analysis of ORR will be assessed by central radiology per mRECIST 1.1. ORR 
will be estimated using frequency, percentage, and two-sided 95% CI based on the exact 
binomial distribution (Clopper-Pearson) for the Safety Population.  
Additionally, the best overall response following the hierarchical order of CR, PR, stable 
disease (SD), progressive disease (PD), and not evaluable (NE) will be tabulated for the 
prespecified sub-populations in the Safety Population. Non-CR/Non-PD will be treated as SD. 
The following sensitivity analysis will be conducted on the response to assess the robustness 
of the primary analysis: 
• ORR by starting dose within sub-populations specified in Section 2.4 in the Safety 
Population for patients who have had the opportunity for at least 8 months of follow-up 
or have discontinued study treatment 
• ORR by starting dose within sub-populations specified in Section 2.4 in the RE 
Population 
• ORR as assessed by the Investigator in the Safety Population will be summarized for 
best overall response. Tables of concordance between best overall response by central 
radiology assessment and by the Investigator will be reported. 
Logistic regression will be fit to assess the effect of factors individually on the ORR, including 
starting dose, maximum daily dose level, dose intensity, age, ECOG status, size of largest 
tumor mass, etc., stratified by mutation type (exon 18 vs not). Factors that are significant at 
0.2 level in univariable models will be entered in the final multivariable model. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
25 
Unstratified analysis based on the Safety Population may be conducted.  
 Analysis of Secondary Efficacy Endpoints 
 Duration of Response  
Duration of response is defined as the time from first documented response (CR/PR) to the 
date of first documented disease progression or death due to any cause, whichever occurs first. 
The date of disease progression will be per mRECIST 1.1. Patients without confirmed CR or 
PR will be excluded from this analysis. Patients who are still in response at time of data cutoff 
will be censored at their last valid assessment. Complete censoring rules (both European 
Medicines Agency [EMA] and United States [US] Food and Drug Administration [FDA]) are 
specified in Table 4. The analysis will be primarily based on FDA Guidance for Cancer Trial 
Endpoints (FDA, 2007). The censoring rules based on the EMA Guideline on the evaluation 
of anticancer medicinal products in man will be used as sensitivity analysis (EMA, 2017).  
Duration of response will be analyzed using KM methods and will include the estimated 
median with two-sided 95% CI and 25th and 75th percentiles. DOR at specific time-points 
(e.g. 3-, 6-, and 12-month, etc.) will be computed, along with the standard errors using 
Greenwood’s formula (Klein, 2003).  
Sensitivity analysis will be conducted for DOR based on Investigator assessment per 
mRECIST 1.1, or central radiology assessment per Choi criteria for the Safety Population by 
mutation types. Both FDA and EMA censoring rules will be applied. 
 Progression Free Survival  
Progression free survival is defined as the time from the start of treatment to the date of first 
documented disease progression or death due to any cause, whichever occurs first. The date 
of disease progression will be per mRECIST 1.1. Specifically, if not all scans were done on 
the same date, the first scan date will be used. If a patient has not had an event, PFS is censored 
at the date of last valid assessment that is stable or better. See Table 4 for censoring rules. 
The KM method will be used to estimate the survival distribution function. The median PFS 
along with its two-sided 95% CI and 25th and 75th percentiles will be estimated. In addition, 
the event rates (or event-free) at specific time-points (e.g. 3-, 6-, and 12-month, etc.) will be 
computed, along with the standard errors using Greenwood’s formula (Klein, 2003). The plots 
of survival curves using the KM method will be presented.  
A Cox proportional hazards model will be used to estimate hazard ratios of factors like starting 
daily dose, maximum daily dose level, dose intensity, age, ECOG status, size of largest tumor 
mass, etc., along with 95% CIs. The model will be stratified by mutation type (exon 18 vs 
not). Factors that are significant at 0.2 level in univariable models will be enter the final 
multivariable model. 
Unstratified analysis based on the Safety Population may be conducted.  
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
26 
Table 4: 
Duration of Response and Progression Free Survival Censoring Rules 
Situation 
Date of Progression or 
Censoring 
FDA Censoring 
Rules 
EMA Censoring 
Rules 
No baseline assessments and 
alive after 2 scheduled 
assessments (defined by 
140 days) 
Date of first dose 
Censored 
Censored 
Progression documented 
between scheduled visits 
Date of last radiological 
assessment showing new 
lesions or an increase in 
measured lesions 
Event 
Event 
No progression 
Date of last radiological 
assessment with evidence of 
no progression (or first dose 
date if no assessment) 
Censored 
Censored 
New anticancer/ non-protocol 
treatment started prior to 
progression 
Date of last radiological 
assessment with evidence of 
no progression prior to the 
start of new anticancer 
treatment 
Censored 
Event at date of 
disease 
progression/death 
Death before the second 
scheduled post-baseline 
assessment (defined by within 
140 days after first dose) 
Date of death 
Event 
Event 
Death between scheduled 
assessments  
Date of death 
Event 
Event 
Death or progression 
immediately after an extended 
lost to follow-up time (2 more 
missed scheduled assessments 
defined by at least x1 days) 
Date of last radiological 
assessment with evidence of 
no progression (first dose 
date if first 2 scheduled 
assessments are missing) 
Censored 
Event at date of 
disease 
progression/death 
1 x= 140 days if the death or progression date is ≤336 days from first dose date; x=210 days if the death or 
progression date is ≥337 days from first dose date. 
 Clinical Benefit Rate 
Clinical benefit rate is defined as the proportion of patients with a confirmed CR/PR, or SD 
lasting for 4 cycles. The response will be assessed per mRECIST 1.1. Clinical benefit rate will 
be estimated using frequency, percentage, and two-sided 95% CI based on the exact binomial 
distribution.  


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
27 
 Response Rate by Choi Criteria 
Overall response rate per Choi response criteria (Weng, 2013) will be estimated using 
frequency, percentage, and two-sided 95% CI based on the exact binomial distribution 
(Clopper-Pearson).  
The best overall response per Choi criteria following the hierarchical order of CR, PR, SD, 
progressive disease, and NE will be tabulated. 
 Progression Free Survival on Last Prior Anti-Cancer Therapy 
Progression free survival on last prior anticancer therapy is defined as the time from the start 
of last prior anticancer therapy to progression on that therapy.  
Patient is considered PD on the last prior anti-cancer therapy if its best response was PD, or 
discontinuation was due to progressive disease. If the date of PD is partially missing, the 
imputation rule is the same as that for incomplete stop date for AE (Appendix 7.1.4); if the 
date of PD is completely missing, last dose date will be used as the disease progression date. 
Imputation rule for partial missing last dose date is in Appendix 7.1.3. PD date of on last prior 
therapy will be imputed to first dose date of study drug – 1 if the progression is on or after the 
first dose date of the study drug due to partial dates imputation. For patients who have no 
documented disease progression on the last prior anti-cancer therapy, PFS will be censored at 
1 day before the first dose of avapritinib.  
The KM method will be used to estimate the survival distribution function. The median PFS 
along with its two-sided 95% CI and 25th and 75th percentiles will be estimated. In addition, 
the event rates (or event-free) at specific time-points (e.g. 3-, 6-, and 12-month, etc.) will be 
computed, along with the standard errors using Greenwood’s formula (Klein, 2003). The plots 
of survival curves using the KM method will be presented.  
Statistical testing will be conducted between the PFS on study drug and PFS on last prior 
anticancer therapy. Methods that accounts for paired censored data, e.g. paired 
Prentice-Wilcoxon test will be performed due to the in-patient correlation of the two PFSs.  
The analyses described will apply to safety sub-populations of Qiagen D842V, D842V, and 
exon-18. 
 Mutation Analysis 
KIT and PDGFRα mutations present in tumor tissue and ctDNA will be analyzed.  
Baseline mutations will be summarized descriptively including those documented by Qiagen 
assay (tumor), Sysmex/PGDX assay (tumor and ctDNA), and on the CRF (tumor) in the order 
of presence. 
Change (in percentage) from baseline to C3D1 in MAF including KIT and PDGFRα will be 
summarized for mutations documented by Sysmex ctDNA assay in DD population. For 
patients with multiple mutations, the minimum change in MAF will be used.  


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
28 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
29 
 Subgroup Analysis 
For ORR, DOR, PFS as assessed by central radiology, and OS, the following subgroup 
analyses will be conducted for safety sub-populations of PDGFRα exon-18, and 4L+ and 
limited to patients with starting dose of 300/400 mg. Corresponding forest plots will be 
provided based on the odds ratio or hazard ratio for each subgroup.  
• Age (<65 years, ≥65 years) 
• Gender (male, female) 
• Region (US, Europe, Asian) 
• Race (White, non-White) 
• Largest target lesion (≤10 cm, >10 cm). 
4.7 Safety Analyses 
Safety data will be summarized and presented by starting dose (‘<300 mg’, ‘300 mg’, 
‘400 mg’, ‘300/400 mg’, and ‘all doses’) for the Safety Population, unless otherwise specified. 
The analyses for MTD and DLT will be summarized by starting dose without grouping, and 
“all doses” descriptively for patients in the DD Population. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
30 
 Adverse Events  
Adverse Events will be analyzed in terms of treatment-emergent adverse events (TEAEs) 
which are defined as any AE that occurs during or after administration of the first dose of 
study drug through 30 days after the last dose of study drug, any event that is considered study 
drug-related regardless of the start date of the event, or any event that is present at baseline 
but worsens intensity or is subsequently considered study drug-related by the Investigator. 
Adverse Event refers to TEAEs unless otherwise specified throughout this document. All AEs 
will be coded using MedDRA version 18.1. The severity will be graded per the National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), 
version 4.03. 
Relationship of AE to treatment is defined as AE that is considered (possibly or probably) to 
be related to the study drug by the Investigator according to the following criteria: 
• Not Related: Exposure to the study treatment did not occur, or the occurrence of the 
AE is not reasonably related in time, or the AE is considered unlikely to be related to 
the study treatment 
• Possibly Related: The study treatment and the AE were reasonably related in time, and 
the AE could be explained equally well by causes other than exposure to the study 
treatment 
• Probably Related: The study treatment and the AE were reasonably related in time, 
and the AE was more likely explained by exposure to the study treatment than by other 
causes, or the study treatment was the most likely cause of the AE. 
A patient experiencing multiple AEs under the same PT (SOC) will be counted only once for 
that PT (SOC) by maximum severity. A patient experiences the same AE more than once with 
more than one relationship to study drug, the strongest causal relationship to study drug will 
be given precedence. Any missing severity, causality, or outcome will not be imputed and 
classified as ‘Missing’. Detailed imputation rule for missing AE dates are in Section 7.1. 
Number of patients with at least one AE will be summarized (Table 5). The following tables 
summarizing incidence of various aspects of AEs and serious adverse events (SAEs) by 
descending frequency of SOC and PT: 
1. AE Summary (including all subsequent items) 
2. AE by PT/ by SOC and PT 
3. AE related to study drug by PT/by SOC and PT 
4. SAE by PT/by SOC and PT 
5. SAE related to study drug by PT/by SOC and PT 
6. Grade 3/4/5 AE by PT/by SOC and PT 
7. Grade 3/4/5 AE related to study drug by PT/by SOC and PT 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
31 
8. AE by PT/by SOC and PT, and NCI CTCAE Grade 
9. AE related to study drug by PT/by SOC and PT, and NCI CTCAE Grade 
10. SAE by PT/by SOC and PT, and NCI CTCAE Grade 
11. SAE related to study drug by PT, and NCI CTCAE Grade 
12. AE leading to interruption of study drug regardless of causality by PT/ by SOC and 
PT 
13. AE leading to reduction of study drug regardless of causality by PT/ by SOC and PT 
14. AE leading to permanent discontinuation of study drug regardless of causality by PT/ 
by SOC and PT. 
All AEs will be listed by patient.  
Dose limiting toxicities will be presented by dose level and PT in the DD Population. 
Subgroup analysis will be conducted for endpoints 1 – 7 above (details in Table 5)  for patients 
with a starting dose of 300/400 mg in the Safety Population. Corresponding forest plots will 
be provided based on the odds ratio for each of the following subgroups: 
• Age (<65 years, ≥65 years) 
• Gender (male, female) 
• Region (US, Europe, Asian) 
• Race (White, non-White). 
 Adverse Events of Special Interest 
Adverse events of special interest (AESI) will be summarized by category (cognitive effects 
and intracranial bleeding) and relevant PTs.  
• Cognitive effects consisting of 3 PTs: cognitive disorder, memory impairment, 
confusional state 
• Intracranial bleeding consisting of 3 PTs: haemorrhage intracranial, cerebral 
haemorrhage, subdural haematoma. 
The general rules for summarizing AE specified in Section 4.7.1 apply for AESIs for 
avapritinib. The following tables will be presented by AESI Category and PT: 
• AESI by AESI category and PT 
• Serious AESI by AESI category and PT 
• AESI by AESI category and PT and NCI CTCAE Grade 
• AESI leading to permanent discontinuation of study drug regardless of causality by 
PT. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
32 
Table 5 
Summary of Adverse Event Tables: 
Safety Endpoint 
Main 
Table 
by PT 
by SOC, PT 
by PT, 
CTCAE 
by SOC, PT, 
CTCAE 
Overall 
Subgroup1 
Overall 
Subgroup1 
Overall 
Overall 
Summary Table (each item below one row) 
X2 
 
 
 
 
 
 
AE 
 
X 
X 
X 
X 
X 
X 
SAE 
 
X 
X 
X 
X 
X 
X 
Grade 3+ AE 
 
X 
X 
X 
X 
 
 
Related AE 
 
X 
X 
X 
X 
X 
X 
Related SAE 
 
X 
X 
X 
X 
X 
 
Related Grade 3+ AE 
 
X 
X 
X 
X 
 
 
DLT 
 
X 
 
 
 
 
 
AE Leading to Permanent Study Discontinuation 
 
X 
 
X 
 
 
 
Adverse Events Leading to Dose Interruption  
 
X 
 
X 
 
 
 
Adverse Events Leading to Dose Reduction  
 
X 
 
X 
 
 
 
Listing (Death, Discontinuation, SAE, DLT) 
X 
 
 
 
 
 
 
AESI by Category and  
 
X 
 
 
 
X 
 
Serious AESI by Category and  
 
X 
 
 
 
X 
 
AESI Leading to Permanent Study Discontinuation 
 
X 
 
 
 
 
 
Time to Onset of AESI 
X 
 
 
 
 
 
 
Cumulative Incidence of AESI  
X 
 
 
 
 
 
 
Abbreviations: AE = adverse event; AESI = adverse event of special interest; CTCAE = Common Terminology Criteria for 
Adverse Events; DDP = Dose determining Population; DLT = dose limiting toxicity; PT = preferred term; SAE = serious 
adverse event; SOC = system organ class; TKI = tyrosine kinase inhibitor. 
1 
Among patients with 300/400 mg starting dose by Subgroup of Age at Informed Consent, Gender, Region, Race, 
and Number of prior lines of TKIs. 
2 
Subgroup analysis will be conducted among patients with 300/400 mg starting dose by Subgroup of Age at 
Informed Consent, Gender, Region, Race, and Number of prior lines of TKIs. 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
33 
 Deaths 
Death will be summarized during the active treatment phase and within 30 days after the last 
date of the study treatment by SOC and PT.  
A listing of patients who died will be provided specifying the date of death, the cause, and the 
date of last study treatment dose. On treatment death (from first dose date to last dose date + 
30 days) will be clearly marked. 
 Clinical Laboratory Evaluations 
The laboratory parameters with both baseline and post-baseline assessments will be 
summarized by starting dose (‘<300 mg’, ‘300 mg’, ‘400 mg’, ‘300/400 mg’, and ‘all doses’) 
and visit for the Safety Population. If there are repeated values for a specific visit, the last 
reported value will be used for that visit. Baseline is defined as the last assessment prior to 
start of study treatment. 
Clinical laboratory values will be graded according to NCI CTCAE version 4.03 for applicable 
parameters. Shift tables of laboratory data from baseline to worst grade during treatment will 
be presented. For serum chemistry parameters (including sodium, potassium, magnesium, and 
glucose) shift tables in maximum CTCAE grades of worst (high) and worst (low) assessment 
will be presented separately. 
Overall summary and changes from baseline will be presented for hematology and serum 
chemistry (including coagulation) laboratory values.  
Listings will be provided for each laboratory parameter. All results outside predefined normal 
ranges, and CTCAE grade will be flagged in the data listings. 
Urinalysis will be presented in listing only. 
Boxplot of selected lab tests (including leucocytes, neutrophils, platelets, hemoglobin, alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin) values will 
be presented by visit.  
4.8 Vital Signs 
Results for height, weight, BMI, systolic and diastolic blood pressure (BP), heart rate, and 
body temperature will be summarized by starting dose and visit for the Safety Population. 
Changes in BP, pulse rate, and body temperature from baseline will be summarized by starting 
dose (‘<300 mg’, ‘300 mg’, ‘400 mg’, ‘300/400 mg’, and ‘all doses’) and visit. 
4.9 Electrocardiograms  
Electrocardiogram overall interpretation (normal, abnormal not clinically significant [NCS], 
abnormal clinically significant [CS], and NE) will be presented for actual values and changes 
from baseline [expressed as improvement, no change, and deterioration] by dose level  


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
34 
summarized by starting dose (‘<300 mg’, ‘300 mg’, ‘400 mg’, ‘300/400 mg’, and ‘all doses’) 
and visit for the Safety Population.  
• Improvement = abnormal CS to abnormal NCS/normal, abnormal NCS to normal  
• Deterioration = normal to abnormal NCS/CS, abnormal NCS to abnormal CS  
• No change = normal to normal, abnormal NCS to abnormal NCS, abnormal CS to 
abnormal CS. 
If either result is missing for any patient, then an ‘Unknown’ category will be presented. 
4.10 ECOG Performance Status 
Overall summary and changes from baseline will be presented for ECOG performance by 
starting dose (‘<300 mg’, ‘300 mg’, ‘400 mg’, ‘300/400 mg’, and ‘all doses’) and visit for the 
Safety Population. 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
35 
5. INTERIM ANALYSES 
No interim analysis is planned for this study.  
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
36 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
37 
7. APPENDICES 
7.1 Data Imputation Guidelines 
No imputation will be made for completely missing date unless otherwise specified. General 
imputation rules mentioned below apply to partially missing or impossible dates:  
• If the stop date is not missing, and the imputed start date is after the stop date, the start 
date will be imputed by the stop date 
• If the start date is not missing, and the imputed stop date is before the start date, then 
the imputed stop date will be equal to the start date 
• Any imputed dates need to be logical. For example, last dose date should not be later 
than death date. 
When imputation rules in subsequent sections contradicts the general rule, always follow the 
general rule. 
 Adverse Event Date Imputation 
Follow the general rule specified in Section 7.1. 
Incomplete Start Date: 
Missing day, month, and year 
• No imputation will be made; the corresponding AE will be included. 
Missing day and month 
• If the year is the same as the year of the first dose date, then impute day and month as 
the day and month of the first dose date 
• If the year is prior to the year of the first dose date, then impute day and month as 
31 Dec 
• If the year is after the year of the first dose date, then impute day and month as 01 Jan. 
Missing day only 
• If the month and year are the same as those of the first dose date, then impute day as 
the day of the first dose date 
• If either the year of partial date is before the year of the first dose date, or the years 
are the same, but the month of partial date is before the month of the first dose date, 
then impute day as last day of the month 
• If either the year of partial date is after the year of the first dose date, or the years are 
the same, but the month of partial date is after the month of the first dose date, then 
impute day as first day of the month. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
38 
Incomplete Stop Date: 
Missing day, month, and year 
• No imputation will be made. 
Missing day and month 
• If the year is the same as the year of the last dose date, then impute day and month as 
the day and month of the last dose date 
• If the year is prior to the year of the last dose date, then impute day and month as 
31 Dec 
• If the year is after the year of the last dose date, then impute day and month as 01 Jan. 
Missing day only 
• If the month and year are the same as those of the last dose date, then impute day as 
the day of the last dose date; 
• If either the year of partial date is not the same as the year of the last dose date, or the 
years are the same, but the month of partial date is not the same as the month of the 
last dose date, then impute day as last day of the month. 
 Concomitant Medication Date Imputation 
Follow the general rules specified in Section 7.1 and rules in Section 7.1.1. 
 Prior Therapies Date Imputation 
Follow the general rule specified in Section 7.1. 
For start date partial as month and year are available, then impute day as ‘01’. E.g. impute 
partial date of ‘DEC2013’ as ‘01DEC2013’. 
For start date partial as year only is available, then impute day and month as ‘01JAN’. E.g. 
impute partial date of ‘2013’ as ‘01JAN2013’. 
For end date partial as month and year are available, then impute day as last day of the month. 
E.g. impute partial date of ‘JUN2013’ as ‘30JUN2013’. 
For end date partial as year only is available, then impute day and month as the last day of the 
year. E.g. impute partial date of ‘2013’ as ‘31DEC2013’. 
If the imputed starting date is earlier than initial diagnosis date, it should be set as the initial 
diagnosis date. No overlap between the exposure to prior therapies and study drug will be 
allowed and any overlap of exposure will be queried at data review stage. The end date of 
prior therapies will be imputed to first dose date of study drug – 15 if there is overlap due to 
imputation of partial dates. When there are multiple lines of prior therapies, the end date of 
prior therapies will be imputed to first dose date of the subsequent line of therapy -1 if there 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
39 
is overlap due to imputation of partial dates. If the end year for one prior therapy is the same 
as the start year for the next prior therapy, impute Jun 30 and Jul 1 of that year for the end and 
start days if missing months and days.  
 Death Date Imputation 
• If death date is completely missing, will use latest alive date + 1 
• If both month and day are missing, then use the first date (01 JAN) of the year, or latest 
alive date + 1, whichever is later 
• If only day is missing, then use the first day of the month, or latest alive date + 1, 
whichever is later. 
 Post-Therapies Date Imputation 
Follow the general rule specified in Section 7.1. 
 Other Imputations 
Follow the general rule specified in Section 7.1. 
7.2 Table, Listing, and Figure Format  
In the top left portion of each table/listing, a table/listing number followed by the title of the 
table/listing will be presented. After the title line, optional sub-title or population information 
can be presented. Horizontal lines will appear before and after the column heading of the 
table/listing. Footnotes will be put under the main body of text at the bottom of the page.  
The sponsor name, protocol number, programmer user identification, status of the table/listing 
(i.e. draft or final) and SAS program name will appear bottom left in a string and the page 
number will appear on the bottom right corner of each table/listing. The date and time of 
creation of table/listing will appear bottom left under the sponsor name. The source listing 
number will appear bottom left.  
A landscape layout is for both table and listing presentations for post-text tables. A portrait 
layout is for in text table. 
The left and right margins of all tables and listings will be a minimum of 2.1 cm from the left 
and 1.9 cm from the right. The top and bottom margins will be a minimum 2.92 cm. Header 
and footer will be both 1.27 cm. 
There is no special requirement of font type and size, but an 8-point font size for tables and 
7or 8-point for listings is proposed using Courier New font. A maximum SAS line size = 141 
and page size = 44 for 8-point font size, and line size = 161 and page size = 50 for 7-point will 
be used to fit on both United Kingdom and US paper sizes. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
40 
In a listing, in the case that a patient’s record has been continued to the next page, an 
appropriate identification (e.g. the patient identification number) must be presented at the 
beginning of that page. 
7.3 Conventions 
Unless otherwise specified, in summary tables of continuous variables, the minimum and 
maximum values will be displayed to the same number of decimal places as the raw data, the 
mean and median will be presented to one extra decimal place compared to the raw data, and 
the StdDev will be displayed to two extra decimal places compared to the raw data. Wherever 
possible data will be decimal aligned. 
Unless otherwise specified frequency tabulations will be presented by number and percentage, 
where the percentage is presented in brackets to 1 decimal place (XX.X%). 
P-values, if applicable, will be presented to 3 decimal places. If a p-value is less than 0.05 but 
is greater than or equal to 0.01, then an asterisk (*) will be added next to this value. If a p-value 
is less than 0.01 but is greater than or equal to 0.001, then two asterisks (**) will be added 
next to this value. Finally, if the p-value is less than 0.001 then three asterisks (***) will be 
added next to this value and it will be presented as <0.001. If the rounded result is a value of 
1.000, it will be displayed as >0.999.  
Any date information in the listing will use the date9. format, for example, 07MAY2002. In 
the listing, a unit associated with a variable will be presented only once within parentheses 
either below or next to that variable in the heading portion. If a parameter has multiple units, 
each unit will be displayed only once, as applicable. 
All tables will have their source listing referenced in a footnote. Listings should be sorted by 
analysis group, patient and visit and have the source data received by data management 
referenced in a footnote. All tables and listings will be converted into Microsoft Word 
documents and collated into two complete documents.  
 
 
 
 
 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
41 
8. REFERENCES 
Cassier PA, Fumagalli E, Rutkowski P, Schoffski P, Van Glabbeke M, Debiec-Rychter M, et 
al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated 
gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012 Aug 
15;18(16):4458-64. 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck 
S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij 
J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
Eur J Cancer. 2009; 45:228–47. 
EMA. Guideline on the evaluation of anticancer medicinal products in man [Online]. 
Available 
at: 
https://www.ema.europa.ed/docs/en_GB/document_library/Scientific_ 
guidelines /2017/11/WC500238764.pdf. Updated 22 Sep 2017. 
Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. 
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant 
gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007 
Mar 1;13(5):1367-73. 
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and 
secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in 
imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 20;26(33):5352-9. 
Kang YK, Ryu MH, Yoo, C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to 
control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib 
and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013 
Nov; 14(12):1175-82. 
Klein JP, Moeschberger ML. Survival analysis technique for censored and truncated data 
(second edition). Springer-Verlag; 2003. 
Stivarga® [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 
2017 
[Online]. 
Available 
at: 
http://labeling.bayerhealthcare.com/html/products/pi/ 
Stivarga_PI.pdf. Accessed 31 August 2017. 
Sutent® [Prescribing Information]. New York, NY: Pfizer Labs; 2014 [Online]. Available at: 
http://labeling.pfizer.com/ShowLabeling.aspx?id=607. Accessed 09 March 2015. 
US FDA. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs 
and Biologics [Online]. Available at: https://www.fda.gov/downloads/Drugs/Guidances/ 
ucm071590.pdf. Updated May 2007.  
Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, et al. Choi criteria are 
superior in evaluating tumor response in patients treated with transarterial radioembolization 
for hepatocellular carcinoma. Oncol Lett. 2013 Dec; 6(6):1707–12. 


Avapritinib 
Statistical Analysis Plan Study BLU-285-1101 
Confidential 
42 
Yoo C, Ryu MH, Jo J, Park I, Ryoo BY, Kang YK. Efficacy of imatinib in patients with 
platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors. Cancer 
Res Treat. 2016 Apr;48(2):546-52.